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Abstract 
Triple-negative breast cancers lack the three main breast cancer biomarkers; 
oestrogen-, progesterone- or HER2-receptors and chemotherapy is the only 
established treatment option for patients. Chemotherapies are associated with 
physically debilitating, off-target toxicities and tumours often develop resistance 
to cytotoxic compounds. Nanomedicine has the potential to improve 
chemotherapy efficacy and has enabled the development of small, therapeutic 
carriers such as microparticles (MPs). These can be made from biodegradable 
polymers, loaded with (sometimes poorly soluble) chemotherapeutic agents and 
their surfaces coated in tumour targeting proteins. CD95L has been reported to 
be upregulated in cancer cells identifying it a promising target. In this study, the 
CD95 receptor, CD95R, was fused to the Fc region of human IgG1, and 
baculoviral-mediated expression was optimised in Sf21 and Hi5 insect cells. The 
protein was purified by affinity chromatography and used to coat microparticles. 
CD95R-coated MPs improved the uptake into triple-negative, MDA-MB-231 cells, 
ostensibly via a mechanism involving CD95L. Anti-CD95L antibodies were 
validated following expression of CD95L-Myc-DDK in otherwise naïve HEK293T 
cells. The expression of supposed target ligand CD95L was then tested in MDA-
MB-231 cells and found to be undetectable. Furthermore, the CD95R-coated 
particles were efficiently taken up by non-cancerous primary fibroblasts. The 
reasons for the enhanced uptake of CD95R-coated MPs were explored in MDA-
MB-231 cells. Differences in the surface charge of the coated-MPs, characterised 
by dynamic light scattering (DLS) and electrophoresis, were ruled out as a cause. 
However, inhibition of the common endocytic pathways did suggest that coated-
MP uptake likely occurs via macropino- or phagocytosis. The use of this system 
for targeted cancer treatment or for wider applications are discussed. 
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SDS     Sodium Dodecyl Sulphate  
SFM     Serum Free Media  
SH3     Src Homology 3 
shRNA    Short Hairpin RNA  
siRNA    Small Interfering RNA  
SM     Starting Material  
SOC     Super Optimal broth with Catabolite repression  
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SPA/Protein-A   Staphylococcal Protein A  
SPPL2A    Signal Peptide Peptidase Like 2A 
SV40     Simian Virus 40 
TCA     Trichloroacetic Acid  
TEMED    Tetramethylethylenediamine  
TLP     Templated Lipoprotein Nanoparticles  
TNBC    Triple Negative Breast Cancer  
TNF     Tumour Necrosis Factor  
UTR     Untranslated Region  
VEGF-A    Vascular Endothelial Growth Factor A  
W1 – 3    Wash 1 – 3  
WASP    Wiskott-Aldrich Syndrome Protein  
X-gal     5-bromo-4-chloro-3-indolyl ß-D-galactopyranoside 
µg     Microgram 
µl     Microlitre 
µM     Micromolar  
µm     Micrometre   
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1. Introduction  
1.1. Breast cancer  
1.1.1. Breast cancer epidemiology  
Breast cancer is the most common form of cancer among women, impacting 2.1 
million women in 2018, accounting for almost 1 in 4 female cancer cases (Bray 
et al., 2018). In 2018, it is estimated that 627,000 women died from breast cancer, 
representing 15% of all cancer deaths among women (Bray et al., 2018). Breast 
cancer incidence rates are highest in Australia/New Zealand, Northern Europe 
(such as the UK, Sweden, Finland and Denmark), Western Europe, Southern 
Europe and Northern America (Bray et al., 2018). While breast cancer rates are 
higher among women in more developed countries, rates are increasing in nearly 
every region globally. 
 
1.1.2. Risk factors for breast cancer 
Hereditary and genetic factors, including a personal or family history of breast or 
ovarian cancers, and inherited mutations (in BRCA1, BRCA2 and other breast 
cancer susceptibility genes) account for only 5 – 10% of breast cancer cases 
(Bray et al., 2018). Studies of migrants have shown that non-hereditary factors 
are the major drivers of breast cancer incidence and comparisons of low-risk 
populations migrating to high-risk populations have revealed that breast cancer 
incidence rates rise in successive generations (Ziegler et al., 1993). Elevated 
incidence rates are attributed to higher prevalence of known risk factors related 
to menstruation (early age at menarche, later age at menopause), reproduction 
(nulliparity, late age at first birth, fewer children), exogenous hormone intake (oral 
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contraceptive use and hormone replacement therapy), nutrition (alcohol intake) 
and anthropometry (greater weight, weight gain during adulthood and body fat 
distribution); whereas breastfeeding and physical activity are known protective 
factors (Bray et al., 2018, Schottenfeld and Fraumeni Jr, 2006). 
 
1.1.3. Breast cancer types  
Breast cancer can be classified in a number of ways to assist the clinical 
diagnosis and management of patients. Histologically, breast cancer is classified 
depending on whether the cancer has arisen from the ducts or the lobules of the 
breast. Ductal carcinoma in situ (DCIS) arises from clonal proliferation and 
atypical hyperplasia of cells from the terminal and lactiferous (glandular) ducts of 
the breast tissue, confined within the epithelial basement membrane. Invasive 
ductal carcinoma arises once the cells have invaded through this basement 
membrane (Harris et al., 2004). The majority of invasive forms of breast cancer 
(80%) arise from the ducts of the breast. The remaining cases of breast cancer 
evolve from the terminal duct-lobular apparatus; lobular carcinoma in situ (LCIS), 
which can also break through the basement membrane and become invasive 
(Frykberg, 1999). In contrast to ductal carcinoma, lobular carcinomas tend to be 
slower growing (Korkola et al., 2003). Inflammatory breast cancer (IBC) arises 
when cancer cells grow along and block the lymph vessels of the breast. IBCs 
are the most virulent form of breast cancer, characterized by involvement of the 
skin and rapid progression of the disease (Woodward and Cristofanilli, 2009).  
 
Another important form of classification for breast cancers is their hormone 
receptor status. Breast cancers are routinely tested for the presence or absence 
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of three key proteins; the oestrogen receptor (ER), the progesterone 
receptor (PR), and the human epidermal growth factor (EGF) receptor 2 (HER2). 
The presence of these receptors provides tumourigenic benefits and, crucially, 
they are targeted by endocrine therapies (see section 1.1.5). Luminal ER-
positive, HER2-negative (ER+HER2–) breast cancer, which is characterised by 
expression of the ER but absence of  HER2 amplification, accounts for 70% of all 
breast cancers (Turner et al., 2017). HER2 positivity accounts for about 15 – 20% 
of breast cancers (Loibl and Gianni, 2017). The other ~15 – 20% of breast 
tumours express none of these three markers and are collectively referred to as 
triple-negative breast cancers (TNBCs; ER−, PR−, HER2−) (Kalimutho et al., 
2015). TNBCs are a heterogeneous subtype of breast cancer which are prevalent 
in younger women (under 40 years of age), and have a poor clinical outcome 
(Kalimutho et al., 2015). 
 
1.1.4. Breast cancer treatments  
The aim of treating in situ or locally invasive breast cancer is ultimately curative 
and directed towards preventing recurrence. The main types of treatment for 
breast cancer are surgery, radiation therapy (RT), chemotherapy (CT) and 
endocrine (hormone) therapy (ET) (Nounou et al., 2015). Breast conservation 
surgery is the trending approach for the treatment of localised breast cancer 
(DCIS) (Matsen and Neumayer, 2013). Surgery can be preceded by neoadjuvant 
therapy to shrink the tumour, and followed by adjuvant therapy to minimize the 
risk of metastases (Nounou et al., 2015). RT, where cancer cells are exposed to 
a high level of radiation directly, can then be utilised to kill cells that are missed 
during surgery (Dhankhar et al., 2010). For other types of breast cancer, a 
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mastectomy is recommended, followed by a mix of RT, ET or CT after surgery, 
as required.   
 
1.1.5. Endocrine and HER2-directed therapy 
Oestrogen is the main hormone involved in the development and growth of breast 
tumours (Smith and Dowsett, 2003). The purpose of ET is to balance or block 
oestrogen and is indicated in all patients with detectable ER expression (Nounou 
et al., 2015). The choice of medication is determined by a patient's menopausal 
status, differences in drug efficacy and side effect profile. For example, 
premenopausal women are usually prescribed Tamoxifen, which is an ER 
antagonist. Postmenopausal women however, are normally offered aromatase 
inhibitors which suppress plasma oestrogen levels by inhibiting aromatase, the 
enzyme responsible for the synthesis of oestrogens from androgenic substrates 
(Smith and Dowsett, 2003). Breast cancers which express the HER2 receptor 
can be treated with targeting drugs such as Trastuzumab (Herceptin®). This is a 
monoclonal antibody that inhibits ligand-independent HER2 signalling, inhibits 
the shedding from the extracellular domain and can trigger antibody-dependent 
cellular cytotoxicity (Loibl and Gianni, 2017). Trastuzumab is often given in 
combination with CT (such as taxanes), or given as an antibody-drug conjugate, 
such as Kadcyla (Trastuzumab-Emtansine); Emtansine is a cytotoxic, 
microtubule-inhibitory agent (Loibl and Gianni, 2017). For TNBC patients 
however, no targeted therapies are available, and CT will be recommended in the 
vast majority of cases.  
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1.1.6. Chemotherapy for breast cancer 
The benefit from CT in breast cancer is more pronounced in ER-negative 
tumours. CT will be recommended for TNBC, HER2-positive or metastatic breast 
cancers. Adjuvant CT for treating breast cancer usually involves anthracycline-
containing combinations of drugs. These combinations include Fluorouracil, 
Doxorubicin and Cyclophosphamide (FAC) or Fluorouracil, Epirubicin and 
Cyclophosphamide (FEC). More recently however, taxane based 
chemotherapeutics, such as paclitaxel and docetaxel, are used in combination 
with anthracycline regimes to reduce the chance of cancer metastasis. A meta-
analysis of 13 randomised trials concluded that administration of paclitaxel 
resulted in a 5% absolute reduction in recurrence of breast cancer (disease-free 
survival) in contrast to 3% with the use of anthracyclines (De Laurentiis et al., 
2008). Paclitaxel (commercially known as Taxol) exerts its anti-cancer activity in 
a unique way, by polymerising and stabilising microtubules and inducing 
apoptosis. It is used to treat a wide range of cancers, including breast cancer. 
 
1.2. Chemotherapy 
1.2.1. Limitations of chemotherapies 
Adjuvant CT, used to treat breast cancer and many other types of cancer, are 
commonly associated with major and debilitating physical side effects. The side 
effects of Paclitaxel therapy for example, include neutropenia, alopecia and 
neurotoxicity (de Weger et al., 2014). This systemic toxicity is due to the non-
specific nature of chemotherapeutic agents affecting both normal and cancerous 
cells (Danhier et al., 2010). Additionally, paclitaxel is very poorly soluble in 
aqueous solutions which makes drug delivery challenging. As a result, Taxol 
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preparations contain toxic cremophor and ethanol to solubilise the drug for clinical 
applications (Ateh et al., 2011). Cremophor causes further side effects in patients 
such as serious hypersensitivity reactions (Wang et al., 2012) and patients often 
require premedication with steroids and antihistamines (Wood et al., 1995, Ateh 
et al., 2011). Cytotoxic drug treatment is also limited by drug metabolism and 
clearance mechanisms often involving the overexpression of drug transporter 
proteins, which can efflux drugs from cancer cells (Fletcher et al., 2010). These 
issues highlight the need for treatments which target directly to cancer cells to 
ensure delivery of the optimum dose of drug, in order to improve patient survival 
and quality of life.  
 
1.2.2. Targeted cancer treatments  
Nanomedicine has the potential to improve the efficacy of CT treatments. By 
combining nanotechnology and medicine, this field of research has enabled the 
development of small particle, therapeutic carriers such as microparticles (MPs) 
(Wang et al., 2012). MPs can be made from biodegradable polymers such as 
poly(lactic-co-glycolic acid) (PLGA), loaded with chemotherapeutic agents and 
their surfaces functionalised by coating or opsonising with targeting proteins 
(Kohane, 2007). These targeting proteins are selected to bind to tumour-specific 
markers, allowing uptake and internalisation of MPs into tumour cells (Wang et 
al., 2012). Upon internalisation, PLGA MPs degrade into lactic and glycolic acids 
which can be readily excreted or metabolised by the body, making them 
biocompatible (Jain et al., 2000). This drug delivery system has been shown to 
result in higher drug concentrations within solid tumours and lower off-target 
toxicity (Wang et al., 2012). MPs can be loaded with drugs including those that 
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are too toxic to be administered intravenously or those that are poorly soluble 
(Wang et al., 2012) removing the need for toxic additives in the formulation to 
overcome the solubility issue. MPs therefore offer the potential advantages of 
improved bioavailability and sustained and controlled drug release within the 
target cell (Kohane, 2007).  
 
1.3. The TNF family 
The tumour necrosis factor (TNF) family of proteins consist of more than 20 
proteins with a broad range of functions including control of cell death, immune  
differentiation and regulation (Fulda and Debatin, 2006). Members of this family 
are trimeric ligands which bind their corresponding trimeric receptors. The TNF 
receptors share similar cysteine-rich extracellular domains (ECD) and a 
cytoplasmic death domain (DD) (Fulda and Debatin, 2006). The cysteine-rich 
domains are thought to fold independently and are stabilised by extensive, intra-
chain disulphide bonding (Orlinick et al., 1997). The DDs are required to 
transduce death signals from the cell surface to intracellular signalling pathways 
(see section 1.4.2) (Fulda and Debatin, 2006). 
 
1.4. CD95R 
1.4.1. CD95R topology 
Human CD95R (Fas/APO-1/TNFRSF6) belongs to the TNF receptor family and 
is localised to the plasma membrane, where is has been shown to assemble into 
homotrimers even in the absence of ligand (Siegel et al., 2000). CD95R mediates 
apoptosis when bound to its natural ligand, CD95L (CD178/TNFSF6) (section 
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1.4.2). It is ubiquitously expressed in the body, but is particularly abundant in the 
thymus, liver, heart and kidney (Peter et al., 2015). Human, full length CD95R is 
a 45kDa, type I transmembrane protein with 335 amino acids (Orlinick et al., 
1997). It has a 25 amino acid (aa) signal peptide, a 148 aa ECD (rich in cysteine 
residues), a 17 aa transmembrane alpha-helix, and a 145 aa cytoplasmic death 
domain. There are two N-linked glycosylation sites in the ECD (N118 and N136) 
(Shatnyeva et al., 2011). N-linked glycosylation is introduced upon entry of the 
polypeptide into the lumen of the endoplasmic reticulum and involves the transfer 
of a carbohydrate moiety to an asparagine residue within a specific amino acid 
consensus sequence (N-X-S/T) (Shatnyeva et al., 2011). As a type I 
transmembrane protein, the N-terminal region of CD95R is extracellular. Full 
length CD95R has not been crystallised however, a part of the ECD 
(corresponding to amino acids 52 – 129 in full length CD95R; Figure 1.1) has 
been crystallised in complex with Fab fragment E09 (PDB; 3THM); the structure 
was resolved to 2.1Å and shows extended loops and turns with anti-parallel β-
strands, with no helices (Chodorge et al., 2012). 
 
1.4.2. CD95R and apoptosis  
The CD95R death receptor is well known for its involvement in programmed cell 
death and tissue homeostasis by the immune system (Chen et al., 2010). 
Apoptosis is a regulatory mechanism of programmed cell death, which is vital for 
maintaining tissue homeostasis. Apoptosis can proceed through two main 
pathways (extrinsic/receptor-mediated and intrinsic/mitochondrially mediated) 
(Iverson and Orrenius, 2004). Upon activation by its ligand CD95L, CD95R can 
trigger apoptosis via the extrinsic pathway (Shatnyeva et al., 2011). A CD95L 
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trimer binds three CD95R molecules, resulting in the conformational change of 
the receptors’ DDs (Nisihara et al., 2001). The DDs then recruit the adaptor 
protein Fas-associated death domain (FADD) to which procaspase-8 can bind 
(Sayers, 2011). The resulting complex of proteins is called the death-inducing 
signalling complex (DISC). Caspase-8 is released from DISC, which goes on to 
activate effector caspase-3, caspase-6 and caspase-7 (Ashkenazi, 2008). This 
cascade of reactions subsequently leads to apoptosis. This pathway is one that 
is activated indirectly by chemotherapeutic agents such as doxorubicin, 
methotrexate and bleomycin (Meza-Lamas et al., 2006) upregulating CD95R 
expression and inducing autocrine or paracrine expression of CD95L (Meza-
Lamas et al., 2006, Wesselborg et al., 1999).  
 
 
Figure 1.1. Crystallised fragment of human CD95R ectodomain. 
The structure of the crystallised fragment of CD95R ECD, corresponding to amino acids (aa) 52 
- 129 in full length human CD95R. The fragment was crystallised in complex with Fab fragment 
E09 (not shown). Arrows represent ß-strands, C129 is the C-terminal aa and L52 is the N-terminal 
aa. Structure was resolved to 2.1 Å (PDB; 3THM) (Chodorge et al., 2012).   
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1.4.3. CD95R/L and the immune system  
The CD95L/R system also plays an important role in immune system 
homeostasis (Voss et al., 2008). Activation-induced cell death (AICD) is a 
homeostatic mechanism used by the immune system to control T-cell responses 
and prevent autoimmunity by promoting tolerance to self-antigens (Askenasy et 
al., 2005). After activation, T cells express CD95R and CD95L and with repeated 
antigenic stimulation become sensitive to CD95R/L-mediated autocrine and 
paracrine apoptosis (Dhein et al., 1995). This serves to regulate immune 
responses and control the pool of antigen-activated T cell clones (Askenasy et 
al., 2005). CD95R- and CD95L- deficient mice (lpr/lpr and gld/gld, respectively) 
suffer autoimmune diseases (Takahashi et al., 1994a). A lpr (lymphoproliferation) 
mutation in mice causes defective CD95R expression, resulting in 
lymphadenopathy and systemic lupus erythematosus-like autoimmune disease 
(Watanaba et al., 1992). Gld (generalised lymphoproliferative disease) mice 
express a mutant form of CD95L, suffering from a phenotype similar to lpr mice, 
including lpr and autoimmune disease (Peter et al., 2015). Additionally, a genetic 
disorder in humans is caused by mutations in CD95R/L, called autoimmune 
lymphoproliferative syndrome (ALPS), resembling mice with lpr and gld 
mutations, respectively (Peter et al., 2015). 
 
1.4.4. CD95R and cancer  
CD95R is often downregulated during cancer progression (Chen et al., 2010) and 
it is thought that this may be a cancer-specific mechanism for survival, in order to 
avoid apoptotic-induced cell death. However, complete loss is rarely seen and 
reducing CD95R expression has also been found to have a growth inhibiting 
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effect in many cancer cell lines (colon, renal, breast and liver) (Chen et al., 2010) 
suggesting the involvement of CD95R in non-apoptotic activities. For example, 
CD95R, via a pathway involving JNK and Jun, promotes growth of ovarian and 
liver cancer in mouse models (Chen et al., 2010). Once cancer cells acquire 
resistance to CD95R-mediated apoptosis, further stimulation of CD95R is 
tumorigenic (Peter et al., 2015). CD95R signalling has been shown to increase 
the motility and invasiveness (migration through Matrigel-coated membranes) of 
22 apoptosis-resistant cancer cell lines (Barnhart et al., 2004). This occurs via 
three signalling pathways resulting in activation of NF-кB and Erk1/2, and 
involves active caspase-8 and urokinase plasminogen activator (Barnhart et al., 
2004). In a study using cells from ALPS patients, as well as cellular and mouse 
model systems, non-apoptotic signalling through CD95R involved activation of 
NF-ĸß and the three MAP kinases, Erk1/2, JNK1/2 and p38 (Barnhart et al., 2004, 
Legembre et al., 2004a, Legembre et al., 2004b). The elimination of CD95R/L 
was previously reported to kill cancer cells via a unique form of cell death, labelled 
DICE (death induced by CD95R/L elimination) (Ceppi et al., 2014). However, 
more recent publications suggest this effect is not due to loss of CD95R or 
CD95L, but the result of unique off-target effects from the siRNAs and shRNAs 
designed against CD95R and CD95L (Putzbach et al., 2017). This is discussed 
in more detail in Chapter 4 (section 4.1.5).  
 
1.5. CD95L  
1.5.1. CD95L structure  
Human CD95L is a 40kDa protein with 281 amino acids belonging to the TNF 
superfamily (Takahashi et al., 1994b, Suda et al., 1993). It has an 179 aa ECD, 
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a 22 aa transmembrane alpha-helix, an 80 aa cytoplasmic domain (Takahashi et 
al., 1994b) and as a type II transmembrane protein, the C-terminal region of 
CD95L is extracellular. The protein has 3 N-linked glycosylation sites in the ECD 
(N184, N250 and N260) and one intramolecular disulphide bond (C202 – C233) 
(Voss et al., 2008) and self-associates to form homotrimers. CD95L can be 
released from the cell surface producing a soluble form of the protein which 
remains trimeric. The topology and features of CD95L are discussed in more 
detail in Chapter 4 (section 4.1.1).  
 
A fragment of the CD95L ECD (amino acids 143 - 281) has been crystallised as 
a trimer, in complex with the decoy receptor DcR3 (PDB; 4MSV); the structure 
was resolved to 2.5Å (Figure 1.2 and 1.3) (Liu et al., 2014). In Figure 1.2A, a 
monomer of the crystallised fragment of CD95L ECD is shown. The structure 
shows eleven β-strands, arranged in two anti-parallel β-sheets. The positions of 
the three N-linked glycosylation sites are indicated with the asparagine side 
chains shown in stick format and coloured elementally on the monomeric CD95L 
ECD fragment in Figure 1.2B, which is shown interacting with a monomer of 
DcR3. Decoy receptor 3 is a secreted member of the TNF family, which is typically 
expressed at low levels in healthy individuals but is highly elevated in various 
cancers, likely serving as a mechanism for tumour immune evasion (Bai et al., 
2000). DcR3 has been shown to prevent the induction of apoptosis of cancer cells 
by CD95L-expressing immune cells, by blocking CD95L interaction with CD95R 
(Strasser et al., 2009).   
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There are two points of interaction between CD95L and DcR3 (Figure 1.2B), 
which may provide insight into the CD95L:CD95R recognition surface, which is 
yet to be co-crystallised. For Figure 1.2B, the sequences of the crystallised 
fragment of the CD95R ECD (Figure 1.1) and the crystallised DcR3 were aligned 
and the region of homology is shown in orange, indicating a similar CD95L 
binding region. The homologous region of the crystallised fragment of CD95R 
ECD aligns to amino acids 14 – 83 in the crystallised DcR3 and amino acids 46 
– 115 in full length, human DcR3. In Figure 1.3, the functional complex/hexamer 
(Liu et al., 2014; personal communication; PDB; 4MSV) that forms between 
trimeric CD95L and DcR3 is shown. Figure 1.3A shows a side view of the complex 
and Figure 1.3B shows a view of the complex, looking down onto the CD95L 
expressing cell. This may be a similar arrangement to the CD95L:CD95R 
functional complex, with two trimeric forms of the proteins interacting.   
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Figure 1.2. Crystallised fragment of human CD95L ectodomain in complex with DcR3.  
(A) The structure of a monomer of the crystallised fragment of CD95L ECD, corresponding to 
amino acids (aa) 143 - 281 in full length human CD95L is shown in cartoon format. Pink arrows 
represent ß-strands, while the only helical secondary structure is shown in cyan. L143 is the N-
terminal aa and L281 is the C-terminal aa. (B) The CD95L ECD fragment was crystallised in 
complex with DcR3 (Decoy Receptor 3). A monomer of CD95L ECD (shown in cartoon format) is 
shown here interacting with a monomer of DcR3 (shown with surface rendering in slate and 
orange). The asparagines of the 3, N-linked glycosylation sites of CD95L (N184, N250 and N260) 
are shown in stick format and coloured elementally. The region of DcR3 that is homologous with 
the crystallised fragment of CD95R ECD (Figure 1.1 and aligned here on the right) is coloured 
orange in the surface rendered cartoon. The homologous region of the crystallised fragment of 
CD95R ECD aligns to aa 14 – 83 in the crystallised DcR3 and aa 46 – 115 in full length, human 
DcR3 (PDB; 4MSV) (Liu et al., 2014).   
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Figure 1.3. The functional complex of trimeric, crystallised CD95L ectodomain and DcR3.  
(A) A side view of the complex between the trimeric, crystallised fragments of CD95L ECD 
interacting with DcR3. The bottom of the image demonstrates the location of the CD95L 
expressing cell. CD95L is shown coloured by secondary structure (predominantly pink), while 
DcR3 is coloured blue (B) The complex viewed from above, looking down onto the CD95L 
expressing cell. C193 is the N-terminal amino acid (aa) of DcR3 and T33 is the C-terminal aa (Liu 
et al., 2014; personal communication; PDB; 4MSV) (Liu et al., 2014). 
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1.5.2. CD95L and the concept of immune privilege  
CD95L is expressed in immune-privileged sites such as epithelial cells in the eye, 
neurons and astrocytes of the central nervous system and Sertoli cells in the 
testis (Griffith et al., 1995, Voss et al., 2008). The purpose of this is to prevent 
inflammation, by inducing apoptosis of CD95R-positive cells which may invade 
such tissues (Griffith et al., 1995, Linkermann et al., 2005).  
 
1.5.3. CD95L and cancer  
CD95L is normally expressed by immune cells such as natural killer (NK) cells to 
induce apoptosis (Ateh et al., 2011), however its expression has been linked to 
tumour cells. The expression of CD95L by tumours has long been thought to 
provide a counterattack against the immune system, killing infiltrating T cells and 
preventing apoptosis. However, the counterattack theory has been subject to 
debate, as CD95L-expressing tumours are rapidly rejected and induce 
inflammation in mice (Igney and Krammer, 2005). Recently, CD95L expression 
has been detected in the endothelium of vascularised solid human and mouse 
tumours, but not in normal vasculature, suggesting a role in immune tolerance of 
the tumour similar to the immune privilege of the CNS, testes and the eye (Motz 
et al., 2014). The expression of CD95L in the endothelial cells of the vasculature 
is thought to be induced by common factors in the tumour microenvironment such 
as tumour-derived vascular endothelial growth factor A (VEGF-A), interleukin 10 
(IL-10) and prostaglandin E2 (PGE). The evidence for and against expression of 
CD95L by tumour cells has changed drastically since a key paper was published 
in 2017 (Putzbach et al., 2017) and warrants careful reappraisal of the literature. 
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This paper and the complex issues surrounding this topic are explained in more 
detail in Chapter 4.  
 
1.7. The CD95R ECD for targeted chemotherapeutic delivery 
A paper published in 2011 by Ateh et al., found a novel use for CD95R in a 
chemotherapeutic, drug delivery system using microparticles. By coating or 
opsonising the surface of MPs (>0.5 µm in diameter) with the extracellular domain 
of CD95R fused to the Fc region of human IgG1 (CD95R-Fc) they could enhance 
the uptake of MPs in a range of cells including neurones, medulloblastoma, 
breast and ovarian cancer cells, in vitro (Ateh et al., 2011). Initially, 0.5 and 1µm, 
fluorescent polystyrene particles were coated with commercially available 
CD95R-Fc and uptake was tested using flow cytometry and confocal microscopy 
in these different cell types. In each case, CD95R-Fc opsonisation led to 
increased uptake in comparison to non-coated particles or IgG (to control for the 
-Fc domain) coated particles. For example, in MDA-MB-231 cells (a highly 
invasive, triple-negative, breast adenocarcinoma cell line) the uptake of 0.5µm 
MPs increased from 15% to around 70% when coated with CD95R-Fc (Ateh et 
al., 2011). Interestingly, increased uptake of CD95R-Fc coated particles could be 
prevented in Daoy (desmoplastic cerebellar medulloblastoma) cells by 
preincubating the cells with CD95R-Fc for a minimum of 15 minutes (Ateh et al., 
2011). Uptake was also tested using PLGA, biodegradable MPs, loaded with 
ethidium homodimer, a membrane impermeable nucleic acid dye. Coating in 
CD95R-Fc increased ethidium homodimer uptake by Daoy cells by nearly 10-fold 
compared to excess dye added directly to cell cultures (Ateh et al., 2011). 
Paclitaxel-loaded, PLGA particles were then tested, and with a CD95R-Fc 
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coating, they were cytotoxic to Daoy cells to a similar extent as dose-matched, 
free Paclitaxel.  
 
Drug delivery, using the paclitaxel-loaded PLGA particles, was then investigated 
in two different in vivo models. The first used a subcutaneous xenograft of Daoy 
medulloblastoma cells in NOD/SCID (a type of immunodeficient) mice. PLGA 
MPs with or without a paclitaxel cargo and with or without CD95R-Fc coating 
were injected directly into the tumour and the percentage change in tumour 
volume was recorded for 7 days. An equivalent dose of free paclitaxel was also 
injected to compare to the MP treatments. Paclitaxel-loaded PLGA particles, 
regardless of coating, inhibited tumour growth to a greater extent than paclitaxel 
alone after a single intratumoural injection (Ateh et al., 2011). There was also an 
effect with placebo PLGA particles (CD95R-Fc coated PLGA particles without 
paclitaxel) which was attributed to CD95R-Fc interfering with CD95R/L mediated 
tumour proliferation. The result observed with uncoated, drug-loaded particles 
was thought to be due to the large MPs being retained within the tumour, enabling 
local release of the paclitaxel. In this experiment, the CD95R-Fc coating did not 
provide any measurable benefit to the reduction in tumour volume. However, the 
same MPs were tested in a murine model of peritoneal ovarian cancer 
dissemination (IGROV1-luciferase expressing cancer cells), a more clinically 
relevant cancer model (Ateh et al., 2011). All treatments were administered via 
intraperitoneal injection. Live imaging showed a >65-fold reduction in tumour 
bioluminescence by week 4 with the CD95R-Fc coated, paclitaxel-loaded MP 
treated group, compared with an equivalent dose of Taxol (paclitaxel dissolved in 
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Cremophor and ethanol) (Ateh et al., 2011). In this case, non-coated, drug-loaded 
MP treatment matched Taxol, and both placebo treatments were ineffective. 
 
1.7.1. Proposed mechanism and benefits of CD95R-coated 
MPs for drug delivery 
Since there was a large database of evidence for the expression of CD95L by 
cancer cells (but rebutted in Chapter 4), it was hypothesised that the enhanced 
uptake of CD95R-Fc coated MPs was due to a CD95R:CD95L interaction. More 
specifically, the CD95R on the surface of the MP was thought to bind to the 
CD95L on the surface of the cancer cell initiating an internalisation mechanism, 
possibly phagocytosis. Phagocytosis is commonly associated with professional 
phagocytes of the innate immune system, such as macrophages and neutrophils 
(Rabinovitch, 1995). However “non-immune” cells including cancer cells, also 
have phagocytic capacity which is regulated by poorly understood cell membrane 
signals (Rabinovitch, 1995, Ateh et al., 2011). This could explain why pre-
incubating cells with CD95R-Fc prevented MP uptake, since free CD95R-Fc 
would bind to and block the cell surface CD95L, preventing interaction with the 
coated particles. If this mechanism is correct, CD95R-Fc coated particles could 
provide a targeted, chemotherapeutic, drug delivery method, improving 
intracellular drug concentrations and removing the need for toxic paclitaxel 
preparations (as described in section 1.2.2). However, there was very little, direct 
evidence to demonstrate the tumour expression of CD95L in the in vivo models 
used to test uptake in the 2011 study. Immunofluorescent (IF) staining of CD95L 
in the cancer cell lines used in vitro was presented. However, the anti-CD95L 
antibody used for IF was not stated nor validated. A more detailed investigation 
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was therefore warranted to seek evidence of CD95L expression and determine 
the route of uptake of the CD95R-Fc coated MPs.  
 
1.8. Objectives of the current study  
The exact mechanism of CD95R-coated particle uptake is not known. More 
evidence is needed to demonstrate the involvement of CD95L, and whether it is 
expressed by cancer cells. Characterising the pathways involved in MP uptake 
and the CD95R/CD95L targeting mechanism will be important for optimising the 
delivery of chemotherapeutics to their intended site of action. For this study, 
uptake mechanisms will be investigated primarily in MDA-MB-231 cells, a triple-
negative, breast cancer cell line. TNBC is not only prevalent in younger women 
with a poor clinical outcome but no targeted therapies are available, and 
chemotherapy is the front-line treatment option. An improved drug delivery 
system for chemotherapeutics, such as targeted PLGA MPs, would be well suited 
for these patients to reduce major and debilitating physical side effects.  
 
The primary objectives of this study were to develop an expression and 
purification system to purify significant amounts of CD95R-Fc suitable for uptake 
studies in MDA-MB-231 cells (Chapter 3), to determine the expression level of 
CD95L by this cell line (Chapter 4) and to investigate potential mechanisms of 
uptake (Chapter 5). 
 
 
49 
 
1.9. Project aims 
• Express and purify CD95R-Fc 
• Formulate CD95R-Fc coated microparticles to test targeted delivery to 
cancer cells  
• Understand the efficacy of the targeting mechanism by investigating 
CD95L expression in the cancer cells of interest  
• Characterise the mechanisms involved in coated microparticle uptake 
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2. Materials and Methods 
2.1. Bacteria culture medium 
Lysogeny Broth (LB):  1% tryptone, 0.5% yeast extract, 1% NaCl 
 
LB Agar:    1% tryptone, 0.5% yeast extract, 1% NaCl 
 
SOC Medium:   2% tryptone, 0.5% yeast extract, 0.05% NaCl, 0.02%  
    KCl, 0.04% glucose, 0.01M MgCl2, 0.01M MgSO4 
 
Solid or liquid growth media were supplemented with ampicillin to a final 
concentration of 100µg/ml or kanamycin to final concentration of 50µg/ml. 
 
2.2. Bacterial culture and storage  
Bacteria were grown in liquid growth media with shaking (230rpm), or on plates 
in an incubator set to 37°C. Bacteria were frozen for long term storage at -80°C 
in a mixture of LB medium and 15% glycerol. 
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2.3. Molecular biology  
2.3.1. Plasmids 
The baculovirus transfer vector, Mouse CD95R/Fc_pOET1, was provided by 
OET, encoding mouse CD95R ectodomain (residues 1 - 169), linker region 
(residues 170 - 177), and Fc portion of human IgG (residues 178 - 407) (see 
Figure 3.2 for amino acid sequence). Briefly, the cDNA sequence for Mouse 
CD95R-Fc fusion protein was optimised for expression in insect cells with 
additional 5’ XbaI, 5’ UTR (AACTCCTAAAAAACCGCCACC), stop codon (TAA) 
and 3’ SmaI sequences. The gene was synthesised and the sub-cloned into 
pOET1 transfer plasmid.   
 
The mammalian expression plasmid pCMV6-FasLG, coding for CD95L with a C-
terminal, Myc-DDK tag, was provided by BioMoti and purchased from OriGene 
(RC204894; Figure 2.1).  
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Figure 2.1. pCMV6-CD95L-Myc-DDK plasmid map  
Map of the pCMV6, mammalian expression plasmid (Origene) which expresses CD95L-Myc-
DDK. Map displays the Simian Virus 40 (SV40) origin of replication (ORI), the cytomegalovirus 
(CMV) promotor and the CD95L-Myc-DDK gene.  
 
 
The pCMV6 vector (OriGene) permits high level and efficient expression of 
recombinant proteins in mammalian cells, under the control of the strong 
cytomegalovirus (CMV) promoter (Schmidt et al., 1990). Additionally, it contains 
the Simian Virus 40 (SV40) origin of replication, which enables the vector to 
replicate in cells which express the SV40 T antigen (such as HEK293T cells)  
(Gluzman, 1981). 
 
Plasmids were also used as controls. pTracer-CD36 (which expresses human 
CD36 attached to a green fluorescent protein, GFP) and pCINeoCD36-12His 
(which expresses human CD36 ECD with a C-terminal 12 histidine tag and an N-
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terminal honeybee melittin secretory signal) were used as transfection controls 
and provided by Kenneth Linton.  
 
2.3.2. Preparation of plasmid DNA 
Plasmid DNA preparations were generated using the QIAGEN plasmid midi kits 
(for up to 100µg of plasmid DNA) following the manufacturer’s protocol 
(QIAGEN). 100µl of bacteria (from a 3ml overnight culture) were used to inoculate 
a 100ml culture and grown overnight at 37°C with vigorous shaking. Cells from 
the 100ml culture were harvested by centrifugation for 15 minutes at 6000xg at 
4°C. The cell pellet was resuspended in 4ml Buffer P1 (resuspension buffer; 
50mM Tris-Cl, pH 8.0, 10mM EDTA, 100ug/ml RNase A). Once the cell pellet 
was completely resuspended, 4ml of Buffer P2 (lysis buffer; 200mM NaOH, 1% 
SDS) added to the solution, mixed by inversion and incubated at room 
temperature for 5 minutes. Nucleic acids and proteins within the lysate were 
subsequently denatured due to the alkalinity of the Lysis buffer. Following 
incubation in Lysis Buffer, 4ml of Buffer P3 was added (neutralisation buffer; 3.0M 
potassium acetate, pH 5.5), the solution mixed and incubated on ice for 15 
minutes, causing the aggregation of insoluble genomic DNA and high molecular 
weight RNA as well as the precipitation of protein-SDS complexes. To remove 
these aggregates, the lysate was centrifuged at ≥20,000xg for 30 minutes at 4°C, 
for two rounds. QIAGEN-tip 100 columns were prepared by adding 4ml of Buffer 
QBT (equilibration buffer; 750mM NaCl, 50mM MOPS, pH 7.0, 15% isopropanol, 
0.15% Triton X-100). The supernatant from the cell lysate was then added to the 
prepared columns. The QIAGEN-tip was then washed with 2 x 10ml of Buffer QC 
(wash buffer; 1.0M NaCl, 50mM MOPS, pH 7.0, 15% isopropanol) before eluting 
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DNA with 5ml of pre-warmed, Buffer QF (elution buffer; 1.25M NaCl, 50mM Tris-
Cl, pH 8.5, 15% isopropanol). DNA was precipitated by adding 3.5ml of 
isopropanol to the eluted DNA and the mix was centrifuged at ≥ 15,000xg for 30 
minutes at 4°C. The supernatant was decanted, and the DNA pellet washed with 
70% ethanol and centrifuged again at ≥ 15,000xg for 10 minutes. The supernatant 
was decanted, and the pellet left to air-dry for 5 minutes before re-dissolving in a 
suitable buffer, such as TE buffer (10mM Tris-Cl, pH 8.0, 1mM EDTA). Recovered 
plasmid DNA was quantified using a NanoDrop (ND-100, Thermo Scientific), 
measuring the optical density at a wavelength of 260nm. Estimation of purity of 
the plasmid DNA was achieved through measuring the A260:A280 ratio; a ratio 
of 1.8 - 2.0 was indicative of a pure sample. 
 
2.4. Insect cell culture  
2.4.1. Insect cell culture medium and reagents 
For virus propagation and protein production, Sf21 cells were cultured in 
suspension, in Sf-900™ II Serum Free Media (SFM; Thermo Fisher Scientific) 
and Hi5 cells in Ex-cell 405 media (Sigma). For plaque assay, Sf21 cells were 
grown in TC-100 media (Thermo Fisher Scientific) supplemented with 10% Fetal 
Bovine Serum (FBS, Thermo Fisher Scientific). Both conditions included 1% 
antibiotic/antimycotic (AA; HyClone) to a final concentration of 100units/ml 
penicillin G, 100µg/ml streptomycin sulphate, and 25µg/ml amphotericin B. Cells 
were cultured at 27°C in a 311DS, Labnet obital shaker at 120rpm.  
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2.4.2. Insect cell co-transfection and baculovirus generation 
Sf21 cells were co-transfected with the transfer vector (CD95R/Fc_pOET1) and 
flashBAC GOLD (Oxford Expression Technologies, OET) genomic DNA as 
instructed by the manufacturer. 1 x 106 cells/2mls were seeded onto a 3.5cm 
tissue culture dish (BD Biosciences) in TC100 medium without FBS or antibiotics.  
 
For the co-transfection, the following reagents were mixed: 
 100ng  Baculoviral genomic DNA (flashBAC GOLD)  
 500ng  Transfer Plasmid (CD95R/Fc_pOET1) 
 1.2µl   baculoFECTIN II transfection reagent (OET) 
 100µl   TC100 media without FBS or antibiotics 
 
The solution was gently mixed and incubated at room temperature for 15 - 20 
minutes. Medium was then aspirated from the monolayer of insect cells and the 
baculoFECTIN II:DNA complex mixture added drop-wise to different areas of the 
dish.  Each dish was then incubated overnight at 27°C in a humidified sealed box 
containing (lined with paper soaked in 50mM EDTA). After 24hrs, 1ml TC100 
containing 10% FBS and antibiotics was added to each dish and incubated for a 
further 4 days, as before. Following incubation, the medium containing the 
recombinant virus p0 stock was harvested into sterile tubes.  
 
Generation of FlashBAC ULTRA-CD95R-Fc was outsourced to OET. 
Recombinant virus was produced by co-transfection of flashBACULTRA viral 
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DNA and CD95R/Fc_pOET1 construct with baculoFECTIN liposome forming 
agent in Sf9 insect cells following a similar procedure as described above (OET; 
personal communication). A p1 stock was received from OET and amplified into 
a working stock (as described in section 2.4.4). 
 
2.4.3. Plaque assay to determine baculovirus titre 
Plaque assays were used to assess the titre of recombinant baculoviruses. Sf21 
(1 x 106) cells, grown in TC-100 media, were seeded onto 3.5cm dishes to give 
50% confluency. Media was aspirated and 200μl of virus stock diluted to 10-4, 10-
5 and 10-6 was added to duplicate dishes. The dishes were incubated for 1 hour 
at room temperature. The supernatant was aspirated and replaced with 1.5ml 1% 
seaplaque, low meting temperature agarose in 75% TC-100. The agarose was 
left at room temperature to set and then overlaid with 1ml TC-100. The dishes 
were incubated in a sealed box lined with tissue soaked in 10mM EDTA. After 3 
days incubation, 1ml of 0.03% neutral red in phosphate-buffered saline (PBS) 
was added to each dish and incubated at 27°C for 2 hours. The media and stain 
were then aspirated, the dishes inverted and left at room temperature in the dark 
overnight. Neutral red stains live cells, allowing the visualisation of virus plaques 
of lysed or dying cells as clear regions within the red background monolayer.  
 
2.4.4. Amplification of baculovirus stocks  
To obtain working stocks, baculovirus was amplified over a number of stages. At 
each stage the premise remains the same; with a low ratio of virus particles to 
insect cells (multiplicity of infection; MOI) used to permit cell growth to continue 
whilst allowing multiple cycles of viral infection, replication and budding to occur.  
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p0 to p1 stock amplification (flashBAC GOLD virus) 
A suspension culture containing 25ml Sf21 insect cells at a density of 2 x 106 
cells/ml in Sf900 II SFM media was infected with 500µl p0 viral stock. The cells 
were incubated overnight, before being diluted with 25ml of fresh Sf900 II SFM 
media. After a total of 5 days, the cells were removed by centrifugation at 2060xg 
for 10 minutes at 4°C. The supernatant was recovered and stored at 4°C as p1 
stock. The baculovirus titre was calculated by plaque assay. 
p1 stock to working stock amplification (flashBAC GOLD and ULTRA viruses) 
100ml of Sf21 cells, at a density of 2 x 106 cells/ml in Sf-900™ II SFM, were 
infected with p1 virus stock resulting in a multiplicity of infection (MOI) of 0.1 virus 
particle per cell, according to the viral titre determined by plaque assay. The cells 
were incubated overnight, before being diluted with 100ml of fresh Sf900 II SFM 
media. After incubation for 5 days at 27°C, the cells were removed by 
centrifugation at 2060xg for 10 minutes at 4°C. The supernatant was recovered 
and stored at 4°C as a working stock (WS).   
 
2.4.5. Small-scale infection for protein production  
In order to determine the time course and MOI required for CD95R-Fc 
expression, 10ml cultures of Sf21 cells in Sf-900™ II SFM or Hi5 cells in Ex-cell 
405 media, at a density of 1 x 106 cells/ml, were infected with WS at different MOI, 
0.1, 1 and 3 (with one uninfected, control culture), and incubated for 5 days at 
27°C. 500μl of each culture was sampled every 24 hours over the 5 day period, 
spun at 9600xg in a microcentrifuge to remove the insect cells, and the 
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supernatant recovered for analysis by western blot (see section 2.7.7, 2.7.8 and 
2.7.11). 
 
In order to produce protein which would go on to be purified, 10ml cultures of 
Sf21 cells in Sf-900™ II SFM or Hi5 cells in Ex-cell 405 media, at a density of 1 
x 106 cells/ml, were infected with WS. Sf21 cells were infected at a MOI of 0.1 
and incubated for 5 days, whereas Hi5 cells were infected at a MOI of 3 and 
incubated for 3 days, at 27°C. Cells the cells were removed by centrifugation at 
2060xg for 10 minutes at 4°C. The supernatant was recovered and bound directly 
to protein-A resin (see section 2.7.1).  
 
2.5. Mammalian Cell Culture 
2.5.1. Cell lines, medium and reagents  
Monolayers of triple negative, human breast adenocarcinoma cell line MDA-MB-
231 were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo 
Fisher Scientific) with high glucose (4.5 g/L) supplemented with 5% (v/v) FBS 
(Sigma). MDA-MB-231 cells were kindly provided by Cleo Bishop.  
 
Monolayers of human embryonic kidney (HEK293T) cells were cultured in DMEM 
(Thermo Fisher Scientific) with high glucose (4.5 g/L) supplemented with 10% 
(v/v) FBS (Sigma). HEK293T cells were kindly provided by Kenneth Linton.  
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Monolayers of primary dermal fibroblasts (isolated from a 42 year old female, 
facelift patient) were cultured in DMEM (Thermo Fisher Scientific) with high 
glucose (4.5 g/L) supplemented with 10% (v/v) FBS (Sigma). Primary dermal 
fibroblasts were kindly provided by Cleo Bishop.  
 
All cells were cultured with additional penicillin-streptomycin (Sigma; diluted to a 
final concentration of 100 units penicillin and 0.1 mg/ml streptomycin) at 37°C 
with 5% CO2 in a water saturated atmosphere. Adhered MDA-MB-231 cells were 
removed using Versene (Thermo Fisher Scientific).  All other adhered cells were 
removed using TrypLE Express or trypsin EDTA (Thermo Fisher Scientific). All 
cells were washed with sterile-filtered, phosphate buffered saline (PBS), pH 7.4 
(Sigma). All manipulations were performed in a sterile environment, with 
disposable plastic ware and glassware. 
 
2.5.2. Transfection reagents 
Cells were transfected with the cationic polymer polyethyleneimine (PEI) (Sigma). 
PEI was prepared by dissolving 45mg PEI in 8ml sterile water, corrected to pH 
7.2 with dilute HCl, filtered through a sterile filter (0.2µm) and kept at RT. Glucose, 
5% (w/v) was prepared by dissolving 2.5g glucose in sterile water, passed 
through a sterile filter (0.2µm) and kept at room temperature. 
 
2.5.3. Inhibitor preparation and storage  
The inhibitors used to block CD95L-sheddases were GM1006 (Merck), a cell 
permeable, broad spectrum MMP inhibitor (of MMP - 1, 2, 3, 7, 8, 9, 12, 14, 26) 
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and GI254023X (Sigma), which is marketed as selective ADAM10 inhibitor. Both 
inhibitors were resuspended in dimethyl sulphoxide (DMSO), an organic solvent, 
and aliquots stored at -20°C. Both inhibitors were used at a working concentration 
of 20µM.  
 
Inhibitors were also used to block endocytic pathways. Inhibitors of 
macropinocytosis were Cytochalasin D (Santa Cruz) used at 20µM and 5-(N,N-
dimethyl)-Amiloride hydrochloride (Amiloride; Cayman Chemical) used at 50µM. 
Inhibitors used to block clathrin-dependent endocytosis were Chlorpromazine 
(Santa Cruz) used at 15µM and Dynasore monohydrate (Santa Cruz) used at 50 
µM. Inhibitors of caveolin-dependent endocytosis were Nystatin (Sigma) and 
Filipin III, from Streptomyces filipienensis (Sigma); both used at 50nM. Mannan, 
from Saccharomyces cerevisiae (Sigma) was used at 1mg/ml to block mannose-
receptor mediated endocytosis and Nocodozole (Sigma) was used at 5µM to 
block microtubule involvement in particle internalisation. All inhibitors were 
solubilised in DMSO and aliquots stored at -20°C, except Mannan, which was 
dissolved in H2O and stored at 4°C.  
 
2.6. Mammalian cell (HEK293T) transfection  
2.6.1. For western blot and flow cytometric analysis  
HEK293T cells (3 x 105) were seeded as a monolayer on 6-well plates (Nunclon) 
in 2ml DMEM, 24 hours prior to transfection. The transfection mixture included 
5µg DNA (pCMV6-FasLG (CD95L); Origene) at a concentration of 1 µg/µl, with 
0.5% glucose (w/v) adjusted to a final volume of 8.5µl with sterile water. Then 
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1.5µl PEI was added followed by DMEM (2ml), before applying to cells. The cells 
were harvested 48 hours post transfection and either lysed (see section 2.7.6) or 
analysed by flow cytometry (see section 2.9.3). For inhibitor experiments, 24 
hours post transfection, the media was aspirated from cells, they were washed 
with 2ml PBS and then incubated with 20µM GM1006 or 20µM GI254023X, or 
both inhibitors in combination, for 24 hours, in 2ml, FBS-free DMEM with high 
glucose (4.5 g/L; Thermo Fisher Scientific). 24 hours later, the cells were 
harvested and analysed by flow cytometry (see section 2.9.3).  
 
2.6.2. For immunofluorescent staining  
HEK293T cells (3 x 105) were seeded as a monolayer on 6-well plates (Nunclon) 
in 2ml DMEM. Before seeding, sterile 18mm coverslips were placed into each 
well and treated with 1ml Poly-L-Lysine (Sigma) for 1 hour at room temperature. 
Cells were transfected 24 hours later (see section 2.6.1). Cells were fixed 48 
hours post transfection (see section 2.10) and immunostained. For inhibitor 
experiments, cells were treated as previously described (see section 2.6.1) and 
then immunostained.  
 
2.7. Protein Biochemistry  
2.7.1. Batch purification of CD95R-Fc 
12ml of spent insect culture was incubated with 125, 250 or 500µl MabSelect, 
protein-A resin (slurry in 20% ethanol; GE Healthcare) overnight, at 4°C. The 
resin was spun at 228xg using a swing out rotor, to form a pellet and then washed 
three times by resuspension in 5ml sterile PBS (pH 7.4), spinning each time to 
62 
 
pellet the resin before the next wash. The protein was eluted in 4 x 1ml, 100mM 
citric acid (pH 3) spinning between each elution to pellet the resin.  
 
2.7.2. Dialysis  
CD95R-Fc protein from the first elution fraction was buffer exchanged into PBS 
(pH 7.4) using a Slide-A-Lyzer Dialysis Cassette (10K MWCO) (Thermo 
Scientific), following the manufacturer’s protocol. Briefly, the elution was added 
to the dialysis cassette and dialysed against 300x the volume of sample with 
dialysis buffer (PBS), in a beaker at 4°C for 1 hour with gentle stirring. The 
process was repeated for another hour with fresh dialysis buffer and then allowed 
to dialyse overnight in a third batch of dialysis buffer.  
 
2.7.3. PD-10 column for buffer exchange 
Buffer exchange was performed using a PD-10 desalting column (GE 
Healthcare), following the manufacturers protocol. The column was equilibrated 
with 25ml PBS (pH 7.4) only or PBS with additional BSA (50ug BSA for every 1ug 
CD95R-Fc) and the first elution (E1) fraction added. A following 7 x 1ml of PBS 
only or PBS & BSA was added, collecting each fraction separately. 25ml of PBS 
only was then run through the column to wash it, and it was stored in 20% ethanol 
at 4°C.  
 
2.7.4. Trichloroacetic acid precipitation of protein samples 
Protein solutions were precipitated using trichloroacetic acid (TCA) prior to 
separation by SDS-PAGE (see section 2.7.7 and 2.7.8). 0.15% DOC was made 
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by dissolving 75mg sodium deoxycholate in 50ml H2O. The solution was stirred 
to give a uniform slurry. 0.8M NaOH was added drop-wise until the solution 
cleared. On ice, DOC was added to the protein sample (10% of the protein 
sample volume) and incubated for 5 min. 72% TCA was added (10% of the 
protein sample volume) and incubated on ice for 10 minutes. The sample mixture 
was spun at 14000xg in a microcentrifuge for 20 minutes and the supernatant 
removed. The protein pellet was resuspended in 4% SDS, 0.2M Tris (pH 7.5), 
0.15M NaOH (pH 10) and loading buffer added (see section 2.7.7) before 
separation by SDS-PAGE (section 2.7.8).  
 
2.7.5. MDA-MB-231 and primary dermal fibroblast, whole-cell 
extracts 
MDA-MB-231 cells or primary dermal fibroblasts (2 x 106 or otherwise specified) 
were pelleted at 3000xg, media aspirated and cells washed in 1ml PBS. A 5x 
stock of lysis buffer was made (5% sodium dodecyl sulphate (SDS) in PBS, 
750mM NaCl, 50mM HEPES). Cells were resuspended in 250µl PBS and 250µl 
2x lysis buffer (consisting of 400µl 5x lysis buffer, 40µl, 20x protease inhibitor 
cocktail (Roche), 20µl EDTA (0.5M, pH 8), 1µl (25 U/µl) Benzonase® 
Endonuclease (Novagen) and made up to 1ml with PBS). The endonuclease was 
allowed to act for 15 min at room temperature before DNA was sheared using a 
21-gauge then a 25-gauge needle. Samples were centrifuged at 17,000xg for 15 
minutes at 4°C to remove any insoluble material. The supernatant was collected 
in fresh tubes and stored at -80°C.  
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2.7.6. HEK293T whole-cell extracts 
48 hours post transfection (see section 2.6.1), HEK293T cells (1 x 106) were 
pelleted at 3000xg, media aspirated, and cells washed in 1ml PBS. Whole-cell 
extracts were then prepared as previously described (see section 2.7.5).  
 
2.7.7. Preparation of protein samples for SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) 
Protein samples or whole-cell extracts were mixed with 4 x LDS sample buffer 
(Life Technologies) plus 4% (CD95R-Fc protein samples) or 8% (whole-cell 
extracts) 2-mercaptoethanol and incubated at 75°C for 5 minutes prior to loading 
the gel. For expression tests (Figure 3.3 and 3.4) samples were heated to 90°C 
for 3 minutes.  
 
2.7.8. SDS-PAGE  
Proteins were separated by electrophoresis through vertical 1.0mm thick 
polyacrylamide gels (0.1% SDS, 10% or 8% acrylamide), using the procedure 
described by Laemmli (Laemmli, 1970). The required reagents and volumes to 
make the resolving (8% and 10%) and stacking gels, along with SDS-PAGE 
running buffer are described in Table 2.1. The stacking gel was overlaid onto 
polymerised separating gel after addition of tetramethylethylenediamine 
(TEMED) and ammonium persulphate (APS) to initiate polymerisation. Gels were 
run at 120 volts (V) in SDS-PAGE running buffer for 2 hrs or until the dye front 
had reached the bottom of the gel.  
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Resolving gel (8%/10% - 5ml):  2.3ml/1.9ml H2O 
 1.3ml/1.7ml acrylamide mix (30% 
acrylamide/bis-acrylamide mix (37.5:1 
ratio); National Diagnostics) 
 1.3ml 1.5M Tris (pH 8.8) 
 50µl 10% SDS 
 50µl 10% ammonium persulphate 
 3µl/2µl TEMED  
Stacking gel (3ml): 2.1ml H2O    
 500µl acrylamide mix (National 
Diagnostics) 
 380µl 1.5M Tris (pH 8.8) 
 30µl 10% SDS 
 30µl 10% ammonium persulphate 
 3µl TEMED  
SDS-PAGE running buffer:  25mM Tris-HCl 
 190mM Glycine 
 1% SDS    
 
Table 2.1. SDS-PAGE stacking and resolving gels and SDS-PAGE running buffer 
The required reagents and volumes to make 8% or 10% resolving gels and stacking gels along 
with SDS-PAGE running buffer.  
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2.7.9. Colloidal blue staining 
Following separation by SDS-PAGE, proteins were visualised by fixing the gel 
(50% methanol, 7% acetic acid) for 15 minutes. The gels were then washed 3 
times for 5 minutes with dH2O and stained in GelCode® Blue Stain Reagent 
(Thermo Scientific) o/n. Gels were then destained by washing 3 times for 5 
minutes, and overnight in dH2O.  
 
2.7.10. Protein quantification and purity  
For BSA protein quantification, BSA standards (1, 0.8, 0.6, 0.4 and 0.2 µg) were 
made in PBS (pH 7.4) and run alongside protein samples using SDS-PAGE and 
stained with colloidal blue. The gel was scanned and the density of the BSA 
standards were measured using ImageJ software (NIH) and the standard curve 
plotted using GraphPad Prism software (version 5). Using the BSA standard 
curve, the linear equation (Equation 2.1.) was used to measure the concentration 
of protein based on the density of protein bands.  
 
𝑦 = 𝑚𝑥 + 𝑐 
Equation 2.1. The Linear Equation 
m = gradient of the straight line and c = the y intercept 
 
Percentage purity of a protein sample was calculated after SDS-PAGE and 
staining of the gel, using ImageJ. The pixels in a lane containing a protein sample 
was compared to a blank lane, to account for any background signal on the gel 
(Figure 2.2A).  
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Figure 2.2. Calculating percentage purity using ImageJ. 
(A) Example gel with a blank lane (yellow box 1) and a lane containing a protein sample (yellow 
box 2). (B) Total amount of pixels in the blank lane of the gel, representing background noise. (C) 
The total amount of pixels in the lane containing the protein sample. The large peak demonstrates 
the protein of interest which is calculated as a percentage in comparison to the total pixels in the 
lane, minus the background noise.  
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The pixels in the peak for the protein of interest (Figure 2.2C) are then calculated 
as a percentage in comparison to pixels in the rest of the lane (minus any 
background pixilation in the blank lane (Figure 2.2B)), which describes the 
presence of contaminating proteins. The resulting percentage is the level of purity 
of the protein of interest. 
 
2.7.11. Western Blot 
Samples were separated by SDS-PAGE (see section 2.7.8) and transferred onto 
a polyvinylidene fluoride (PVDF) membrane (Roche Diagnostics). The PVDF 
membrane is activated by soaking in 100% methanol followed by washing in 
dH2O. The membrane along with 3mm filter paper (Whatman) was then soaked 
in transfer buffer (25 mM Tris-HCl, 190 mM Glycine and 5% Methanol). 
Electroblotting was carried out at 400 mA for 1 hour using a Mini Trans-blot cell 
(Biorad) with an ice pack, according to manufacturer’s protocols. Following 
transfer, the membrane was blocked for 1 hour at room temperature in blocking 
buffer containing 5% w/v skimmed milk powder in PBS-tween (PBS-T, 0.1% v/v 
Tween 20 in PBS (pH 7.4)). Membranes were washed in PBS-T and then 
incubated overnight at 4°C with the required primary antibody (see table 2.2. for 
primary antibodies and dilutions) in 5% milk, PBS-T. Membranes were washed 3 
times in PBS-T for 10 minutes and incubated for 1 hour at room temperature with 
secondary antibody polyclonal goat anti-mouse immunoglobulins-HRP (Dako) at 
a 1:10,000 dilution for HEK293T whole-cell lysates and at a 1:2000 dilution for 
MDA-MB-231 and primary dermal fibroblast whole-cell lysates, for detection of 
CD95L. For detection of CD95R-Fc, no primary antibody was used; membranes 
were incubated for 1 hour at room temperature with 1:100,000 dilution (in 5% 
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milk, PBS-T) of anti-human IgG (Fc specific)-Peroxidase (Sigma). Membranes 
were washed 3 times in PBS-T for 10 minutes, and bound antibody was detected 
using Immobilon™ Western, Chemiluminescent HRP Substrate (Millipore) and 
visualised on ECL Hyperfilm™ (GE Healthcare).  
 
Primary Antibody Supplier Dilution  
Mouse, anti-human 
CD178 (CD95L) clone 
G247-4 
 
BD Pharmingen 1:1000  
Mouse, anti-c-MYC Sigma 1:4000 
Mouse, anti-FLAG, 
clone M2 
 
Sigma 1:4000 
Monoclonal anti-β-
tubulin, produced in 
mouse 
 
Sigma 1:4000 
Mouse, anti-human PI3-
Kinase C2β 
 
BD Biosciences  1:1000 
Table 2.2. Primary antibodies used for protein detection via Western Blot.  
Antibody names, suppliers and dilutions used.  
 
2.7.12. Glycosidase digestion of glycoproteins 
Proteins were deglycosylated using Peptide-N-glycosidase-F (PNGase-F) or 
Endoglycosidase-H (Endo-H) (New England Biolabs) according to 
manufacturer’s protocol. Briefly, 1 – 20µg of protein was incubated for 10 minutes 
with denaturing buffer (0.5% SDS, 1% 2-mercaptoethanol) at 100°C, and then on 
ice for 2 min. 500U of PNGase-F was added with G7 buffer (50mM Sodium 
Phosphate, pH 7.5) supplemented with 1% NP40, or 1000U of Endo-H was 
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added with G5 buffer (0.5M Sodium Citrate, pH 5.5). Samples were incubated at 
37°C for 2 hours. Control samples were also prepared in the same way, without 
PNGase-F or Endo-H in order to compare any shift in protein mobility following 
SDS-PAGE.  
 
2.8. Microparticle opsonisation (coating) 
Dragon Green fluorescent, 0.53µm polystyrene microparticles (MPs; 530nm; 
FS03F/5069) were pre-formed by Bangs Laboratories, USA. Spherical 
polystyrene microparticles (MPs) were pulse-vortexed for one minute before use. 
They were coated by physical adsorption with 0.5µg CD95R-Fc protein 
(expressed in-house, with or without additional BSA, or commercially-sourced 
from OET or Sigma) or human IgG – Fc fragment (Abcam) per 1µg MP, or sham 
coated in PBS (negative control). For BSA (Sigma), an excess was used for 
coating (80µg BSA: 1µg MP). Coating mixtures were made up to 100µl using PBS 
and incubated at 37°C for 90 minutes with mixing every 20 minutes.  
 
2.9. Flow cytometric analysis  
2.9.1. Flow cytometric analysis of microparticle uptake  
MDA-MB-231 cells or primary dermal fibroblasts (1.4 x 105) were seeded in 6-
well plates (Nunclon) in DMEM (Thermo Fisher Scientific) supplemented with 2% 
(v/v) FBS (Sigma) and cultured for 24 hours. MPs were coated (see section 2.8) 
and were added to the cells (4.05 x 106 per well) and incubated for a further 24 
hours. Unbound MPs were removed by washing each well of cells 3 times with 
2ml PBS, and gently tapping the sides of the 6-well plate to dislodge any particles. 
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Cells were harvested by adding 0.25% TrypLE™ Express (Thermo Fisher 
Scientific), neutralised with 2ml DMEM (Thermo Fisher Scientific) supplemented 
with 2% (v/v) FBS (Sigma), centrifuged at 228xg for 5 minutes and resuspended 
in 100µl PBS. Suspensions were analysed by flow cytometry (FACScan; Becton 
Dickinson). Data was acquired for 10,000 cells, gating on cells with normal size 
but including a large range of granularity (since MP uptake makes the cells 
appear more granular), using CellQuest™ Pro Software. Data were analysed 
using the FlowJo software package (Tree Star).  
 
2.9.2. Flow cytometric analysis of microparticle uptake with 
endocytic inhibitors 
MDA-MB-231 cells were seeded as previously described (section 2.9.1). 24 
hours later, cells were pre-treated with each inhibitor for one hour (see section 
2.5.3) in FBS free DMEM (Thermo Fisher Scientific), prior to incubation with 
coated MPs (see section 2.8) for 12 hours. Cells were then washed, harvested 
and analysed by flow cytometry as previously described (section 2.9.1).  
 
2.9.3. Flow cytometric analysis of CD95L expression 
HEK293T cells were transfected as described in section 2.6.1. Additionally, one 
well was transfected with 5µg P-tracer, full-length CD36 (GFP expressing) at a 
concentration of 2µg/µl, as a control for transfection efficiency, or with 
pCINeoCD36-12His (which expresses human CD36 ECD with a C-terminal 12 
histidine tag and an N-terminal honeybee melittin secretory signal) at a 
concentration of 1µg/µl, as a "mock transfection" control. All cells were harvested 
48 hours post-transfection using 1ml Versene (Thermo Fisher Scientific). 
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Versene was neutralised with 2ml DMEM (Thermo Fisher Scientific) 
supplemented with 10% (v/v) FBS (Sigma). Cells were counted and 1 x 106 
transfected, untransfected and mock-transfected cells, and all harvested GFP-
expressing cells, were pelleted at 220xg for 5 min and media aspirated. GFP-
expressing cells were resuspended in 400µl phenol-red free DMEM (Sigma) 
supplemented with 1% (v/v) FBS (Sigma) in polypropylene FACS tubes (5ml; BD 
Biosciences) and stored at 4°C in the dark, ready for flow. Transfected, mock-
transfected and untransfected cells were resuspended in 100µl phenol-red free 
DMEM (Sigma) supplemented with 1% (v/v) FBS (Sigma). 1µg of the primary 
antibody used (mouse anti-human CD178 (CD95L) NOK-1 clone (BioLegend), 
mouse, anti-human CD178 (CD95L) clone G247-4 or mouse, anti-c-MYC 
(Sigma)) was incubated with 1 x 106 cells in 100µl for 30 minutes at 4°C. The 
tubes were agitated every 5 minutes to maintain cells in suspension. Cells were 
then washed 3 times with 1ml, phenol-red free DMEM (Sigma) supplemented 
with 1% (v/v) FBS (Sigma), spinning at 220xg between washes to pellet the cells. 
1µg of secondary antibody, goat, anti-mouse Alexa Fluor® 488 (Invitrogen) was 
incubated with 1 x 106 cells in 100µl for 30 minutes at 4°C. The tubes were 
agitated every 5 minutes to maintain cells in suspension. Cells were then washed 
3 times with 1ml phenol-red free DMEM (Sigma) supplemented with 1% (v/v) FBS 
(Sigma), spinning at 220xg between washes to pellet the cells. Cells were 
resuspended in 400µl phenol-red free DMEM (Sigma) supplemented with 1% 
(v/v) FBS (Sigma) in polypropylene FACS tubes (5ml; BD Biosciences) and 
stored at 4°C in the dark. Suspensions were analysed by flow cytometry 
(FACscan; Becton Dickinson). Data was acquired for 10,000 cells of normal size 
and granularity using CellQuest™ Pro Software. Data were analysed using the 
FlowJo software package (Tree Star).  
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2.10. Immunofluorescent staining   
HEK293T cells were cultured and transfected 24 hours post-seeding (see section 
2.6.2). MDA-MB-231 cells (1.4 x 105) were seeded as a monolayer on 6-well 
plates (Nunclon) in 2ml DMEM. Before seeding, sterile 18mm coverslips were 
placed into each well and treated with 1ml Poly-L-Lysine (Sigma) for 1 hour at 
room temperature. For inhibitor treatment on MDA-MB-231 cells, 24 hours after 
seeding, the media was aspirated from cells, they were washed with 2ml PBS 
and then incubated with 20µM GM1006, for 24 hours, in 2ml, FBS-free DMEM 
with high glucose (4.5 g/L; Thermo Fisher Scientific). Forty-eight hours post 
transfection (HEK293T cells) or post-seeding (MDA-MB-231 cells), all the 
medium was aspirated from the wells and cells washed in 2ml PBS (with calcium 
and magnesium). Cells were fixed with 3.7% (w/v) paraformaldehyde (PFA) with 
5% (w/v) sucrose for 15 minutes at room temperature. Cells were washed 3 times 
with 2ml PBS for 2 minutes. Cells which required permeabilisation were then 
incubated with 2ml, 0.1% (v/v) Triton X-100, which had been previously chilled to 
4°C, for 5 minutes. Cells were washed again 3 times with 2ml PBS for 2 minutes. 
All cells were then blocked in 5% (v/v) goat serum (Sigma) in PBS for 1 hour at 
room temperature. Coverslips were then incubated with 200µl of primary antibody 
(mouse, anti-human CD178 (CD95L) NOK-1 clone (BioLegend) at a 1:100 
dilution (in the block buffer), mouse, anti-human CD178 (CD95L) clone G247-4 
at a 1:100 dilution or mouse anti-c-MYC (Sigma) primary antibody at a 1:200 
dilution) for 90 minutes at room temperature. Following 3 washes with 2ml PBS 
for 2 minutes, the coverslips were incubated with 200µl secondary antibody, goat 
anti-mouse Alexa Fluor® 488 (Invitrogen) at a 1:1000 dilution (in the block buffer) 
along with DAPI (4’,6-diamidino-2-phenylindole; Invitrogen) at a 1:1000 dilution, 
for 1 hour at room temperature, in the dark. The final 3 washes were with 2ml, 
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0.05% (v/v) PBS-T for 2 minutes. Coverslips were mounted onto microscope 
slides using FluorSave™ Reagent (Calbiochem) overnight at room temperature 
and stored in the dark at 4°C. MDA-MB-231 cells were viewed on a Leica 
DFC365, epi-fluorescent microscope, with a 63x oil immersion objective with a 
numerical aperture of 1.25. Images were processed and analysed using ImageJ 
(NIH). HEK293T cells were viewed using a Zeiss LSM710 confocal laser 
scanning microscope based on an Axiovert inverted microscope (Carl Zeiss) with 
a 40x oil immersion objective with a numerical aperture of 1.3. Laser lines 488nm 
and 405nm were used to excite Alexa Fluor® 488 and DAPI, respectively. The 
pinhole was set to 1 airy unit. Images were acquired with sequential scanning 
and image processing and analyses were performed using Zen 2010 software 
and ImageJ (NIH).  
 
2.11. RNA extraction, cDNA conversion and RT-qPCR 
analysis 
2.11.1 Isolation of total RNA from human cells  
Small-scale (µg quantities) preparation of total RNA from human cells was carried 
out using the QIAGEN RNeasy® Mini Kit (QIAGEN) as described by the 
manufacturer. Transfected (see section 2.6.1) or untransfected HEK293T cells, 
or MDA-MB-231 cells were harvested, counted and 1 x 107 cells pelleted by 
centrifugation at 300xg for 5 minutes. Media was aspirated, and cells were lysed 
by the addition of 600µl Buffer RLT (supplemented with 1.0% 2-mercaptoethanol) 
with vortexing to disrupt the cell pellet. The lysate was homogenised by 
centrifuging through a QIAshredder spin column (QIAGEN) for 2 minutes at 
14,000xg. One volume of 70% ethanol (Sigma) was added to the homogenised 
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lysate and mixed by pipetting six times. The sample, including any precipitate 
formed, was transferred to a RNeasy spin column (in a supplied 2ml collection 
tube) and was centrifuged for 15 seconds at 8,000xg, after which the flow-through 
was discarded. The column with bound RNA was subsequently washed with 
700µl Buffer RW1 by centrifuging for 15 seconds at 8,000xg followed by two 
further 500µl washes with Buffer RPE using the same spin conditions. In each 
case the flow-through was discarded. The column was transferred to a fresh 2ml 
collection tube and spun for a further minute at 14,000xg to remove any residual 
Buffer RPE from the last wash. Subsequently, the column was transferred to a 
new 1.5ml Eppendorf microcentrifuge tube and 50µl RNase-free water was 
added directly to the spin column before being centrifuged for 1 minute at 
14,000xg to elute the bound RNA. The concentration and purity of the eluted RNA 
was determined by spectrophotometric analysis as described in Section 2.11.2 
and stored at -80°C. 
 
2.11.2 Determination of RNA quality 
RNA concentrations in nucleic acid preparations were determined by 
spectrophotometry by measuring the absorbance at 260nm (A260) using the 
NanoDropND-1000 (ThermoFisher Scientific). The quality of nucleic is indicated 
by the ratio between the absorbance at 260 and 280nm. For pure RNA the 
A260/A280 ratio should be ~2.0. Smaller ratios usually indicate contamination by 
protein or organic chemicals. As a secondary measure of nucleic acid purity, the 
A260/A230 ratio was also measured which should be in the range of 2.0 to 2.2 for 
RNA. Only nucleic acids that passed these criteria were used in downstream 
applications.  
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2.11.3 Reverse-transcription of mRNA to cDNA 
cDNA synthesis was carried out using the GrandScript cDNA synthesis Kit (PCR 
Biosystems) as per the manufacturer’s instructions. Briefly, 1µg RNA (see section 
2.11.1) was mixed with 4.0µl, 5x cDNA synthesis mix (proprietary), 1.0µl reverse 
transcriptase (RTase; proprietary) and nuclease-free H2O to a total volume of 
20µl before incubation at 42°C for 30 minutes, followed by incubation at 70°C for 
10 minutes to denature the RTase. cDNA was stored at -20°C for up to one week 
or used immediately for downstream applications.  
 
2.11.4. RT-qPCR of cDNA using SYBR® Green 
cDNA from the reverse transcription of 1µg mRNA extracted from cells (see 
section 2.11.3) was diluted to 200ng/µl in RNase-free water and used in the 
reaction, as detailed in table 2.3, using SYBR® Green PCR master mix (Thermo 
Scientific) and 20µM of forward and reverse primers for either CD95L or GAPDH. 
Primer sequences were generated using the Harvard Primer Bank (found at: 
http://pga.mgh.harvard.edu/primerbank/) and were purchased from Eurofins 
Genomics (GAPDH) or Sigma (CD95L). A list of primer sequences used is found 
in table 2.4. Each condition was run in triplicate and each 10µl reaction mixture 
was transferred to a well of a 96-well reaction plate (Life Technologies) and the 
plate was sealed using optical adhesive film (Life Technologies). 
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Reagent 
 
Volume (µl)  
SYBR® Green PCR master mix (2x) 
 
5.5 
RNase-free H2O 
 
2.5 
Forward Primer (20 µM) 
 
0.5 
Reverse Primer (20 µM) 
 
0.5 
cDNA (200 ng/µl) 
 
1 
Total Volume 
 
10 
Table 2.3.  RT-qPCR reaction mixture (10 µl total volume) 
 
 
 
Target 
Gene  
 
Forward Primer (5' - 3') Reverse Primer (5' - 3') 
GAPDH 
 
GGCTGCTTTTAACTCTGG GGAGGGATCTCGCTCC 
CD95L 
 
TGCCTTGGTAGGATTGGGC GCTGGTAGACTCTCGGAGTTC 
Table 2.4.  A list of the forward and reverse primer sequences used.  
 
 
 
Stage Temperature Time Number of 
cycles 
 
Initial denaturation 
 
95°C 10 minutes 1 
Denaturation 
Annealing/Extension 
95°C 
60°C 
 
15 seconds 
1 minute 
40 
Hold 72°C 
 
5 minutes 1 
Melt Curve 
 
95°C 
60°C 
95°C 
60°C 
15 seconds 
1 minute 
15 seconds 
15 seconds 
 
1 
1 
1 
1 
Table 2.5. RT-qPCR reaction conditions.   
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The plate was kept on ice before being loaded onto the qPCR machine (7500 
Real Time PCR system, Applied Biosystems) and run with the conditions outlined 
in table 2.5. Ct values were generated using the 7500 software version 2.3 
(Applied Biosystems) using the 'Auto threshold' function. 
 
2.12. siRNA transfection  
2.12.1. siRNA transfection protocol 
MDA-MB-231 cells (3 x 105) were seeded as a monolayer on 6-well plates 
(Nunclon) in 2ml DMEM (Thermo Fisher Scientific) with 5% FBS (Sigma). 24 
hours post seeding, siRNA sequences (see table 2.6) at 20µM, were made up to 
200µl using Opti-MEM (Thermo Fisher Scientific) - mixture A. For the 
oligofectamine (transfection reagent) only control condition, no siRNA was used. 
Oligofectamine transfection reagent (Invitrogen) was mixed in a 1:1 ratio with 
Opti-MEM (equal to the volume of siRNA used) - mixture B. Each mixture was 
incubated at room temperature for 10 minutes. The contents of mixture B was 
then added to mixture A for each condition and incubated at room temperature 
for 25 minutes. Media was aspirated from each well and cells washed with 2ml 
PBS. 800µl Opti-MEM was added to each well (1ml to the non-treated well), and 
the siRNA mixture carefully added to each well. The cells were incubated for 4 
hours at 37°C before adding 500µl of Opti-MEM supplemented with 30% FBS 
(Sigma). 12 hours later, the siRNA mix was aspirated from cells and 2ml DMEM 
added, supplemented with 5% FBS (Sigma). 48 hours following transfection, cells 
were harvested and whole cell extracts prepared (see section 2.7.5). Transfection 
reagent and siRNA against PI3-Kinase C2β were kindly provided by Tania 
Maffucci.  
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siRNA 
name 
siRNA 
target 
Supplier siRNA target sequence (5' - 3') 
 
si-CD95L 07 
 
CD95L Dharmacon GCCCUUCAAUUACCCAUAU 
si-CD95L 08 
 
CD95L Dharmacon GGAAAGUGGCCCAUUUAAC 
Non-
targeting si 
 
N/A 
(control) 
Dharmacon UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
 
si-C2ß 
 
PI3-
Kinase 
C2β 
 
Qiagen AAGAATGCGACGCCTGGCAAG 
Table 2.6. siRNA target sequences.  
 
 
2.12.2. Western Blot analysis for siRNA knockdown 
Whole cell extracts were prepared and analysed by Western blot as detailed in 
sections 2.7.5, 2.7.7, 2.7.8 and 2.7.9. Primary antibodies used were mouse, anti-
human CD178 (CD95L) clone G247-4, anti-β-tubulin (Sigma) and mouse, anti-
human PI3-Kinase C2β (BD Biosciences). Secondary antibody polyclonal goat 
anti-mouse immunoglobulins-HRP (Dako) was used at a 1:2000 dilution for 
CD95L detection, 1:10,000 for β-tubulin detection and 1:10,000 for C2β detection.  
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2.13. IN Cell analysis of microparticle uptake  
2.13.1. Endpoint analysis of particle uptake  
MDA-MB-231 cells (1.4 x 105) were seeded in 6-well plates (Nunclon) in DMEM 
(Thermo Fisher Scientific) supplemented with 2% (v/v) FBS (Sigma) and cultured 
for 24 hours. MPs were coated (see section 2.8) and were added to the cells 
(4.05 x 106 per well) and incubated for a further 24 hours. Unbound MPs were 
removed by washing each well of cells 3 times with 2ml PBS, and gently tapping 
the sides of the 6-well plate to dislodge any particles. Two hours prior to imaging, 
live, adhered cells were stained with 1µg/ml Hoescht (Thermo Fisher Scientific), 
diluted into DMEM (2% FBS). After two hours, cells were washed with 2ml PBS 
to remove any excess stain and then incubated with CellMask™ deep red plasma 
membrane stain (Thermo Fisher Scientific), at a 1:1000 dilution in DMEM (2% 
FBS), for 20 minutes. Cells were washed again with 2ml PBS and DMEM 
supplemented with 5% FBS was added before imaging on the IN Cell Analyser 
6000 (GE Healthcare). Nine fields of view were imaged in each well, using a 40x 
objective with a numerical aperture of 0.6, covering an area of 0.966mm2 and 
capturing ~200 cells per well. The plasma membrane of each cell was imaged 
using the confocal aperture (the pinhole was set to 1 airy unit, (AU)) and a 3-D, 
Z-stack of 6 x 1.7µm slices (excluding the top of the cells) was taken in order to 
capture all particles within the cell. Image processing and analyses were 
performed using the developer software version 1.9.1 (GE Healthcare). The 
software identifies the nucleus and cell membrane based on size and 
fluorescence (blue pixels for the nucleus and red for the membranes). The two 
are linked together to determine the number of cells per well. MPs are identified 
using similar parameters and the number of cells with particles determined by 
linking particles (or foci) to the nucleus and membrane of a cell. Each particle is 
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counted separately, allowing the analyses to calculate the number of particles 
internalised by each distinct cell. Stringencies were introduced to ensure only 
internalised particles were counted including that a particle should be 100% 
surrounded by the cell membrane; even if one pixel of a particle is not, the particle 
is not counted. The outer edge of the membrane was excluded during processing, 
so particles close to outside of the cell were also excluded from the count.  
 
2.13.2. Live-cell imaging of particle uptake 
MDA-MB-231 cells were seeded and then stained as described in section 2.13.1. 
CD95R-Fc coated MPs (section 2.8) were added to cells, 30 minutes prior to 
imaging. The plate was sealed with a breathe-easy® sealing membrane (Sigma) 
and cells supplied with 5% CO2 and kept at 37°C whilst the cells were imaged on 
the IN Cell Analyser 6000. Nine fields of view, which equate to an area of 
0.966mm2, were imaged every 15 minutes for 5 hours. Image processing and 
analyses were performed using the developer software version 1.9.1 (GE 
Healthcare). 
 
2.14. Dynamic light scattering and ζ- potential 
measurements 
MPs were coated (see section 2.8) and samples made up to 1ml PBS. 
Measurements were made using a Zetasizer Nano ZS (Malvern), using a 
disposable folded capillary zeta cell, DTS1070 (Malvern). Measurement settings 
included material selection of polystyrene latex, dispersant of PBS and 
measurements were made at 37°C. Triplicate measurements were made with 10 
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runs, 30 seconds per run per measurement. Size measurements were made prior 
to zeta potential measurements, and particle diameter data are represented using 
the z-average diameter function. The Zetasizer utilises dynamic light scattering 
(DLS) and the Brownian motion of particles for characterisation. The Brownian 
motion of particles or molecules in suspension causes laser light to be scattered 
at different intensities. Analysis of these intensity fluctuations yields the velocity 
of the Brownian motion and hence the particle size using the Stokes-Einstein 
relationship (see equation 2.2).  
 
𝑑𝐻 =  
𝑘𝑇
3 𝜋 ƞ 𝐷
 
Equation 2.2. The Stokes-Einstein equation 
dH = hydrodynamic diameter, k = Boltzmann’s constant, T = absolute temperature, ƞ = viscosity 
and D = diffusion coefficient.  
 
Velocity of the Brownian motion is defined by the translational diffusion coefficient 
(D). The translational diffusion coefficient can be converted into a particle size 
(dH), tracking particles in a vehicle of known viscosity at a known temperature, 
using the Stokes-Einstein equation.  
 
2.15. Statistical analyses 
Mean values are shown, with standard error of the mean (SEM) represented by 
error bars. To compare two groups of data, a Welch’s t test (comparing mean), a 
paired t test (comparing means of paired samples) or Mann-Whitney U 
(nonparametric) test was performed using GraphPad prism 7 (GraphPad 
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Software Inc.). A one-way analysis of variance (ANOVA) was used to analyse the 
differences between the means of three of more independent groups, with 
Bonferroni’s test, to compare every mean with every other mean; this was also 
completed using GraphPad prism 7 (GraphPad Software Inc.). Unless otherwise 
stated, at least three independent experiments were performed before statistical 
analysis.  
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3. Expression and Purification of CD95R-Fc 
Fusion Protein 
3.1. Introduction 
The ability to express and purify large quantities of recombinant protein with a 
high level of purity is important for numerous fields including biomedical study, 
the pharmaceutical industry and biotechnological applications. Well defined 
expression systems involve the use of bacterial, yeast, insect and mammalian 
cells for protein expression. Each system has its benefits and limitations, the 
choice of which usually depends on biochemical properties of the target protein 
(He et al., 2014).   
 
The use of Escherichia coli (E. coli) for protein expression is a popular choice, 
with a large range of vectors and strains available which have been modified for 
successful expression. This system is convenient, inexpensive and it is possible 
to produce high yields of protein. However, due to a lack of some molecular 
chaperones and post-translational modification pathways, many proteins, 
especially eukaryotic proteins misfold when overexpressed, forming cytosolic 
inclusion bodies (Sodoyer, 2004). Protein recovered from these inclusion bodies 
must be denatured, purified and then refolded which adds extra, complicated 
steps to the purification process. Yeast systems are also cost effective and the 
cells can grow to a high density and express large quantities of intra- or 
extracellular recombinant protein (Sodoyer, 2004). Yeast cells can add post-
translational modifications such as disulphide bonds and O- and N-linked 
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glycosylation (Macauley‐Patrick et al., 2005). Still, differences in glycosylation 
patterns of higher eukaryotic proteins expressed in yeast systems are observed 
with over-glycosylation being a common problem. This is important since the 
correct glycosylation patterns of recombinant proteins may be important for their 
biological activity and help to prevent immune responses when used as 
pharmaceuticals (Macauley‐Patrick et al., 2005).  
  
Mammalian and insect cell expression systems are typically described as 
expensive and time-consuming as these cells have longer doubling times and 
high maintenance. However, they are popular choices for expressing very 
complex proteins or proteins which require precise post-translational 
modifications.  Using a baculoviral/insect cell system for expression presents 
numerous advantages over a mammalian system. Insect cells are easy to grow 
on well-defined culture media and the system is safe to use. Yet, the adaptability 
of insect cells lines to large-scale procedures, such as microcarriers, can be 
troublesome (Sodoyer, 2004). Despite this, the insect cell system is the most 
prevalent for obtaining eukaryotic membrane proteins and has been used to 
express a large number of integral membrane proteins (He et al., 2014). 
Eukaryotic membrane proteins are of particular importance as they are key 
players in numerous biological processes and targets of therapeutic drugs and 
antibodies. 
 
CD95R (Fas/APO-1/TNFRSF6) is a death receptor found on the surface of all 
cells (section 1.4). It is best known for its involvement in apoptosis and tissue 
homeostasis by the immune system (Chen et al., 2010). This chapter describes 
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the use of a baculovirus, insect cell expression system to express and purify large 
quantities of mouse CD95R ECD fused to the Fc region of human IgG1. The aim 
is to produce milligram quantities of highly purified CD95R for coating MPs, to 
allow investigation of the mechanism involved in particle uptake.  
 
3.1.1. Baculovirus expression system 
The Baculoviridae are a large family of insect viruses which primarily infect insect 
larvae of the order Lepidoptera, which includes moths and butterflies (van 
Regenmortel et al., 2000). The Baculovirus genome consists of a double-
stranded covalently closed circular DNA that can be 80 to 180 kbp in size 
(Contreras‐Gómez et al., 2014). The genomes of sequenced baculoviruses have 
identified 31 core genes which are conserved, the functions of which can be 
divided into DNA replication and transcription, virion packaging and assembly, 
cell cycle arrest and the primary infection of the insect host midgut cells (oral 
infectivity) (Yang and Zhang, 2012, Contreras‐Gómez et al., 2014). 
 
The life cycle of baculoviruses has been characterised and found to be biphasic, 
with 2 infectious phenotypes: Occluded Virions (OV) and Budded Virions (BV) 
(Yang and Zhang, 2012). Typically, infection of an insect host will begin with 
ingestion of OV, coated in a polyhedrin and P10 protein occlusion body which 
protects the virus from environmental stressors. In the insect midgut, this 
protective coating is degraded by the alkaline environment, releasing baculoviral 
capsids which fuse to and enter the midgut cells; the primary infection. The virus 
then replicates within the midgut cells, and new baculoviral capsids translocate 
to the plasma membrane, budding to form BVs which consist of a single 
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nucleocapsid enclosed in host plasma membrane modified with glycoprotein 
(gp)64 (Jehle et al., 2006) which infect cell to cell; the secondary infection. In the 
second round of infection, BVs will form OVs, which is triggered long after initial 
infection by the very late phase of gene expression, which leads to production of 
polyhedron and p10 in large amounts (Contreras‐Gómez et al., 2014). The 
secondary infection results in release of the OVs after cell lysis and death of the 
insect, which is an important stage in horizontal transmission of infection 
(Contreras‐Gómez et al., 2014).  
 
For gene expression in insect cells, the most commonly used baculovirus vector 
is Autographa californica multiple nucleopolyhedrovirus (AcMNPV) and many 
insect cell lines are highly susceptible to infection by this virus (Contreras‐Gómez 
et al., 2014). The ability of baculoviruses such as AcMNPV to produce large 
quantities polyhedrin and P10 for occlusion body formation is exploited for 
heterologous gene expression. Usually in OV synthesis, the level of polyhedrin 
protein is produced abundantly, accounting for some 50% of the total cell protein 
(Merrington et al., 1997). In cell culture, OV forms of virus for horizontal 
transmission are redundant (budded virus being the key infectious agent) and 
polyhedrin and P10 protein expression is therefore not essential because it is not 
required to produce BVs. Because of this, these redundant genes can be 
replaced by a gene-of-interest under the control of polh and p10 promoters. 
These promoters are ‘very strong’ promoters allowing high expression levels of 
the recombinant protein at the late stage of infection (Merrington et al., 1997). 
However, as these promoters are active in the very late phase when cells 
undergo lysis and release OVs, intracellular proteases are also released which 
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can cause proteolytic degradation of the expressed recombinant protein 
(Brondyk, 2009). Expressing a protein at the early stages of infection or use of 
protease inhibitors can help to prevent this from happening (Contreras‐Gómez et 
al., 2014). In conclusion, baculoviruses such as AcMNPV are engineered to 
replicate as highly infectious BVs which infect cell-to-cell in insect cell culture, 
expressing large quantities of the recombinant protein under the control of strong 
promoters.  
 
3.1.2. Generation of recombinant baculovirus 
The AcMNPV has a circular genome of 130 kbp (Kuzio et al., 1999), which is 
large and difficult to insert a gene-of-interest into. To overcome this, the target 
gene is first cloned into a transfer vector with sequences that flank the redundant 
polyhedrin gene in the baculovirus genome. There are two main systems used to 
generate a recombinant baculovirus. In the first system, the baculovirus and 
transfer vector are co-transfected into insect cells and homologous recombination 
occurs between the sequences of the polyhedrin gene in the viral DNA, and the 
homologous sequences flanking the gene-of-interest in the transfer vector 
(Merrington et al., 1997). In the recombinant virus genome, the gene-of-interest 
then sits in place of the polyhedrin gene, under control of the strong polh 
promotor. The second system uses a 'bacmid', a recombinant baculovirus 
modified so that it can be maintained in E. coli cells. Introduction of a transfer 
vector, containing the target gene, results in the transposition of the target gene 
into the bacmid genome (Je et al., 2001). Selection for the required recombinant 
DNA is carried out in E. coli (Je et al., 2001). The Linton lab uses insect cell 
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recombination systems, the first system described, since some cDNAs have been 
found to be unstable in E. coli (Byrne et al., 2009). 
 
As with all homologous recombination systems, it is necessary to separate the 
recombinant virus from parental virus. A few methods are available to do this. 
Plaque-assays or plaque-purifications are one method, however they are 
generally inaccurate and time consuming due to a low frequency of recombination 
events (which in the first vector systems could be < 1%) (Kitts and Possee, 1993). 
Another method of separation involves the insertion of the E. coli lacZ gene, 
which encodes the ß-galactosidase enzyme which breaks down lactose, into the 
polyhedrin locus under control of the polh promotor (Possee and Howard, 1987). 
Recombination with the gene-of-interest in the transfer vector then removes the 
lacZ gene from the viral genome. Recombinant virus plaques would then be 
colourless when X-gal (5-bromo-4-chloro-3-indolyl ß-D-galactopyranoside) is 
added, since they lack the enzyme to break it down, thus can be differentiated 
from the blue parental plaques. However, issues still arise using this method as 
recombinant plaques can be masked by blue parental plaques (Merrington et al., 
1997).  
 
In order to improve recombination frequency, a unique restriction site (Bsu36I) 
was added at the polyhedron locus to linearize the virus. Double stranded breaks 
are highly recombinogenic and when a transfer vector based on the polyhedrin 
locus is co-transfected with the linear virus, a higher proportion of recombinant 
viruses (30%) are produced (Kitts et al., 1990). Linearization of the baculovirus 
however, decreases transfection efficiency by 15 - 150 fold compared to the 
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circularized virus (Kitts et al., 1990). Further modifications produced 90% 
recovery of recombinant viruses, using the BacPAK6 system (Kitts and Possee, 
1993). This involves the lacZ gene insertion as described earlier, with Bsu36I 
restriction sites flanking genes either side of lacZ. Digestion of BacPAK6 with 
Bsu36I causes linearization and disrupts ORF 1629, which is an essential gene 
for AcMNPV replication (Possee et al., 1991). A transfer vector can be 
constructed containing ORF 1629 and the recombinant gene under the polh 
promotor, restoring infectivity only to the recombinant virus via homologous 
recombination. Bsu36I digestion however, is not always 100% efficient and there 
will still be a mix of recombinant and parental viruses which require purification.  
 
3.1.3. The flashBAC baculovirus expression system  
The flashBAC system (Oxford Expression Technologies; OET) removes the need 
to isolate recombinant from parental virus. The system has similarities to the 
BacPAK6 technology described above. The AcMNPV genome of flashBAC lacks 
part of ORF 1629 and the polyhedron gene is replaced with an origin of replication 
for a bacterial artificial chromosome (BAC) (Hitchman et al., 2009). The BAC 
allows the viral DNA to be propagated within bacterial cells, from which it can be 
isolated and purified. 
 
As before, lack of ORF 1629 prevents virus replication in insect cells. After co-
transfection of the flashBAC DNA and the transfer vector into insect cells and 
homologous recombination, ORF 1629 functionality is restored only to 
recombinant viruses and generation of a wild-type virus is impossible. 
Furthermore, the gene-of-interest in placed under control of the polh promoter, 
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simultaneously removing the BAC sequence (Hitchman et al., 2009). Non-
recombinant virus is unable to replicate and recombinant virus will replicate to 
produce BV which can be harvested from culture medium of transfected insect 
cells for amplification and use. 
 
3.1.4. The flashBAC GOLD expression system 
An improvement on the original flashBAC expression system is flashBAC GOLD 
(OET), which has some further modifications. Genes have been identified in the 
baculovirus genome, which are not necessary for replication in insect cells. These 
include chitinase (chiA) which produces an enzyme with exo- and endochitinase 
activity, responsible (along with cathepsin) for the breakdown of the host cuticle 
for the release of virus for horizontal transmission (Hawtin et al., 1995, Hawtin et 
al., 1997). Using microscopy, chitinase has been found to be targeted to and 
densely packed in a para-crystalline array in the endoplasmic reticulum, of 
AcMNPV infected insect cells (Thomas et al., 1998). As a result, chitinase 
interferes severely with the function and efficacy of the insect cell secretory 
pathway (Saville et al., 2004) which is necessary for the secretion of recombinant 
proteins. Additionally, v-cath, which encodes V-cathepsin, has also been 
removed. V-cathepsin is a protease which is synthesized as an inactive 
proenzyme that accumulates in the endoplasmic reticulum, and is activated by 
chitinase upon cell death (Kaba et al., 2004, Hom et al., 2002). The deletion of 
both chiA and v-cath from the flashBAC Gold baculovirus genome is therefore 
designed to free up more processing space within the endoplasmic reticulum, 
improving the secretory pathway efficacy and yield of recombinant proteins. 
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3.1.5. The flashBAC ULTRA expression system 
The genes p10, p26 and p75 have been deleted from flashBAC ULTRA (OET) 
DNA, along with the modifications already described. Deletion of p10 increases 
polh promoter activity, leading to higher production of recombinant protein over a 
longer timeframe (Hitchman et al., 2010). The removal of both p74 and p26 has 
no effect on viral replication; P74 plays a role in oral infectivity of OV and midgut 
attachment (Faulkner et al., 1997) and p26 codes for a protein of unknown 
function, but has the same 5′ terminus as p10 (Rankin et al., 1986). These further 
modifications remove an unnecessary genetic burden from the recombinant viral 
genome (Hitchman et al., 2010), resulting in a more productive baculovirus 
expression vector.  
 
3.1.6. Insect cells 
Insect cells have the capability to introduce most post-translational modifications 
to recombinant proteins as found in mammalian cells. Asparagine, (N)-linked 
glycosylation occurs at the same site on the recombinant protein in insect and 
mammalian cells (N-X-S/T) (Schwarz and Aebi, 2011). However, glycosylation is 
less complex in insect cells, which add simple oligo-mannose sugar chains 
(Harrison and Jarvis, 2006) compared to complex sugar groups with terminal 
sialic acids in mammalian cells (Contreras‐Gómez et al., 2014). These 
differences can alter the biological characteristics of a recombinant protein 
(Contreras‐Gómez et al., 2014) and potentially cause allergenic reactions in 
humans (Harrison and Jarvis, 2006). However, human CD95R fused to human 
Fc domain has previously been expressed successfully using a baculovirus in 
Sf9 cells, and shown to bind CD95L (Muraki and Honda, 2010). This suggests 
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that the glycosylation is sufficient for functional human CD95R to be expressed, 
folded, trafficked and secreted by insect cells. 
 
The two most common cell lines used for membrane protein expression are 
Spodoptera frugiperda (Sf9/Sf21) and Trichoplusia ni (Hi5) derived from pupal 
ovarian tissue from the fall armyworm and ovarian cells of the cabbage looper, 
respectively (Vaughn et al., 1977, Wickham et al., 1992). Sf9 cells are a clonal 
isolate of the Sf21 cell line and both cell lines exhibit similar properties. Sf21 and 
Hi5 cells are capable of growing in suspension to produce high yields of 
recombinant protein when infected with baculovirus. However, there are often 
differences between the yield and behaviour of heterologous proteins when 
expressed in these two cell lines (He et al., 2014). For example, Hi5 cells have 
been found to be superior to Sf21 cells in producing recombinant ß-galactosidase 
(Wickham et al., 1992). However, this can be variable depending on factors such 
as the protein being expressed (Taticek et al., 2001) and the multiplicity of 
infection (MOI). It is therefore necessary to test expression of a recombinant 
protein empirically in multiple insect cells lines in order to optimise protein 
production using the baculoviral system. 
 
3.1.7. Affinity Chromatography 
Affinity chromatography is a form of liquid chromatography that utilises biological-
like interactions for the separation and specific analysis of sample components 
(Hage, 1999). Affinity chromatography has several advantages since it is an easy, 
fast and selective for capturing a target protein (Hober et al., 2007). 
Staphylococcal protein A (SPA; Protein-A) was one of the first discovered 
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immunoglobulin-binding molecules which has been developed for use in affinity 
chromatography systems (Hober et al., 2007). SPA is a cell wall associated 
protein domain exposed on the surface of Staphylococcus aureus, a Gram-
positive bacterium (Hober et al., 2007). Protein-A has an affinity for IgG from 
various species such as human, rabbit and guinea-pig (Richman et al., 1982) and 
the protein contains a region of five homologous binding domains which are 
independently capable of binding the fragment crystallisable region (Fc region) of 
IgG (Hober et al., 2007). Recombinant proteins which are expressed with an Fc 
tag can exploit this specific affinity for purification purposes. Other forms of affinity 
chromatography such as IMAC (immobilised-metal affinity chromatography) 
makes use of interactions that can occur between immobilized metal ions and 
proteins, for example, nickel ions (Ni2+) and histidine-tagged recombinant 
proteins (Hage et al., 2012). IMAC may not be as specific if other proteins in the 
sample contain naturally occurring histidine residues. These will have an affinity 
for the IMAC matrix and may co-elute with the recombinant protein, resulting in 
significant contamination of the final product (Bornhorst and Falke, 2000). A 
further advantage of using an Fc-tag is that the Fc portion is likely to fold 
independently, and can therefore aid solubility and stability of its partner molecule 
(Czajkowsky et al., 2012, Carter, 2011) potentially improving the yield of fusion 
proteins expressed in E. coli. In the past, some drawbacks of using protein-A 
have been the low binding capacities (below 40mg/ml) and high costs of Protein-
A resins, however, resins are now available with reported dynamic binding 
capacities of over 60mg/ml (GE Healthcare) (Ghose et al., 2014).  
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3.1.8. Functionality of expressed CD95R  
Previous literature has demonstrated that CD95R expressed in insect cells (Sf9) 
can form a stable complex with CD95L expressed in yeast, therefore maintaining 
its functional activity (Muraki and Honda, 2010). Another commonly used assay 
to measure recombinant CD95R functionality, tests its ability to inhibit a well-
described biological function of CD95L, the induction of apoptosis of Jurkat cells 
(Cheng et al., 1994). The functionality of recombinant human CD95R fused to Fc 
(CD95R-Fc) expressed in Chinese hamster ovary (CHO) cells (BioMoti), mouse 
CD95R-Fc expressed in Sf21 insect cells and human CD95R-Fc expressed in 
mouse myeloma (NSO) cells (both sourced from Sigma), was tested by BioMoti 
(Figure 3.1). Briefly, CD95L was incubated with different concentrations of 
CD95R-Fc, and then added to Jurkat cells for 3 hours at 37°C. The Jurkat cells 
are then lysed and the cleavage of caspase substrate Ac-DEVD-AFC was used 
to determine the extent of apoptosis, since apoptosis is paralleled by an 
increased activity of caspases (e.g. caspases 3 and 7). Furthermore, caspase 
activity correlates with the percentage of apoptotic cells determined 
morphologically after staining the cells with propidium iodide and Hoechst-33342. 
EC50 (half-maximal effective concentration) values for each protein were 
calculated and the potency of the three proteins were in the same order of 
magnitude (human CD95-Fc prepared from NSO cells, 807ng/ml, human 
CD95R-Fc prepared from CHO cells, 380ng/ml, and mouse CD95-Fc prepared 
from Sf21 cells, 447ng/ml). 
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Figure 3.1. Human and mouse CD95R-Fc prepared from rodent and insect cells behaves 
similarly to inhibit CD95L-dependent induction of apoptosis in Jurkat cells (BioMoti). 
250ng/ml of CD95L was incubated with increasing concentrations of CD95R-Fc purified from 
different host cells: Human CD95R-FC from Chinese hamster ovary cells (CHO; BioMoti), mouse 
CD95R-Fc from Sf21 cells (Sigma) and human CD95R-Fc from mouse myeloma cells (NSO; 
Sigma). The CD95L/CD95R-Fc mix was then added to Jurkat A3 cells. Cells were lysed and the 
cleavage of the caspase substrate Ac-DEVD-AFC (+/- standard deviation) was measured for each 
protein to determine the extent of apoptosis. EC50 values were calculated as follows: Human 
CD95-Fc, NSO (Sigma), EC50: 807ng/ml; human CD95R-Fc, CHO (BioMoti), EC50: 380ng/ml and 
mouse CD95-Fc, Sf21 (Sigma), EC50: 447ng/ml. 
 
 
Via its interaction with CD95R, CD95L induces apoptosis, which is the key 
physiological feature of death signalling by CD95R/CD95L. This shows that 
across a range of expression systems, mouse and human CD95R-Fc can 
specifically block the CD95R/CD95L interaction, strongly suggesting that the 
recombinant protein is correctly folded, maintains its natural binding ability and 
functionality in a physiologically relevant assay.  
 
In this chapter I describe the use of a baculovirus, insect cell expression system 
to express and purify large quantities of secreted mouse CD95R ECD fused to 
the Fc region of human IgG1. The aim is to produce milligram quantities of highly 
purified CD95R for coating MPs, to allow investigation of the mechanisms 
involved in particle uptake. 
97 
 
3.1.9. Aims of Chapter 3 
• Test expression and secretion of CD95R-Fc in Sf21 and Hi5 cells  
• Determine the optimal MOI of baculovirus to insect cells to maximise the 
yield of CD95R-Fc 
• Optimise batch purification conditions for CD95R-Fc using protein-A resin 
• Optimise buffer exchange of CD95R-Fc for downstream applications 
• Confirm glycosylation of secreted CD95R-Fc  
• Test functionality of CD95R-Fc to coat microparticles (MPs) for uptake into 
MDA-MB-231 cells  
• Test stability of CD95R-Fc and optimise conditions for long term storage 
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3.2. Results 
3.2.1. Generation of baculovirus FlashBAC Gold-CD95R-Fc 
A gene encoding a chimeric fusion protein of the mouse CD95R ectodomain 
fused to the Fc portion of human IgG was sub-cloned into pOET1 transfer plasmid 
by OET (for a description of the construct see Figure 3.2). The recombinant virus 
'FlashBAC Gold-CD95R-Fc' was produced through homologous recombination 
in insect cells as described in section 2.4.2. The recombinant baculovirus was 
used in a series of Sf21 insect cell infections to amplify the baculovirus titre 
(section 2.4.4). Each infection was performed using a low multiplicity of infection 
(MOI; 0.1 = 1 virus per 10 cells) to produce intermediate (p1) and then working 
stocks of baculovirus. The titre of the working stock was measured by plaque 
assay (detailed in section 2.4.3) and determined to be 6 x 107 plaque-forming 
units (pfu) per ml. 
 
3.2.2. Amplification of baculovirus FlashBAC Ultra-CD95R-Fc 
Generation of FlashBAC ULTRA-CD95R-Fc was outsourced to OET due to 
potential improvements in protein expression levels. FlashBac Ultra-CD95R-Fc 
was amplified into a 200ml working stock (section 2.4.4) and the virus titre 
determined by plaque assay (section 2.4.3) as 1.3 x 108 pfu per ml. Both 
baculoviruses were used to express protein under the same conditions (section 
2.4.5). When purified using affinity chromatography (section 2.7.1; Figure 3.5C & 
D) a similar yield and purity of protein was achieved, therefore there was no 
apparent advantage in using the ULTRA virus (section 3.2.4). The baculoviruses 
were used interchangeably for expression, unless specified.  
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Figure 3.2. Protein sequence for recombinant mouse CD95R-Fc.  
In red – CD95R ectodomain, residues 1 to 169 (corresponding to residues 1 to 169 in the native 
mouse CD95R) with the signal sequence underlined (residues 1 to 21), green – peptide linker, 
residues 170 to 176 and blue – Fc region of human IgG, residues 177 to 407. It is unknown 
whether the signal sequence is uncleaved in mature CD95R-Fc; this would need to be determined 
by N-terminal sequencing.  
 
CD95R-Fc Protein Sequence 
                     10                      20                    30                    40                      50 
MLWIWAVLPL  VLAGSQLRVH  TQGTNSISES  LKLRRRVRET  DKNCSEGLYQ 
 
                      60                     70                       80                       90                    100 
GGPFCCQPCQ  PGKKKVEDCK  MNGGTPTCAP  CTEGKEYMDK  NHYADKCRRC 
 
                110                    120                   130                   140                  150 
TLCDEEHGLE  VETNCTLTQN  TKCKCKPDFY  CDSPGCEHCV  RCASCEHGTL 
 
                  160                   170                   180                   190                  200 
EPCTATSNTN  CRKQSPRNRD  IEARMDPKSC  DKTHTCPPCP  APELLGGPSV 
 
                210                  220                    230                    240                     250 
FLFPPKPKDT  LMISRTPEVT  CVVVDVSHED  PEVKFNWYVD  GVEVHNAKTK 
 
                 260                   270                     280                   290               300 
PREEQYNSTY  RVVSVLTVLH  QDWLNGKEYK  CKVSNKALPA  PIEKTISKAK 
 
                  310                 320                    330                 340                      350 
GQPREPQVYT  LPPSRDELTK  NQVSLTCLVK  GFYPSDIAVE  WESNGQPENN 
 
                360                   370                       380                    390                 400 
YKTTPPVLDS  DGSFFLYSKLT  VDKSRWQQGN  VFSCSVMHEA  LHNHYTQKS 
 
LSLSPGK 
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3.2.3. Determining the time course and multiplicity of infection 
required for CD95R-Fc expression 
To optimise the MOI for expression and secretion of CD95R-Fc from Sf21 and 
Hi5 insect cells, three 10ml cultures of each cell type (at 1 x 106 cells/ml) were 
infected with the working stock of FlashBAC Ultra-CD95R-Fc baculovirus at a 
MOI of 3, 1 and 0.1 virus particles per cell (section 2.4.5). An uninfected, control 
culture for each cell type was also cultured alongside the infected cells. The 
cultures were sampled over a 5-day period and the spent media containing the 
secreted fusion protein was analysed by western blot (section 2.7.11; Figure 3.3 
and 3.4). Equal volumes of harvested media were loaded to allow direct 
comparison of secreted CD95R-Fc protein levels (section 2.7.7). 
 
Figure 3.3 demonstrates the presence of CD95R-Fc migrating with an apparent 
molecular weight close to that predicted for the peptide chain; the expected 
molecular weight of 45.7kDa (Figure 3.2). Increasing levels of CD95R-Fc were 
detected as MOI increases. At a higher MOI, more protein is expressed in Hi5 
cells and for Sf21 cells. This is true until day 4, when expression levels remain 
similar across MOIs. At a lower MOI of 0.1, Sf21 cells are more efficient at 
producing CD95R-Fc protein than Hi5 cells, which can clearly be seen by Day 5 
of expression (Figure 3.3E). 
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Figure 3.3. Effect of MOI on the expression and secretion of CD95R-Fc from Sf21 and Hi5 
insect cells.  
Sf21 and Hi5 cells were infected with working stock of FlashBAC Ultra-CD95R-Fc baculovirus at 
a range of MOIs. Samples were collected on days 1 – 5, post infection and subjected to western 
analyses (A – E). Samples from uninfected Sf21 and Hi5 cell cultures were also loaded as 
negative controls. 0.02% of total volume was loaded onto a SDS polyacrylamide gel and proteins 
separated by electrophoresis. The blot was prepared on a PVDF membrane and probed using 
anti-human IgG-Peroxidase (Sigma-Aldrich). 
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Figure 3.4. Effect of time on the expression and secretion of CD95R-Fc from Sf21 and Hi5 
insect cells.  
Sf21 and Hi5 cells were infected with working stock of FlashBAC Ultra-CD95R-Fc baculovirus, 
over 5 days, at a range of MOIs. MOI = 3 for A and D; MOI = 1 for B and E; and MOI = 0.1 for C 
and F. Samples from uninfected Sf21 and Hi5 cell cultures were also loaded as negative controls. 
0.02% of total volume was loaded onto a SDS polyacrylamide gel and proteins separated by 
electrophoresis. The blot was prepared on a PVDF membrane and probed using anti-human IgG-
Peroxidase (Sigma-Aldrich). 
 
Figure 3.4 shows that with a higher MOI, detectable protein expression begins 
earlier and reaches maximal expression a shorter time period. For example, with 
Hi5 cells at MOI = 3, near maximal expression is reached by day 2 (although 
small increments are apparent on day 3 – 5; Figure 3.4D) but with an MOI = 1, 
maximal expression is reached on day 3 (Figure 3.4E). Together these data 
demonstrate that a lower MOI is sufficient to express maximal levels of protein, 
but a longer incubation time is required to reach this level. This is true of both cell 
lines, except for Hi5 cells at a MOI of 0.1, where maximal levels of protein are not 
reached (Figure 3.3E). This demonstrates that a higher MOI is favourable for 
maximum CD95R-Fc yield in Hi5 cells. Sf21 cells however, can produce maximal 
levels of protein using a lower MOI, as long as the incubation time is extended.   
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In conclusion, both cell types are suitable for protein expression under differing 
conditions. Using Sf21 cells and infecting at a low MOI (0.1) is suitable for 
conservative use of the baculovirus working stock. However, the longer 
expression times required result in the lower molecular weight bands present on 
Figure 3.2 and 3.3 at around 37 and 30 kDa. These are likely degradation 
products of CD95R-Fc and their presence is more noticeable in older cultures 
when the recombinant protein is more likely to encounter proteases released from 
lysed insect cells. When using a low MOI, it is therefore important not to leave 
cultures to grow for unnecessary long periods of time to prevent protein 
degradation. When using Hi5 cells however, a higher MOI (MOI = 3) and therefore 
more baculovirus is required for expression but high yields can be recovered after 
72 hours. Since a high MOI results in a synchronous infection, higher protein 
yields are produced and can be recovered in a shorter time, reducing protein 
degradation.  
 
3.2.4. Batch purification of CD95R-Fc  
CD95R-Fc was purified on a test scale from 12ml of spent Sf21 culture medium 
by incubation with 500µl protein-A resin (slurry in 20% ethanol; section 2.7.1). 
The resin consists of a ligand complex based on protein-A, embedded in a cross-
linked, agarose matrix (Hober et al., 2007) which allows purification of CD95R-Fc 
since it binds specifically to the Fc region of the fusion protein (Figure 3.2; 
residues 177 – 407). The resin was washed 3 times with 10 bed volumes of PBS. 
Bound CD95R-Fc was eluted in four fractions using 100mM citric acid (pH 3). 
Samples from each stage of the purification process were separated by SDS-
PAGE, fixed and stained with colloidal blue to show total protein present (section 
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2.7.7, 2.7.8 & 2.7.9; Figure 3.5A). Eluates (E) 1 and 2 show CD95R-Fc at 46kDa, 
with few other proteins present, indicating pure samples with a good level of 
protein recovered. The percentage purity of E1 was estimated as 90% using 
ImageJ (detailed in section 2.7.10). To identify protein losses in the purification 
process, a sample from each fraction was analysed by western blot (section 
2.7.11; Figure 3.5B). Some protein is lost, primarily in the flow through (FT) and 
the first wash (W1), however these were minimal compared to the yield. The 
amount of protein in E1 was estimated using densitometry in comparison with a 
BSA standard curve (Section 2.7.10). 1ml of E1 was found to contain 144µg of 
CD95R-Fc, representing a potential yield of 1.2mg per 100ml culture. Protein 
expressed by both FlashBAC Gold and Ultra viruses in Hi5 cells were also 
purified as described previously. Samples from the first elutions (E1) were 
separated by SDS-PAGE, fixed and stained with colloidal blue (Figure 3.5C) and 
analysed by western blot (Figure 3.5D). The elutions show CD95R-Fc at 46kDa 
on both the gel and western, with no difference in the molecular weight of protein 
expressed by each different baculovirus. The purity of protein recovered along 
with the yield demonstrates an efficient purification process, with both 
baculoviruses producing protein at the same molecular weight. 
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Figure 3.5. Purification of CD95R-Fc. 
(A) 12ml of spent Sf21 cell culture was incubated with 500µl resin. Resin was washed in 3 x 5ml 
PBS and eluted in 4 x 1ml of 100mM citric acid (pH 3). Samples from each fraction were TCA 
precipitated and loaded onto a SDS polyacrylamide gel and the proteins separated by 
electrophoresis, fixed and stained with colloidal blue. SM: Starting Material (0.16% of total volume 
loaded), FT: Flow Through (0.16% of total volume), W1-W3: Wash 1 – Wash 3 (2% of total 
volume), E1-E4: Elution 1 – Elution 4 (2% of total volume), M: Marker. (B) Fraction samples were 
TCA precipitated and loaded onto a SDS polyacrylamide gel and proteins separated by 
electrophoresis. The blot was prepared on a PVDF membrane and probed using anti-human IgG-
Peroxidase (Sigma-Aldrich). SM: 0.016% of total volume loaded, FT: 0.016% of total volume, W1-
W3: 1% of total volume, E1-E4: 0.04% of total volume. (C) Hi5 cells were infected with either 
FlashBAC Ultra-CD95R-Fc or FlashBAC Gold-CD95R-Fc and 12ml of spent media from each 
culture were purified as in (C). Samples from each E1 were loaded onto a SDS polyacrylamide 
gel and the proteins separated by electrophoresis, fixed and stained with colloidal blue. E1: 1% 
of total volume. (D) Samples from each E1 were loaded onto a SDS polyacrylamide gel and 
proteins separated by electrophoresis. The blot was prepared on a PVDF membrane and probed 
using anti-human IgG-Peroxidase (Sigma-Aldrich). E1: 0.05% of total volume. Dashed line on (C) 
indicates other lanes of the same gel which were removed for convenience.  
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In order to optimise resin volume to spent culture media volume, batch purification 
was also carried out using 125µl and 250µl resin using the same method. Yield 
of protein recovered in the first elution for each resin volume, was estimated using 
densitometry in comparison with a BSA standard curve (section 2.7.10 and 
equation 2.1). As described previously, using 500µl resin gave a yield of 144µg 
of CD95R-Fc in the first elution. Using 125µl resin gave a yield of 132µg of 
CD95R-Fc and 250µl gave a yield of 152µg of CD95R-Fc. Using a larger resin 
volume does not therefore lead to increased recovery of protein. Similarly, using 
more resin does not lead to more non-specific binding since using 500µl gave an 
E1 fraction with 90% purity (Figure 3.6A). It is therefore possible to use a smaller 
volume of resin when batch purifying protein from small volumes of spent insect 
cell culture.  
 
 
Figure 3.6. BSA protein quantification of E1 following purification with different resin 
volumes. 
Samples from the first elution fraction following purification of 12ml spent insect cell culture with 
125, 250 and 500µl resin were loaded onto an SDS polyacrylamide gel alongside known 
quantities of BSA. The proteins were separated by electrophoresis, fixed and stained with colloidal 
blue.  
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3.2.5. Optimisation of buffer-exchange following batch 
purification 
In order to use CD95R-Fc in downstream applications (e.g. deglycosylation by 
PNGase F or coating of MPs for incubation with cancer cells), the protein may 
need to be buffer exchanged from 100mM citric acid (pH 3) into a more suitable 
condition such as PBS (pH 7.4). CD95R-Fc in spent insect cell culture (12ml) was 
purified as described previously (section 2.7.1), using 250µl resin, and the first 
elution fraction buffer-exchanged into PBS using a dialysis cassette (section 
2.7.2; 10K MWCO; Thermo Scientific). The protein in the E1 was quantified by 
densitometry in comparison with a BSA standard curve (section 2.7.10 and 
equation 2.1) before dialysis (Figure 3.7A) and after dialysis (Figure 3.7B). The 
‘E1 2µl’ value was used for quantifying CD95R-Fc before dialysis (Figure 3.7A) 
as the relative units for this protein band was within the linear range of BSA 
standards. 1ml of E1 was found to contain 270µg of CD95R-Fc before dialysis 
however, after dialysis E1 was found to contain 150µg of CD95R-Fc representing 
a loss of 44% after dialysis.  
 
 
In order to optimise the recovery of protein during buffer exchange another 
method was investigated. Protein was purified using the same method as 
previously described, then the E1 fraction was buffer exchanged into PBS using 
a PD-10 desalting column (section 2.7.3; GE Healthcare). Samples from each 
1ml fraction collected after buffer exchange were separated by SDS-PAGE 
(section 2.7.8; Figure 3.8A). CD95R-Fc was present in fractions 4 and 5. 
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Figure 3.7. BSA protein quantification of E1 before and after dialysis. 
Samples from the first elution fraction following purification of 12ml spent insect cell culture were 
loaded onto a SDS polyacrylamide gel alongside known quantities of BSA, before (A) and after 
(B) dialysis. The proteins were separated by electrophoresis, fixed and stained with colloidal blue. 
Dashed line on (B) indicates other lanes of the same gel which were removed for convenience.  
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Figure 3.8. Buffer exchange using a PD-10 desalting column. 
(A) Samples from each fraction collected throughout buffer exchange were loaded onto a SDS 
polyacrylamide gel, separated by electrophoresis, fixed and stained with colloidal blue. 1 – 7: 
Fraction 1 to Fraction 7 and M: Marker. Protein is present in fraction 4 and 5. (B) Samples from 
the first elution (E1) after purification and the fractions containing protein after buffer exchange 
(F4, F5; fractions 4 and 5) were loaded onto a SDS polyacrylamide gel alongside known quantities 
of BSA. The proteins were separated by electrophoresis, fixed and stained with colloidal blue. 
 
The protein in E1 before buffer exchange and in fractions 4 and 5 after buffer 
exchange using a PD-10 column, was estimated using densitometry in 
comparison with a BSA standard curve (section 2.7.10 and equation 2.1; Figure 
3.8B). 1ml of E1 was found to contain 142µg of CD95R-Fc before buffer 
exchange. Fraction 5 was found to contain 120µg of CD95R-Fc and fraction 4, 
20µg. The recovery of protein after buffer exchange using a PD-10 desalting 
column is 98%, compared to 56% by dialysis. To buffer exchange small volumes 
of elution from batch purification into PBS, a PD-10 column will therefore be used 
to minimise loss of protein.  
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3.2.6. The recombinant CD95R-Fc expressed by Sf21 and Hi5 
cells is glycosylated 
Differences in glycosylation have been observed when the same recombinant 
protein is expressed in Sf21 and Hi5 cells. For example, when the heavily 
glycosylated, scavenger receptor CD36 is expressed in these two cell lines, 
heterogeneity in glycosylation is observed not only at different sites, but also 
between glycans occupying the same site (Sanders, 2015). To compare the 
glycosylation status of CD95R-Fc expressed in Sf21 cells and Hi5 cells, spent 
culture media from each cell line infected with the working stock of baculovirus, 
was denatured and treated with PNGase F and analysed by western blot (section 
2.7.12 & 2.7.11; Figure 3.9A). PNGase F is an endoglycosidase capable of 
removing all N-linked glycans (Tretter et al., 1991). Digestion of CD95R-Fc 
secreted from both insect cell lines with PNGase F resulted in a slight increase in 
electrophoretic mobility indicating that CD95R-Fc is glycosylated in both cell lines. 
 
 
Figure 3.9. Deglycosylation of CD95R-Fc secreted from Sf21 and Hi5 insect cells using 
PNGase F. 
3µl and 1µl of spent media containing CD95R-Fc from Sf21 and Hi5 insect cells, respectively, 
was treated with 500U of PNGase-F (+ samples) for 2 hours at 37°C. Control samples were also 
loaded, without any PNGase-F (- samples). Samples were loaded onto a SDS polyacrylamide gel 
and the proteins separated by electrophoresis. The blot was prepared on PVDF membrane and 
probed using anti-human IgG-Peroxidase (Sigma-Aldrich).  
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3.2.7. The purified CD95R-Fc can induce microparticle uptake 
in MDA-MB-231 cells   
Purified CD95R-Fc from Sf21 cells was used to coat fluorescent 0.5µm 
polystyrene microparticles (MPs) via passive adsorption (section 2.8). Briefly, 
proteins are incubated with particles at a ratio of 0.5µg CD95R-Fc protein:1µg 
MP, for 90 minutes at 37°C, with mixing every 20 minutes. Adsorption occurs 
based on hydrophobic attractions between the hydrophobic portions of the 
adsorbed ligands and the polymeric surface of the microspheres (Bangs, 2008a). 
The coated particles are then added to MDA-MB-231 cells for 24 hours and 
unbound particles washed off before analysis using flow cytometry (section 
2.9.1). Cells were also incubated with no particles (PBS only, negative control), 
non-coated particles and OET CD95R-Fc expressed in Sf21 cells (commercially-
sourced protein as a positive control). The population of cells was analysed by 
flow cytometry, gating on cells with normal size but including a large range of 
granularity because polystyrene particle uptake will make the cells appear more 
granular (Figure 3.10A). Fluorescence emitted by the fluorescein label of the MP 
was detected in the FL-1 channel. Efficiency of MP uptake was determined by 
measuring the percentage of the gated cells with a fluorescence level above the 
autofluorescence of cells in the absence of particles (Figure 3.10B - E). Patterns 
of fluorescence from representative experiments were overlaid on a histogram 
(Figure 3.11) with distinct peaks which likely represent different numbers of 
internalised MPs per cell. The percentage uptake over the gated population for 
each condition, along with commercially available CD95R-Fc expressed in Sf21 
cells from Sigma, was analysed by ANOVA for 3 independent repeat experiments 
(section 2.15; Figure 3.12).  
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The percentage uptake (the percentage of cells in the population with 
fluorescence levels above the negative control) for the CD95R-Fc purified in-
house was 56 +/- 5% (Figure 3.12A) and was statistically different (P ≤ 0.0001) 
to the mean uptake of non-coated particles, 7 +/- 3%. The mean uptake for the 
positive controls (OET, 60 +/- 4%; Sigma, 61 +/- 3%) were also statistically 
different, P ≤ 0.0001, to non-coated particles. The percentage uptake of MPs 
opsonised with commercially-sourced CD95R-Fc (OET & Sigma) and CD95R-Fc 
made in-house was not statistically different (P > 0.05) suggesting all proteins 
improve uptake with the same efficiency. Uptake of cells incubated with non-
coated particles and with no particles was not statistically different (P > 0.05). 
 
Cells had the highest median fluorescence when coated with the CD95R-Fc 
made in-house (Figure 3.11), indicating a higher number of internalised MPs per 
cell. This is also demonstrated by a larger spread of events and increased side 
scatter (correlating to increased cell granularity as MPs are absorbed) on the 
scatter plot when comparing uptake of in-house CD95R-Fc coated MPS (Figure 
3.10E) to OET coated CD95R-Fc (Figure 3.10D). The median fluorescence of 
cells with particles from 3 independent, repeat experiments was analysed to 
explore this further (Figure 3.12B). Cells incubated with in-house CD95R-Fc 
coated MPs, had a median fluorescence of 72 +/- 12 AFU. Cells incubated with 
MPs opsonised with the Sigma and OET protein had a median fluorescence of 
73 +/- 7 AFU and 52 +/- 2 AFU, respectively.  
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Figure 3.10. CD95R-Fc coating improves uptake of MPs in MDA-MB-231 cells. 
MDA-MB-231 cells were incubated with fluorescent, 0.5µm MPs for 24 hrs and analysed by flow 
cytometry. Results from one representative experiment.  (A) Scatter plot showing forward scatter 
and side scatter correlating with cell size and granularity, respectively. Cells were gated (blue 
line) to eliminate cell debris. 10,000 gated cells were analysed. (B) A scatter plot of cell 
fluorescence (arbitrary fluorescence units) against side scatter (cell granularity, arbitrary units) for 
cells incubated with PBS. (C) A scatter plot of cell fluorescence against side scatter for cells 
incubated with non-coated particles. Percentage of events in the left-hand panel indicates cells 
with no particles and the right-hand panel indicates of cells with particles. (D) A scatter plot of cell 
fluorescence against side scatter for cells incubated with OET (positive control – commercially 
available) CD95R-Fc coated particles. (E) A scatter plot of cell fluorescence against side scatter 
for cells incubated with in-house CD95R-Fc coated particles. 
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Figure 3.11. Histogram displaying uptake of CD95R-Fc opsonised MPs. 
MDA-MB-231 cells were incubated with fluorescent, 0.5µm MPs for 24 hrs and analysed by flow 
cytometry. Cells were gated to eliminate cell debris. 10,000 gated cells were analysed. Results 
were overlain on a histogram, displaying distribution of fluorescence against number of cells 
(counts) for all conditions. Peaks on left, under 10 arbitrary fluorescence units (AFU) represents 
the auto-fluorescence of the cells without particles (green), and peaks to the right indicate cells 
which have taken up particles. Median fluorescence for cells with particles (i.e. above the 
background autofluorescence cut-off of 10 AFU) was 28 AFU for non-coated particles (blue), 55 
AFU for OET CD95R-Fc coated particles (orange), and 64 AFU for the in-house CD95R-Fc 
coated particles (red). The series of peaks on the right likely reflect the number of particles in the 
cell, as labelled.  
 
However, there was no statistical difference between the median fluorescence of 
cells incubated with the positive control proteins and in-house CD95R-Fc coated 
MPs. Therefore, the protein made in-house is as effective as commercially 
available CD95R-Fc at inducing efficient uptake with a similar number of particles 
internalised per cell.  
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Figure 3.12. Statistical analysis of uptake of CD95R-Fc opsonised MPs.  
MDA-MB-231 cells were incubated with fluorescent, 0.5µm MPs for 24 hrs and analysed by flow 
cytometry. Cells were gated to eliminate cell debris. 10,000 gated cells were analysed. Mean and 
SEM values are from three independent, repeat experiments (n=3). Significance was calculated 
by one-way ANOVA; **** P ≤ 0.0001. (A) Mean percentage uptake of cells incubated with no 
particles (negative control), non-coated, Sigma and OET CD95R-Fc (commercially available 
proteins – positive controls) and in-house CD95R-Fc coated particles. In-house, Sigma and OET 
CD95R-Fc coated MP uptake was statistically different to non-coated MPs. (B) Mean median 
fluorescence of cells with particles, incubated with Sigma, OET and in-house CD95R-Fc coated 
particles. There was no statistical difference between these conditions (P > 0.05). 
 
 
Important coating controls were tested to confirm that the CD95R ectodomain 
was the key moiety of the CD95R-Fc fusion protein for cellular uptake (Figure 
3.13A). Particles were coated with either human IgG – Fc fragment (Abcam), to 
control for the Fc portion of CD95R-Fc, or an excess of bovine serum albumin 
(BSA), as this is present in the preparations of CD95R-Fc sourced from Sigma 
and to control for the effect of a non-specific protein coat (section 2.8). These 
additional control samples were run alongside previous conditions for direct 
comparison; no particles (PBS only, negative control), non-coated particles and 
CD95R-Fc expressed and purified in-house. MPs were prepared as described 
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before and incubated with MDA-MB-231 cells before measuring uptake using 
flow cytometry (section 2.9.1). Furthermore, protein expressed in Hi5 cells by 
either the recombinant FlashBAC Ultra-CD95R-Fc or FlashBAC Gold-CD95R-Fc 
baculoviruses, was purified (Figure 3.5C & D), used to coat particles and 
incubated with MDA-MB-231 cells (Figure 3.13B), in order to elucidate any 
differences between protein expressed by each different virus. The percentage 
uptake for each condition was analysed by ANOVA for 3 independent, repeat 
experiments (section 2.15; Figure 3.13A & B).  
 
The percentage uptake for the expressed, in-house CD95R-Fc was 63 +/- 3% 
(Figure 3.13A) and was found to be statistically different (P ≤ 0.0001) to the mean 
uptake of 7 +/- 2% for non-coated particles, 9 +/- 3% for BSA coated particles, 
and 7 +/- 2% for Fc coated particles. The percentage uptake of MPs opsonised 
with BSA or Fc protein was not statistically different to each other (P > 0.05), and 
neither of these proteins was statistically different to non-coated particles. Uptake 
of MPs by cells incubated with non-coated particles was not statistically different 
(P > 0.05) to the level of cellular fluorescence recorded in the absence of 
particles. This suggests that the CD95 portion of the CD95R-Fc fusion protein is 
responsible for the increased uptake seen. 
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Figure 3.13. CD95R is responsible for increased uptake of CD95R-Fc modified particles, 
irrespective of the baculovirus used for expression.  
MDA-MB-231 cells were incubated with fluorescent, 0.5µm MPs for 24 hrs and analysed by flow 
cytometry. Cells were gated to eliminate cell debris. 10,000 gated cells were analysed. Mean and 
SEM values are from three independent, repeat experiments (n=3). Significance was calculated 
by one-way ANOVA; **** P ≤ 0.0001 and ** P ≤ 0.01. (A) Mean percentage uptake of cells 
incubated with no particles (negative control), non-coated particles, BSA, Fc and in-house-purified 
CD95R-Fc coated particles. In-house-purified CD95R-Fc coated MP uptake was statistically 
different to non-coated MPs, BSA and Fc coated MPs. (B) Mean percentage uptake of cells 
incubated with no particles (negative control), non-coated particles, BSA, Fc and CD95R-Fc 
coated particles expressed using FlashBAC Ultra-CD95R-Fc or FlashBAC Gold-CD95R-Fc 
baculoviruses. Uptake of CD95R-Fc coated MPs, expressed using GOLD or ULTRA, were 
statistically different to non-coated MPs, BSA and Fc coated MPs. No difference was observed 
between the CD95R preparations from GOLD or ULTRA viruses. 
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For Figure 3.13B, a similar trend is seen. Percentage uptake for CD95R-Fc 
expressed by the GOLD virus, 46 +/- 11%, and the ULTRA virus, 46 +/- 9%, was 
found to be statistically different (P ≤ 0.01) to the mean uptake of non-coated 
particles, 6 +/- 0.3%, BSA coated, 6 +/- 1% and Fc coated particles, 6 +/- 0.5%. 
There is no statistical difference in uptake when particles have been coated in 
CD95R-Fc which has been expressed using the GOLD or the ULTRA 
baculoviruses (P > 0.05). 
 
3.2.8. Stability and storage of CD95R-Fc prepared in-house  
Following buffer exchange, CD95R-Fc was stored at 4°C in PBS (pH 7.4). In 
order to optimise storage conditions, two batches of protein were expressed by 
Hi5 cells at an MOI of 3, for 72 hours (section 2.4.5). Spent insect cell media was 
collected and CD95R-Fc was purified (as in section 3.2.4) and buffer exchanged 
into PBS. The batches of protein were stored at 4°C for different lengths of time 
and then analysed by Western blot (Figure 3.14A). There is a distinct increase in 
Fc-containing proteins migrating at 30 kDa after 12 weeks storage (lane 1), 
compared to 3 weeks storage (lane 2), indicating a level of protein degradation. 
Sodium azide is not added to the protein samples, since this protein is used to 
coat MPs which are added directly to cells. Therefore, it is possible that 
contamination or bacterial growth are responsible for this degradation. The 
presence of a signal, migrating at around 90kDa in the 12-week sample, may also 
suggest a small amount of aggregated protein on prolonged storage. 
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Figure 3.14. Long-term storage at 4°C leads to CD95R-Fc degradation which impacts 
uptake efficiency.    
(A) Purified and buffer exchanged CD95R-Fc was stored at 4°C for 12 weeks (lane 1) and 3 
weeks (lane 2). Equal weights of each sample (0.05ug) were loaded onto a SDS polyacrylamide 
gel and the proteins separated by electrophoresis. The blot was prepared on PVDF membrane 
and probed using anti-human IgG-Peroxidase (Sigma-Aldrich). (B) Microparticles (MPs) were 
coated in each protein, incubated with MDA-MB-231 for 24 hrs and cells analysed by flow 
cytometry. Cells were gated to eliminate cell debris. 10,000 gated cells were analysed. Results 
from a single experiment are shown. A scatter plot of cell fluorescence (arbitrary fluorescence 
units) against side scatter (cell granularity, arbitrary units) for cells incubated with MPs coated in 
CD95R-Fc stored at 4°C for 12 weeks. Percentage of events in the left hand panel indicates cells 
with no particles and the right hand panel indicates of cells with particles. (C) A scatter plot of cell 
fluorescence against side scatter for cells incubated with MPs coated in CD95R-Fc stored at 4°C 
for 3 weeks. Percentage of events in the left hand panel indicates cells with no particles and the 
right hand panel indicates of cells with particles. 
 
 
The effect of storage time on protein quality was noticeable when the proteins 
analysed in Figure 3.14A, were used to coat MPs, and incubated with MDA-MB-
231 cells (section 2.9.1). Results from a single experiment show that percentage 
uptake for CD95R-Fc after 12 weeks storage at 4°C was 35% (Figure 3.14B), 
representing a decrease in uptake by 44%, in comparison to CD95R-Fc after 3 
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weeks storage at 4°C (uptake 63%, Figure 3.14C). For short-term storage (up to 
3 weeks) of CD95R-Fc, 4°C in PBS (pH 7.4) appears to be reasonably stable, 
with similar rates of uptake to fresh material (56 +/- 5%, Figure 3.12A). 
 
However, for longer term storage, a different solution was required and freezing 
at -20°C was tested with added BSA to act as a cryoprotectant (Koda et al., 2001), 
and as a “carrier” or “filler” protein, protecting dilute protein solutions (under 
1mg/ml) against degradation and loss. Protein was expressed and purified as 
previously described and half was buffer exchanged into PBS (Figure 3.15A; lane 
1) and the other half was buffer exchanged into PBS and BSA (50ug BSA per 
1ug CD95R-Fc, lanes 2 and 3). Lanes 1 and 2 were both stored at 4°C for 3 
weeks after buffer exchange. The presence of smaller molecular weight proteins 
in lane 1 suggest degradation, however the addition of BSA has a protective 
effect for small amounts of time at 4°C. Lane 3 demonstrates protein which was 
frozen after buffer exchange and thawed 3 weeks later, suggesting that protein 
integrity is maintained through a round of freeze-thaw.  
 
These proteins were then used to coat MPs and incubated with MDA-MB-231 
cells, to test the effect of storage and added BSA on particle uptake (Figure 3.15B 
& C). Results from two repeat experiments are similar to previous results, that 
CD95R-Fc-coated MPs improve uptake (PBS, 4°C; 66 +/- 2%) compared to the 
controls: cells only, 0.8 +/- 0.2% and non-coated particles, 5 +/- 0.6%. 
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Figure 3.15. Additional BSA improves CD95R-Fc stability enabling long term storage. 
(A) Purified CD95R-Fc was buffer exchanged into PBS (lane 1) or PBS & BSA (50ug BSA:1ug 
CD95R-Fc; lanes 2 & 3). Protein was stored at 4°C (lane 1 & 2) or -20°C for 3 weeks (lane 3). 
Equal weights of each sample (0.05ug) were loaded onto an SDS polyacrylamide gel and the 
proteins separated by electrophoresis. The blot was prepared on PVDF membrane and probed 
using anti-human IgG-Peroxidase (Sigma-Aldrich). (B) Microparticles (MPs) were coated in each 
protein, incubated with MDA-MB-231 for 24 hrs and cells analysed by flow cytometry. Cells were 
gated to eliminate cell debris. 10,000 gated cells were analysed. Mean and SEM values are from 
two independent, repeat experiments (n=2). Mean percentage uptake of cells incubated with no 
particles, non-coated particles, or CD95R-Fc coated particles, stored in PBS at 4°C, PBS & BSA 
at 4°C or PBS & BSA at -20°C. (C) Mean median fluorescence of cells with particles, incubated 
with CD95R-Fc coated particles, stored in PBS at 4°C, PBS & BSA at 4°C or PBS & BSA at -
20°C.   
 
 
The addition of BSA to CD95R-Fc does not cause a noticeable change in 
percentage uptake of CD95R-Fc coated particles, nor does a round of freeze-
thaw lead to any detrimental effects (PBS & BSA, 4°C; 67 +/- 5%, -20°C; 71 +/- 
0.5%). When the median fluorescence levels are analysed to assess the number 
of MPs taken up per cell, there is a trend toward increased uptake following the 
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addition of BSA to CD95R-Fc and immediate storage at -20°C but there is 
sufficient difference in the two data sets to suggest that these differences 
represent random variability. The median fluorescence for CD95R-Fc in PBS & 
BSA, 4°C was 147 +/- 26 AFU and at -20°C, 153 +/- 28 AFU compared to CD95R-
Fc in PBS only at 4°C, 134 +/- 3 AFU. Therefore, for long-term storage, CD95R-
Fc was buffer exchanged into PBS and BSA, and kept at -20°C.  
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3.3. Discussion  
The baculovirus/insect cell expression system is a useful tool for the expression 
of recombinant protein. In comparison to bacterial, yeast or mammalian cell 
expression, this system is an appealing alternative especially since insect cells 
are capable of post-translational modifications ensuring correct folding. Human 
CD95R ECD fused to human Fc domain has previously been expressed 
successfully using a baculovirus in Sf9 cells and in Bombyx mori (silkworm) 
larvae (Muraki and Honda, 2010). In this chapter, the successful expression and 
purification of mouse CD95R ECD fused with the Fc region of human IgG1, 
expressed in Sf21 and Hi5 cells, is described. The purified CD95R-Fc was used 
to coat MPs that may offer a novel therapeutic method for targeting and delivering 
cytotoxic drugs to cancer cells, reducing the debilitating side effects of current 
chemotherapy regimens. Via an undescribed mechanism, CD95R-Fc coated 
poly(lactic-co-glycolic) acid (PLGA) MPs are internalised and degraded, resulting 
in the release of loaded, cytotoxic compounds. The future development of this 
system is dependent on the production of recombinant CD95R-Fc to characterise 
and optimise therapeutic delivery.  
 
Recombinant virus generated using the flashBAC GOLD system and an ULTRA 
version outsourced to OET were compared as vehicles for expression of CD95R-
Fc. As CD95R-Fc is a type I membrane protein (see section 1.4.1), the N-terminal 
part of the protein is extracellular therefore, the truncated ECD (with no 
transmembrane domain (TMD) to anchor the protein to the membrane) is 
targeted to be secreted by eukaryotic cells. No differences in yield or purity of 
expressed CD95R-Fc from each virus was observed, therefore the two viruses 
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were used interchangeably. CD95R-Fc expression was also tested in Sf21 and 
Hi5 cells. At a lower MOI, the infected cultures require a longer incubation time 
to reach maximal protein expression. This is because at a high MOI, synchronous 
infection can be achieved (Licari and Bailey, 1991) to produce more protein in 
less time. At a low MOI, a smaller fractions of cells are initially infected (Wong et 
al., 1996) and so a small amount of protein is expressed in the same time frame. 
However, the infected insect cells will produce progeny virus budded from the 
plasma membrane resulting in a second round of infection of remaining cells 
(Wong et al., 1996). This requires more time, hence the time delay for maximal 
protein expression. For infection at low MOI, less ‘working stock’ virus is used 
with the advantage of cost efficiency and, time because there is a reduced 
requirement for rounds of baculovirus amplification. Conversely, baculoviral 
infection causes cell lysis, releasing cellular proteins including proteases into the 
surrounding media. Cruz et al. have suggested that at low MOI, with fewer cells 
infected, higher levels of active proteases may be present in the media since cell 
infection decreases protease synthesis (Cruz et al., 1999). It is possible that with 
a low MOI, CD95R-Fc secreted into the surrounding media could be degraded 
by proteases released from lysed insect cells. This may explain the presence of 
lower molecular weight bands on the western blots that appear in the older 
cultures. They are likely degradation products of CD95R-Fc; a disadvantage of 
using a low MOI and longer incubation time. Sf21 cells were found to be superior 
to Hi5 cells at expressing maximal levels of protein with the lowest MOI (0.1). A 
higher MOI is favourable for maximum CD95R-Fc yields in Hi5 insect cells. Hi5 
cells have been found to be 100-fold less efficient at budding baculoviruses in 
comparison to Sf9 cells (Wilde et al., 2014). As use of a low MOI relies on 
production of the progeny virus and a second round of infection, this likely 
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explains why Hi5 cells do not produce maximal levels of protein at a low MOI. Hi5 
cells are generally considered superior for secreting proteins resulting in high 
product yields (Wilde et al., 2014). However, no noticeable difference was 
observed in maximal yields of protein produced by Sf21 and Hi5 cells by day 5 of 
expression. In conclusion, both cell types are suitable for protein expression 
under differing conditions. Using Sf21 cells and infecting at a low MOI is suitable 
for conservative use of the baculovirus working stock, saving time and cost of 
amplifying baculovirus to replenish stocks. This is especially important when 
using the baculovirus/insect cell system for possible large-scale protein 
production in the future. With Hi5 cells, a higher MOI is necessary but high yields 
can be recovered after 72 hours. Since a high MOI results in a synchronous 
infection, higher protein yields are produced and can be recovered in a shorter 
time, reducing protein degradation. Both cell lines were used interchangeably to 
express CD95R-Fc for future work, with appropriate MOIs and incubation times 
to ensure good protein quality.  
 
For purification of the secreted, recombinant protein from the spent culture 
medium, affinity chromatography was used. MabSelect resin (GE Healthcare) 
consists of a highly cross-linked, agarose matrix with a recombinant protein A 
ligand that has a binding specificity similar to native protein-A. The recombinant 
protein-A is specifically engineered to favour an orientated coupling that gives an 
affinity medium with enhanced binding capacity for IgG (Teng et al., 2000). 
Recombinant proteins which are engineered with an in-frame Fc tag can exploit 
this affinity for purification purposes. CD95R-Fc was purified in this manner, in 
batch, with a highly efficient yield and purity of >90%. The yield with 500µl resin 
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was found to be 1.2mg per 100ml culture with minimal losses after buffer 
exchange, which compares favourably with the previously reported yield of 215µg 
per 100ml culture when human CD95R ECD was expressed with an Fc tag via 
baculovirus in Sf9 cells (Muraki and Honda, 2010). Different resin volumes were 
tested and found little difference in the recovery of protein from the same volume 
of culture media. For 12ml culture, 125ul of resin was sufficient, with only a small 
loss of yield compared to 500ul and would ensure conservative use of the 
MabSelect (GE Healthcare). There was little non-specific binding when a large 
excess (500 ul per 12ml culture volume) of resin was used, testament to the 
avidity of the MabSelect for Fc and demonstrating that the washing conditions 
were adequate.  
 
In order to use CD95R-Fc for downstream applications, two buffer-exchange 
protocols were tested to exchange from the elution buffer into PBS. Using a 
dialysis cassette, only 56% of protein was recovered. This is most likely due to a 
combination of factors including hydrophobic regions of the protein interacting 
with the dialysis membrane, and pipetting losses when working with small 
volumes. A PD-10 desalting column, which uses a Sephadex matrix rather than 
a membrane to buffer exchange protein solutions (Healthcare, 2007) gave  much 
higher percentage of recovery. This will prove useful in future batch purifications 
to buffer exchange volumes up to 2.5ml. For a larger elution volume, a different 
method will need to be investigated for buffer exchange. Furthermore, the PD-10 
desalting column dilutes the protein from a 1ml elution, to two 1ml fractions. 
However, these fractions could be pooled and concentrated using a spin column 
if necessary. These columns contain a membrane with a pore size that is chosen 
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to ensure the protein cannot pass through but that will allow excess solution 
through.     
 
In humans, CD95 is glycosylated at two sites in the ECD at N118 and N136 
(Shatnyeva et al., 2011). The mouse sequence of CD95R (Figure 3.2) has a 
conserved sequence for glycosylation at N114 (due to a 4 amino acid deletion 
compared to the human sequence); the site at N136 is not conserved. In silico 
computer modelling has predicted that N136 may play a role for CD95R/CD95L 
interactions since this glycan is in close proximity to CD95L when bound and 
could form an extensive hydrogen bond network with residues 200–204 of CD95L 
(Shatnyeva et al., 2011). However, this is concluded only from modelling; there 
is no crystal structure of CD95R bound to its ligand to verify this. There are two 
other possible N-glycosylation sites in the mouse CD95R-Fc sequence at N43 in 
the ECD and N257 in the Fc region (Figure 3.2). Deglycosylation experiments 
showed that the fusion protein expressed in both Sf21 and Hi5 was glycosylated 
and the protein mobility shifted on deglycosylation with PNGase F to similar 
molecular weights, suggesting no disparity in glycosylation between these 2 cell 
lines. It was not investigated whether all available sites for glycosylation on 
purified CD95R-Fc have glycans attached. The effect of these glycans on protein 
function has yet to be determined here, however, previous experiments have 
shown that both human and mouse CD95R-Fc expressed using cells from 
different organisms (insect, CHO or NSO) are functional and can bind to CD95L, 
neutralising its apoptotic activity in Jurkat cells (BioMoti; Figure 3.1). Since 
glycosylation of recombinant proteins is less complex in insect cells than 
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mammalian cells, this suggests that any disparity in complexity does not result in 
a change of functionality.  
 
As a measure of the functionality of the purified CD95R-Fc, its ability to coat and 
induce uptake of MPs was measured. MDA-MB-231 human breast cancer cells 
were incubated with MPs coated in CD95R-Fc, or non-coated MPs. A small 
percentage of cells were able to internalise non-coated particles. Polystyrene 
particle uptake has been shown to involve a macrophage receptor with 
collagenous structure (MARCO), one of several scavenger-type receptors 
expressed on the cell surface of macrophages (Kanno et al., 2007). When COS-
7 cells were transfected with either MARCO cDNA or an empty vector, the 
MARCO-transfected cells were able to internalise three sizes of polystyrene 
particles; 20nm, 200nm or 1µm, while no obvious uptake of particles occurred to 
the empty vector–transfected cells (Kanno et al., 2007). It is unknown whether 
MDA-MB-231 cells express MARCO however other scavenger-receptors present 
on the cell surface may be responsible for the polystyrene MP uptake seen. This 
background level of internalisation may also be due to hydrophobic interactions 
between the MPs and the surface of the cell which initiates phagocytosis (Ofek 
et al., 1995). However, uptake of CD95R-Fc coated particles in 56 +/- 5% of cells 
was strikingly and significantly enhanced compared to non-coated particles which 
were taken up by only 7 +/- 3% of cells, strongly suggesting that the CD95R-Fc 
coating is responsible for increased uptake. The increase in CD95R-Fc-coated 
MP uptake compared to non-coated MPs, suggests that a targeting mechanism 
may be responsible. However, while flow cytometry is an excellent tool for 
analysis of thousands of cells in a short space of time, one limitation (at least for 
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the FACScan) is that it does not discriminate between surface bound and 
internalised particles. Steps were taken in the procedure to ensure that surface 
particles were washed from cells before flow cytometry (by repeatedly washing 
adhered cells with PBS and tapping the sides of each plate to dislodge any 
unbound particles) but this is difficult to control. A more precise approach to 
investigate whether the particles have been internalised and not simply bound to 
the cell surface was provided by confocal analysis. These data are described in 
Chapter 5.  
 
The uptake of MPs coated with CD95R-Fc purified in-house was not statistically 
different from the uptake of MPs coated with commercially-sourced CD95R-Fc 
(OET & Sigma). The protein provided by OET was expressed from the same 
FlashBAC ULTRA-CD95R-Fc as used here and was purified using a HiTrap 
Protein-A HP column (OET). The Sigma protein is mouse CD95R-Fc and was 
also expressed in Sf21 cells. The amino acid sequence of the Sigma protein is 
similar to the protein expressed in-house (Figure 3.2) but includes a few minor 
differences in the linker region and an extra 6x histidine tag on the Fc portion. 
When analysed by Western blot, the Sigma protein therefore migrates more 
slowly compared to the protein made in-house. The Sigma CD95R-Fc analysed 
in Figure 3.12 was also used in experiments undertaken by BioMoti, to test the 
functionality and ability of CD95R-Fc to block induction of apoptosis in Jurkat cells 
(Figure 3.1). In this experiment the Sigma protein was found to block CD95L-
induced apoptosis in a dose dependant manner (with an EC50 of 447ng/ml). The 
efficacy to block CD95L-induced apoptosis suggests that the Sigma protein is 
correctly folded. It is therefore likely that the protein made in-house, which is 
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>98% identical and also expressed in, and purified from, Sf21 cells, is correctly 
folded because both proteins significantly improve the uptake of MPs in MDA-
MB-231 cells.  
 
The Fc portion of human IgG1 is fused to mouse CD95R to provide a convenient 
mechanism for purification, since protein-A in the MabSelect resin used binds Fc 
with high avidity and specificity. However, it is also possible that the Fc region will 
confer other properties and may also influence the behaviour of the fusion protein 
in the cancer clinic. The Fc domain could improve the plasma half-life and so 
therapeutic activity of the fusion protein since it binds to the salvage neonatal 
receptor (FcRn) which normally protects IgG from degradation (Czajkowsky et 
al., 2012). As seen via live cell imagining in vascular endothelial cells, when IgG 
is taken up it binds to FcRn in sorting endosomes which mature to multi-vesicular 
bodies (MVBs) (Ober et al., 2004). These return to the cell surface where 
exposure to physiological pH of the bloodstream triggers release of ligands back 
into the circulation in prolonged release or ‘kiss-and-run’ exocytosis (Andersen 
and Sandlie, 2009) thereby explaining the long half-life of this class of antibody 
in the serum (Roopenian and Akilesh, 2007). Conversely, the Fc portion may 
have a negative effect on targeting. The Fc portion of human IgG1 can bind to 
Fc-receptors (FcR), which are present on the surface of specialised phagocytes. 
When activated, FcR receptors transduce signals to the cytoplasm, causing 
internalisation of IgG-coated particles (Swanson and Hoppe, 2004). The 
presence of the Fc portion on the surface of MPs could cause uptake of MPs by 
specialised phagocytes in vivo, an off-target effect which should be considered 
and prevented. In the experiments described herein, it is also possible that the 
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Fc portion of the fusion protein contributes to the induction of uptake of coated 
MPs in the MDA-MB-231 cells. There is conflicting evidence as to whether MDA-
MB-231 cells also express Fc receptors. Adams et al. have suggested the 
presence of FcR receptors in MDA-MB-231 cells using flow cytometry (Adams et 
al., 2006) but proteome analysis of this breast cancer cell line did not identify FcR 
(Strande et al., 2009). It was important therefore to control for this possibility. 
Human IgG - Fc fragment (Abcam) was therefore used to coat MPs and their 
uptake into MDA-MB-231 cells was measured. The uptake of Fc-coated particles 
was not statistically different to the uptake of non-coated particles, suggesting 
that it is not responsible for the uptake observed with CD95R-Fc. This is not 
entirely consistent with previous data which showed that mouse IgG-coated MPs 
does give significant uptake (around 55%) in comparison to non-coated MPs 
(around 15%) in MDA-MB-231 cells (Ateh et al., 2011). Although IgG is a larger, 
more complex protein (around 150 kDa) with variable regions, its interactions with 
receptors leading to internalisation are usually via its Fc region (as previously 
discussed; (Swanson and Hoppe, 2004)). Furthermore, the human Fc fragment 
of human IgG is a more relevant control for the mouse-CD95R/human-Fc chimera 
used herein.  
 
Long term storage of the in-house purified CD95R-Fc in PBS at 4°C is not 
recommended due to protein degradation and aggregation. This is not 
uncommon for recombinant proteins as they are often unstable outside their 
native environments. The direct cause for the degradation is uncertain but could 
be due to low level protease contamination from the insect cells or perhaps 
bacterial contamination since sodium azide is not added to the protein samples. 
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The proteolysis of CD95R-Fc had a negative effect on the uptake of coated 
particles. This is could be because the mix of degradation products in the protein 
solution results in inefficient coating of the particles. The particles are coated 
using passive adsorption, a commonly used coating procedure in which the 
CD95R-Fc is attached to the microsphere by incubating the two together. 
Adsorption occurs based on hydrophobic attractions between the hydrophobic 
portions of the adsorbed ligands and the polymeric surface of the microspheres 
(Bangs, 2008a). Impurities or degradation products will compete with the ligand 
for space on the particle surface through relative affinity and relative 
concentration effects, therefore if the concentration of the impurity is very high, it 
could become the principle coating (Bangs, 2008a). The degradation product 
migrating at 30 kDa on Figure 3.14 is the correct size for the Fc portion (and is 
recognised by the anti-IgG antibody), which when used to coat MPs alone, does 
not statistically improve uptake but it could compete for adsorption sites on the 
MP with the full length or CD95R moiety. To prevent proteolysis of the purified 
CD95R-Fc it was frozen in aliquots at -20°C with the stabilising agent, BSA. This 
was shown to be protective against protein degradation for short periods (days) 
at 4°C, and at least 12 weeks at -20°C.  
 
3.3.1. Limitations and possible future directions 
In this chapter I have used passive adsorption to coat polystyrene particles with 
CD95R-Fc and measured their uptake into triple-negative breast cancer cells. 
The main limitations are the use of a chimeric fusion protein, the polystyrene 
particles are not the final delivery vehicle and the method of coating could be 
improved.  
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Passive adsorption is a simple and flexible method of protein attachment, which 
is commonly used. However, it is not easy to measure the efficiency of coating 
before testing MP uptake. Covalent attachment of proteins to the surface of 
functionalised microspheres is another method of coating that could be 
investigated, which means that the proteins are permanently bound in a favoured 
orientation. A microsphere can be functionalised with a carboxyl or amino acid 
group, and then incubated with an activating agent allowing the ligand or other 
coating material to bind directly to the particle surface (Bangs, 2008b). The effect 
of different protein coats on the MPs will be explored further in Chapter 5. 
 
The IgG antibody heavy chain naturally forms a dimer through the hinge regions’ 
cysteine residues and as a result, most Fc-fusions are expressed as disulphide-
bonded homodimers (Czajkowsky et al., 2012). Via SDS-Page analysis, the 
disulphide bonds are reduced so only the monomer can be seen, although the 
presence of band which could correspond to a dimer was noticed after long term 
storage at 4°C (Figure 3.14A). The presence of different oligomeric forms of 
expressed, in-house CD95R-Fc was not investigated. Different oligomers could 
be isolated using size exclusion chromatography, whereby species of different 
molecular weights (i.e. monomeric CD95R-Fc 46 kDa and dimeric 92 kDa) can 
be eluted separately. The effect of the oligomeric forms of CD95R-Fc on particle 
coating and uptake could then be investigated, as they may affect any cell surface 
interactions involved in uptake. Additionally, the Fc region could be cleaved from 
the CD95R-Fc fusion protein post-purification since it does not have a significant 
effect on particle internalisation. For this, it would be necessary to engineer a 
cleavage site into the linker sequence, to allow efficient and specific removal. The 
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tobacco etch virus (TEV) protease for example, can recognise a specific cleavage 
site (Dougherty et al., 1989) and remove a tag from a fusion protein if it is linked 
by this sequence. Furthermore, the purified CD95R cleaved from the –Fc region 
could be incubated with cells, before testing CD95R-Fc coated MP uptake in 
MDA-MB-231 cells, as was done previously in medulloblastoma cells and found 
to block uptake (Ateh et al., 2011). The targeting mechanism of this system will 
be investigated in the next chapter.  
 
In order to test how the in-house CD95R-Fc affects uptake, polystyrene MPs have 
been used here. Further work could involve formulation of PLGA microparticles. 
PLGA is a biocompatible, biodegradable polymer (Anderson and Shive, 2012) 
which can be loaded with drugs to deliver high drug concentrations within solid 
tumours and lower off-target toxicity (Wang et al., 2012). As with polystyrene 
MPs, CD95R-Fc-coated PLGA particles are also preferentially internalised by 
cancer cells (Ateh et al., 2011). PLGA MPs could be formulated to incorporate a 
fluorophore (in order to follow the particle in cell uptake experiments) and to 
deliver a compound that becomes fluorescent on exposure to the cytosol (in order 
to follow drug delivery).  
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3.4. Summary 
A baculoviral/insect system was optimised for expression of recombinant CD95R, 
fused to the Fc region of human IgG1, in Sf21 and Hi5 cells. The protein was 
purified by affinity chromatography with a potential yield of 1.2mg per 100ml 
culture and a purity of 90%. The purified CD95R-Fc was used to coat 
microparticles (MPs) and found to be significantly taken up by MDA-MB-231 
(breast cancer) cells, in comparison to non-coated particles. Stability of the in-
house CD95R-Fc was tested, and long-term storage conditions were optimised. 
The development of this expression system is a crucial first step towards 
characterising the mechanisms involved in uptake. 
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4. Detecting expression of CD95L  
4.1. Introduction 
CD95L (FasL, APO-1L, CD178) is a TNF family member and type II 
transmembrane protein (Locksley et al., 2001). It binds to its receptor CD95R, 
resulting in a pro-apoptotic signalling cascade and cell death. CD95L function 
allows immune cells such as natural killer (NK) cells or activated T lymphocytes, 
to apoptose virally-infected cells. However, CD95L expression has also been 
reported in tumour endothelial cells, which is thought to be a “tumour 
counterattack” against the immune system (Voss et al., 2008). Very recently 
however, there has been a shift in knowledge regarding CD95L expression in 
cancerous cells, by a leading group in the field. They show evidence that the cell-
death observed in cancer cells was not specifically due to the knockdown of 
CD95L, but due to an off-target RNAi mechanism (Putzbach et al., 2017). This 
puts into question some of the previous conclusions made on the expression of 
CD95L in cancer cells and warrants a careful reappraisal of the literature.   
 
4.1.1. CD95L topology   
Human CD95L is a 40kDa protein with 281 amino acids (Figure 4.1; 
Supplementary Figure 7) (Takahashi et al., 1994b, Suda et al., 1993). It has an 
179 amino acid (aa) ECD, an 22 aa transmembrane alpha-helix, an 80 aa 
cytoplasmic domain (Takahashi et al., 1994b) and as a type II transmembrane 
protein, the C-terminal region of CD95L is extracellular. The protein has 3 N-
linked glycosylation sites in the ECD, one intramolecular disulphide bond and a 
unique proline rich domain (PRD), which is not found in other TNF family ligands 
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(Voss et al., 2008). The PRD is involved in CD95L sorting and trafficking via 
protein-protein interactions with different Src homology 3 (SH3) or WW domain 
(named because of the presence of two tryptophan residues in a certain spacing) 
proteins (Lettau et al., 2014). The protein exerts its action as a non-disulphide 
linked homo-trimer, as with other TNF family members, and its oligomerisation is 
dependent on a “self-assembly” region spanning amino acids 137 to 183 (Voss 
et al., 2008). Human CD95L has 76.9% amino acid sequence identity with mouse 
CD95L and there is cross-reactivity of CD95L with CD95R in both human and 
mouse (Takahashi et al., 1994b). CD95L ECD (amino acids 143 - 281) has been 
crystallised as a trimer, in complex with the decoy receptor DcR3; the structure 
was resolved to 2.5 Å (Liu et al., 2014) (see section 1.5.1). 
 
 
 
 
 
Figure 4.1. Human CD95L structure. 
Schematic representation of CD95L structure. The proline rich domain (PRD) is found before the 
transmembrane domain (TMD). The self-assembly region (SA) is thought to be essential for 
CD95L trimerisation. The C-terminal moiety is characterised by its homology to other TNF ligand 
ectodomains (THD). Cleavage sites have been mapped. CD95L contains three putative 
glycosylation sites (N184, N250, N260) and one intramolecular disulphide bridge in the 
ectodomain. Diagram modified from Voss et al., 2008.  For protein sequence, see Supplementary 
Figure 7.  
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CD95L can be released from the cell surface producing a soluble, 26kDa form of 
the protein which remains trimeric. The soluble form of CD95L (sCD95L) exerts 
reduced cytotoxic capacity in comparison to membrane bound CD95L (which is 
referred to here as CD95L, unless stated otherwise) (Tanaka et al., 1998, 
Schneider et al., 1998). However, there is some evidence to suggest that sCD95L 
competes with the membrane form, to bind CD95R without apoptotic activation, 
dampening down the apoptotic response (Chen et al., 1998, Schneider et al., 
1998). The pro- or anti-apoptotic functions of sCD95L depend on other mediators 
in the environment (Askenasy et al., 2005). The proteases responsible for 
shedding of CD95L are matrix metalloprotease 7 (MMP7), ADAM10 and SPPL2A 
(Figure 4.1) which liberates both the CD95L ectodomain and the intracellular 
domain (ICD) (Voss et al., 2008, Kirkin et al., 2007). In T-cells, CD95L shedding 
by ADAM10 is a prerequisite for the intramembrane cleavage by SPPL2A (Kirkin 
et al., 2007). The intracellular domain can translocate to the nucleus and act as 
a transcriptional regulator in a process known as reverse signalling (Kirkin et al., 
2007). This signalling impairs activation-induced proliferation in B and T cells and 
is involved in negative fine-tuning of certain immune responses, such as 
production of antigen-specific immunoglobulin antibodies  (Lückerath et al., 
2010). The deletion of the ICD has been shown to reduce localisation of CD95L 
to lipid rafts, suggesting a role in targeting to or maintenance within the 
membrane rafts (Cahuzac et al., 2006, Glukhova et al., 2018) (section 4.1.4).  
 
Despite being well known for its role in apoptosis, the role of CD95L can vary 
depending on the cellular microenvironment (Voss et al., 2008). Several 
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derivatives of membrane CD95L have been shown to induce inflammation for 
example (Askenasy et al., 2005) (see section 1.5.3).  
 
4.1.2. CD95L expression in immune cells 
CD95L expression can be constitutive or inducible in hematopoietic cells such as 
NK cells and cytotoxic T-lymphocytes (Voss et al., 2008). Due to its cytotoxic 
activity, the expression of CD95L must be tightly controlled to prevent unwanted 
damage. Prior to induction, immune cells were thought to retain CD95L in 
secretory lysosomes via their PRD domains (Blott et al., 2001). When activated, 
for example, by T cell receptor engagement, CD95L is rapidly transported and 
released into the cytotoxic immunological synapse, referred to as the "kiss of 
death" (Voss et al., 2008). However, some studies have not found co-localisation 
of CD95L with classical markers or components of secretory lysosomes, 
suggesting its storage in other cellular compartments (Lückerath et al., 2010, 
Kassahn et al., 2009). Furthermore, in Schwann cells, the adaptor protein Grb2 
has been found to link CD95L to adaptin β and regulate surface expression, 
suggesting a different mechanism for CD95L trafficking and PM expression 
(Thornhill et al., 2008). 
 
4.1.3. N-linked glycosylation of CD95L 
The three putative, N-glycosylation sites in CD95L have been experimentally 
modified but not found to alter receptor binding or trimerization (Voss et al., 2008) 
which could be due to the glycosylation sites being distant from the binding 
interfaces of CD95R (Liu et al., 2014). However, mutations of the putative N-
linked glycosylation sites correlates with reduced CD95L expression in COS-1 
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cell transfectants (Orlinick et al., 1997) suggesting  that glycosylation positively 
affects CD95L maturation and/or stability. Additionally, when expressed in 
HEK293T cells, the presence of all N-linked glycans seem to be essential for 
secretion of sCD95L (Schneider et al., 1998) and glycosylated sCD95L has a 
greater potency for the induction of Jurkat cell apoptosis, in comparison to non-
glycosylated CD95L (Liu et al., 2014). On SDS-PAGE, non-glycosylated CD95L 
was found to experience significant aggregation, perhaps suggesting that 
glycosylation enhances the biological activities of sCD95L by reducing 
aggregation (Liu et al., 2014). Glycosylation of CD95L ectodomain may have a 
further protective effect against degradation of the protein, since it is localised to 
secretory lysosomes in immune cells and so exposed to a hydrolytic environment 
(Voss et al., 2008). This protective effect of N-linked glycosylation has been 
shown for other lysosomal proteins such as Lamp-1 and Lamp-2, where 
deglycosylating the proteins (using  endoglycosidase H)  leads to rapid 
degradation whereas the glycosylated proteins are stable (Kundra and Kornfeld, 
1999).  
 
4.1.4. CD95L localisation in lipid rafts  
Exogenously expressed and endogenous CD95L has been found to constitutively 
partition into lipid rafts (Cahuzac et al., 2006); dynamic assemblies of cholesterol 
and sphingolipids in the outer-leaflet of the lipid bilayer of the plasma membrane 
that are thought to be important for signal transduction (Simons and Toomre, 
2000). CD95L has been found to associate with caveolin-1, a major protein 
component of rafts, likely via the two caveolin-binding sites in the N-terminal 
domain of CD95L (Glukhova et al., 2018). The deletion of these binding sites 
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impairs CD95L distribution between cellular membranes, reducing its cytotoxic 
activity (Glukhova et al., 2018). This could be because the raft environment 
favours the formation of CD95L oligomers, a prerequisite for triggering CD95R-
mediated cell death (Cahuzac et al., 2006). Lipid rafts are considered to be 
important for signal transduction and with binding of CD95L to CD95R, it was 
found that the amount of raft-associated CD95L increases, indicating increased 
CD95L translocation (Cahuzac et al., 2006). However, the mechanism controlling 
this is unclear; whether CD95L must be in the rafts for optimal contact with 
CD95R or whether its interaction with the receptor results in raft localisation. 
 
4.1.5. The history of CD95L expression in cancer cells  
The CD95R/CD95L system has been linked to multiple tumour-promoting 
activities (Peter et al., 2015) (see sections 1.4 and 1.5). It therefore seemed 
consistent that multiple shRNAs and siRNAs targeting CD95L mRNA slowed 
down cancer cell growth (Chen et al., 2010) and caused cell death, via a 
mechanism involving multiple cell pathways labelled ‘death induced by CD95R/L 
elimination (DICE)’ (Hadji et al., 2014). Additionally, CD95L was identified as a 
gene critical for the survival in multiple cancer cell line screens (Hadji et al., 2014). 
However, a more recent publication has found that these phenotypic effects were 
not due to the loss of CD95L, but due to unique off-target effects, predominantly 
from the siRNAs and shRNAs designed specifically against CD95L (Putzbach et 
al., 2017). These si/shRNAs were found to target 3’UTR of critical survival genes 
causing the observed cell death and this effect has now been labelled ‘death 
induced by survival gene elimination’ (DISE) (Putzbach et al., 2017). The authors 
suggest that CD95R and CD95L are not unique in this effect and that there may 
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be many other coding and also noncoding genes that contain sequences which, 
when expressed as si/shRNAs, will be toxic to cells (Putzbach et al., 2017). These 
conclusions are far reaching and raise questions about the previous experiments 
supposedly demonstrating the presence of CD95L in cancer. For example, the 
MCF-7 cells used to show the effect of CD95L knockdown were engineered to 
express a low amount of human CD95L, due to ‘difficulties in detecting CD95L 
by Western blotting’ (supplementary information; (Hadji et al., 2014)). This 
engineered cell line is the only one used to demonstrate successful CD95L 
knockdown using Western blot; other cell lines tested simply show an increase in 
the percentage of sub G1 cells, indicating apoptosis. In fact, the group have 
stated recently that CD95L expression in most cancer cells is barely detectable, 
yet they hypothesised that elimination of the protein induces death more 
effectively in cells that express less CD95L perhaps because it becomes rate 
limiting more easily  (Peter et al., 2015).  
 
Technical difficulties with antibodies have added to the problems, with many of 
the antibodies used to detect CD95L lacking specificity (Sträter et al., 2001). 
When 12 commonly used antibodies were tested for their reliability in 
immunocyto/histochemistry, only 5 did not significantly bind to controls and only 
one was recommended for immunohistochemistry (clone G247-4) (Sträter et al., 
2001). It is therefore important to validate CD95L antibodies with appropriate 
controls and critically re-interpret the literature in light of antibody usage, although 
more recent CD95L publications do use the G247-4 clone. Additionally, many of 
the ELISA kits used to detect CD95L, whether in cell lines or the blood sera of 
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cancer patients, have been discontinued which may also relate to antibody 
validity.  
 
A recent study has reported that tumour endothelium creates an immune barrier 
by expressing CD95L to induce apoptosis in T-cells thus preventing their 
infiltration into the tumour environment (Motz et al., 2014). In this rigorous study, 
they have used the recommended antibodies for Western blot (G247-4), flow 
cytometry (NOK-1) and tissue staining (G247-4) and have also validated these 
antibodies and presented the control data. Evidence of tumour endothelial 
expression of CD95L is shown, but little or no expression of CD95L was evident 
in most tumours; cancer cell lines were not tested. In fact, the authors extended 
the study to test expression of CD95L in tissue microarrays containing over 600 
samples of human breast, colon, renal, bladder, prostate or ovarian carcinomas, 
but in the vast majority of tumours, the tumour cells expressed no or low levels of 
CD95L (Motz et al., 2014). There were a few exceptions, primarily metastatic 
ovarian cancer (as has been previously reported (Abrahams et al., 2003)) and 
colon cancer (CC) tumours, although no p value is stated for CC (Motz et al., 
2014). The authors reached the conclusion that tumour endothelial tissue 
expression is promoted by tumour-derived vascular endothelial growth factor A 
(VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE) suggesting the 
tumour microenvironment is favoured for expression, since very little CD95L is 
expressed in normal endothelial cells (HMVECs). Although not tested in this 
study, CD95L has also found to be expressed by brain tumours (Kleber et al., 
2008, Gratas et al., 1997). The presence of CD95L was also demonstrated via 
IHC staining of clinical samples of glioblastoma (GBM), using G247-4 (with 
144 
 
appropriate staining controls) although expression was not uniform in the tissue 
with increased staining around tumour vessels but small amounts inside the 
tumour (Kleber et al., 2008). This raises further questions regarding expression 
of CD95L by cancer cell lines alone, and potential need of the tumour 
microenvironment for expression of this protein.  
 
4.1.6. The form of CD95L found in tumour cells 
In the few types of tumours and cancer cell lines where CD95L has found to be 
expressed, the form of CD95L found can differ. In addition to the membrane form 
of CD95L and sCD95L, CD95L also appears to be stored and released via 
microvesicles, within multivesicular bodies (MVBs) with CD95L potentially being 
a transmembrane component of the "inner vesicles" (Voss et al., 2008).  
 
CD95L has also been found in the cytoplasm of melanoma cells, confined to 
MVBs which contain melanosomes (Andreola et al., 2002). In these cells, CD95L 
colocalised with melanosomal markers (e.g. gp100) and lysosomal markers (e.g. 
CD63). The intracellular localisation of CD95L was confirmed within melanoma 
cells using immunocytochemistry, immunoelectron microscopy (identifying 
CD95L within melanosomes, contained within multivesicular bodies) and using 
Western blot analysis of the cytoplasmic fractions of melanoma cells; all of these 
techniques utilised the G247-4 antibody. The MVBs were found to degranulate 
extracellularly releasing CD95L-containing microvesicles. Microvesicular CD95L 
maintains its function as it was found to induce apoptosis in lymphoid cells. 
Interestingly, no surface expression of CD95L was detected on melanoma cells 
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using flow cytometry (NOK-1 mAb) or immunoprecipitation of the cell surface 
proteins (NOK-1 and G247-4).  
 
Similarly, ascites-derived epithelial ovarian cancer cells isolated from late stage 
ovarian cancer patients have been reported to lack cell surface CD95L but 
secrete full length, CD95L from an intracellular compartment via the release of 
microvesicles (Abrahams et al., 2003). A heavily glycosylated form of sCD95L 
was also found to be associated with microvesicles, isolated from the ascites fluid 
of ovarian cancer patients (Abrahams et al., 2003) The presence of CD95L was 
confirmed by Western blot (using G247-4) and both forms of CD95L, released 
from the microvesicles, was found to induce apoptosis of Jurkat T cells. 
Intracellular CD95L staining was found to be colocalised with Lamp-1, a 
lysosomal membrane marker, however, the antibody used for this staining (clone 
N-20) had already been shown to lack specificity, so these data may not be 
correct (Sträter et al., 2001).  
 
In contrast to this, surface expression of CD95L has been detected in murine 
glioma cell line SMA-560 via flow cytometry (using the anti-murine CD95L mAb 
MFL3), but only following intracranial implantation indicating a possible 
requirement of tumour/host interaction for expression (Kleber et al., 2008). This 
suggests that the form of CD95L found on, or secreted by, a cancer cell could be 
cell-type and environment specific.  
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MDA-MB-231 cells are a highly invasive, oestrogen-receptor negative, 
adenocarcinoma cell line that is often used as a model for triple negative breast 
cancer, for which there are few treatment options (see section 1.1.5). MDA-MB-
231 cells have been widely reported to express CD95L (Malleter et al., 2013, Hsu 
et al., 2006, Kunigal et al., 2008) although the validity of this evidence is 
questionable, as will be discussed later. This cell line is therefore, a good 
candidate to test a targeted treatment on, such as drug delivery using CD95R-Fc 
coated microparticles. The targeting effect of CD95R-Fc coated microparticles, 
which may explain the enhanced uptake already seen (Chapter 3), depends on 
CD95L being present and on the surface of MDA-MB-231 cells, allowing the 
CD95R to interact with CD95L specifically. In this chapter I therefore set out to 
investigate CD95L expression at the protein and mRNA level in the target cells 
of interest, MDA-MB-231s, as well as using siRNA knockdown to confirm the 
results. Given the controversies in the field, it was important to first validate the 
antibodies to be used. For this purpose, I transiently expressed CD95L in 
HEK293T (human embryonic kidney) cells. These CD95L-expressing HEK293T 
cells, with or without CD95L-sheddase inhibitors, were also tested to determine 
whether they could be used as a tool to investigate the mechanism of CD95R-
coated MP internalisation.  
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4.1.7. Aims of Chapter 4 
• Transiently express CD95L in HEK293T cells to validate anti-CD95L 
antibodies   
• Characterise and localise recombinant CD95L expression in HEK293T 
cells 
• Test the effect of CD95L-sheddase inhibitors on CD95L plasma 
membrane expression in HEK293T cells 
• Investigate CD95L protein and mRNA expression in MDA-MB-231 cells 
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4.2. Results 
4.2.1. Validation of mAb G247-4 by transient expression of 
CD95L in HEK293T cells  
The antibodies used in the past to detect CD95L have been critically analysed 
and many have been found to lack specificity (Sträter et al., 2001). Therefore, it 
is important to validate any anti-CD95L antibodies used here. To do this, 
HEK293T cells were seeded on 6-well plates and transfected with pCMV6-FasLG 
(coding for Myc-DDK-tagged human CD95L; OriGene; section 2.6.1). The 
construct encodes a C-terminally tagged (Myc and FLAG tag; Myc-DDK), CD95L 
protein. As CD95L is a type II transmembrane protein, the C-terminus of CD95L 
is extracellular after the protein has been trafficked to the plasma membrane.   
 
Forty-eight hours post-transfection, transfected and untransfected HEK293T cells 
were lysed and different fractions of lysate (0.0002%, 0.0004% and 0.002%) were 
run on a 10% polyacrylamide gel (section 2.7.6, 2.7.7 & 2.7.8). The protein was 
transferred onto a PVDF membrane and probed using mouse anti-human CD178 
(CD95L) clone G247-4 (BD Pharmingen) (section 2.7.11; Figure 4.2A). In the 
untransfected samples, no CD95L was detected which suggested no (or at least 
very low) endogenous CD95L expression. The strongest signal demonstrates the 
presence of recombinant CD95L-Myc-DDK at the expected molecular weight of 
40kDa (most easily resolved as a discrete band in the lowest loading of 0.0002% 
of whole cell lysate). The lack of CD95L in untransfected cells and detection of 
the 40kDa species in the transfected samples shows that the transient 
transfection was successful. The lower molecular weight signals at 26kDa and 
28kDa could be degradation products or they could potentially correspond to 
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soluble CD95L-Myc-DDK which has been reported previously in the cell lysates 
of CD95L-transfected COS cells (Tanaka et al., 1995) and HEK293T cells (Lettau 
et al., 2014). These two smaller molecular weight proteins could both be soluble 
CD95L-Myc-DDK but with differential glycosylation, leading to differences in 
protein mobility on the gel. A higher molecular weight species migrating between 
approximately 100kDa and 150kDa is also present at lower abundance (being 
most noticeable with the heaviest loading of cell lysate). To better resolve the 
higher molecular weight species seen in Figure 4.2A, 0.002% of the cell lysate 
was run on an 8% gel (Figure 4.2B). The higher molecular weight species has a 
mobility corresponding to 80kDa. 
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Figure 4.2. Validation of mAb G247-4 by transient expression of recombinant CD95L-Myc-
DDK in HEK293T cells. 
HEK293T cells were seeded on 6-well plates and transfected with a vector coding for CD95L-
Myc-DDK. Samples were harvested 48 h post-transfection; cells lysed and different fractions of 
the total volume (0.002%, 0.0004% and 0.0002%) were reduced, denatured and separated by 
SDS-PAGE on a 10% polyacrylamide gel (A) or 0.002% was separated on an 8% polyacrylamide 
gel (B - D). Equivalent fractions of whole cell lysates from untransfected HEK293T cells were also 
blotted for comparison (A). The blots were prepared on a PVDF membrane and probed using 
anti-human CD95L mAb G247-4 (BD Pharmingen; A, B), anti-FLAG (Sigma; C) or anti-c-MYC 
(Sigma; D).  
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To further confirm that the protein detected by G247-4 is the recombinant CD95L-
Myc-DDK protein, the HEK293T cell lysates were analysed on separate Western 
blots probed with anti-FLAG (Figure 4.2C) and anti-c-MYC (Sigma; Figure 4.2D) 
antibodies which should recognise the C-terminal -DDK (FLAG) and -MYC tags 
on the recombinant CD95L, respectively. Both antibodies detected protein and 
the anti-FLAG antibody detected protein migrating at the same molecular weights 
as G247-4 (Figure 4.2B). The anti-c-MYC antibody also detected the 40kDa 
monomeric CD95L-Myc-DDK (Figure 4.2D), however three protein species can 
clearly be seen with similar mobility, which may correspond to differing 
glycosylation of the protein, as described previously (Tanaka et al., 1995). The 
least abundant, higher molecular weight, species were not detected by the anti-
c-MYC antibody (Figure 4.2D). This could be due to the high dilution of antibody 
used and this result would need to be confirmed by running the blot with a higher 
anti-c-MYC concentration.   
 
 
 
Figure 4.3.  2-mercaptoethanol reduces the presence of high-order CD95L species. 
HEK293T cells were seeded on 6-well plates and transfected with a vector coding for CD95L-
Myc-DDK. Samples were harvested 48 h post-transfection, cells lysed and loaded onto an SDS 
polyacrylamide gel in non-reducing (NR – without 2-mercaptoethanol) or reducing (R – with 2-
mercaptoethanol) conditions. Proteins were separated by electrophoresis. The blot was prepared 
on a PVDF membrane and probed using anti-human CD95L mAb G247-4 (BD Pharmingen). 
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It is possible that the 80kDa band corresponds to a CD95L-Myc-DDK aggregate, 
or a higher order oligomer. CD95L functions as an oligomer and the ECD has 
been crystallised as a trimer (Liu et al., 2014). The cell lysate from HEK293T cells 
was run on a gel under non-reducing (without 2-mercaptoethanol) and reducing 
(with 2-mercaptoethanol) conditions; blotted and probed with G247-4 (Figure 
4.3). In the presence of 2-mercaptoethanol, a significant fraction of the higher 
molecular weight species disappears and more of the 40kDa and 25kDa species 
are observed, strongly suggesting that the 80kDa species is a complex that 
contains CD95L-Myc-DDK. Additionally, the reduction of the higher molecular 
weight species suggests that the disulphide bond is present in the ECD (Figure 
4.1), as shown in the crystal structure of CD95L ECD (Liu et al., 2014) (see Figure 
1.2). It is likely therefore that CD95L-Myc-DDK has been trafficked through an 
appropriate oxidative environment, such as through the ER, to allow the 
disulphide bridge to form although it remains a possibility that a non-physiological 
disulphide bond has formed after cell lysis.   
 
4.2.2. Glycosylation status of recombinant CD95L-Myc-DDK 
expressed by HEK293T cells 
Although Western analysis shows the presence of CD95L-Myc-DDK, it does not 
indicate whether the protein is at the cell surface. Plasma membrane expression 
of CD95L-Myc-DDK is required to allow interaction with the CD95R on CD95R-
Fc coated microparticles. The glycosylation status of an expressed protein can 
provide some indication of its subcellular localisation. To identify any differences 
in glycosylation between the lower and higher molecular weight species of 
CD95L-Myc-DDK, whole-cell lysates were treated with Endoglycosidase-H 
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(Endo-H) or Peptide-N-glycosidase-F (PNGase-F) and analysed by Western blot 
(section 2.7.12 & 2.7.11; Figure 4.4) using the G247-4 antibody. Endo-H-
sensitive, high mannose, N-glycans are added to proteins at the amide nitrogen 
of asparagine residues, within the sequon Asn-X-Ser/Thr (where X is any amino 
acid except proline) in the endoplasmic reticulum (Adrain et al., 2012). These 
sugars are then modified in the Golgi apparatus, by a wide variety of 
glycosyltransferases with the use of soluble precursors such as nucleotide sugars 
(Hirschberg et al., 1998), making them resistant to deglycosylation by Endo-H 
(Adrain et al., 2012). PNGase-F is an endoglycosidase capable of removing all 
N-linked glycans (Tretter et al., 1991) by cleavage of the amino acid side chain 
which converts the glycosylated asparagine into an aspartic acid. Differences in 
sensitivity to these two enzymes can therefore help to indicate the location of a 
protein; whether it is in the endoplasmic reticulum with high mannose glycans or 
it has passed through the Golgi and contains mature glycans. To investigate the 
glycosylation status of CD95L-Myc-DDK, a small fraction (0.0002%) of the 
HEK293T cell lysate from a confluent 3cm well, was incubated with each enzyme, 
loaded onto a 10% polyacrylamide gel and analysed by Western blot (Figure 
4.4A). Digestion of CD95L-Myc-DDK with both Endo-H and PNGase-F resulted 
in resolution of the three smaller molecular weight forms, into one form with 
increased electrophoretic mobility, that migrated as a 34kDa protein.  
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Figure 4.4. Deglycosylation by Endo-H and PNGase-F suggest that the higher molecular 
weight species of recombinant CD95L-Myc-DDK has differentially matured glycans.  
Fractions of cell lysate from transfected HEK293T cells, 0.0002% of total volume (see Figure 4.2) 
for (A) and 0.002% for (B) were reduced, denatured and treated with 500U of PNGase-F (+ 
samples) or 1000U of Endo-H (+ samples) for 2 hours at 37°C. Control samples were also loaded, 
without any PNGase-F or Endo-H (- samples). Samples were loaded onto a 10% (A) and 8% (B) 
SDS polyacrylamide gel and the proteins separated by electrophoresis. The blots were prepared 
on a PVDF membrane and probed using mouse, anti-human CD95L mAb G247-4 (BD 
Pharmingen).  
 
 
These data indicate that the glycans on the 34kDa form of CD95L-Myc-DDK 
(which likely represents the monomer peptide) are likely to be of the high 
mannose variety, sensitive to both Endo-H and PNGase-F. This suggests that 
monomeric CD95L is resident in the endoplasmic reticulum and has not passed 
through the Golgi apparatus.  
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This experiment was repeated with a focus on the higher molecular weight 
species (Figure 4.4B); 0.02% of the HEK293T cell lysate was incubated with each 
enzyme and separated on an 8% polyacrylamide gel for improved separation and 
analysed by Western blot. Again, digestion with both Endo-H and PNGase-F 
resulted in an increase in electrophoretic mobility, from approximately 80kDa to 
around 70kDa when treated with PNGase-F, and from 80kDa to two distinct 
signals of around 75kDa and 70kDa when treated with Endo-H. This difference 
in patterns produced by Endo-H and PNGase-F deglycosylation suggest that the 
glycans on the higher molecular weight species could be differentially matured. 
Some glycans are high mannose and sensitive to Endo-H while some appear to 
be resistant. It is likely therefore that those species with mature glycans have, at 
least, passed through the Golgi apparatus. However, it is still not clear whether 
this material is present on the plasma membrane or retained in an intracellular 
compartment.  
 
4.2.3. Expression of CD95L-Myc-DDK at the plasma membrane 
of transiently-transfected HEK293T cells  
The higher molecular weight species has some Endo-H resistant, but PNGase-F 
sensitive glycans suggesting that the protein has passed through the Golgi 
apparatus, however this does not necessarily mean that the protein is present on 
the PM. Flow cytometry was therefore used to assess cell-surface expression of 
the recombinant CD95L-Myc-DDK. HEK293T cells were transfected as 
previously described with pCMV6-FasLG (coding for Myc-DDK-tagged 
Human CD95L; section 2.6.1) or the plasmid pTracer which expresses a green 
fluorescent protein (GFP; to measure transfection efficiency).  Forty-eight hours 
156 
 
post transfection CD95L-Myc-DDK expressing cells were incubated with a 
different anti-CD95L primary antibody; mouse, anti-human CD178 (CD95L) NOK-
1 clone (BioLegend) that is reported to recognise native CD95L and secondary 
antibody, donkey, anti-mouse IgG-FITC (Santa Cruz Biotechnology). The epitope 
of the NOK-1 antibody is located in the ECD of CD95L, between amino acid 
residues 196 and 240. NOK-1 recognises the epitope in the native fold of CD95L 
(Nisihara et al., 2001), and is therefore suitable for use in flow cytometry of intact 
cells. Untransfected cells were also incubated with the antibodies, to control for 
non-specific binding. Analysis by flow cytometry detected fluorescence emitted 
by the secondary antibody or GFP. Patterns of fluorescence from representative 
experiments were overlain on a histogram (Figure 4.5). 
 
Seventy percent of the cell population transfected with pTracer were positive for 
GFP (as marked by the gate on Figure 4.5) and the median fluorescence of the 
entire cell population was 99.4 AFU, demonstrating that transfection conditions 
were efficient. The median fluorescence of the entire population of untransfected 
cells was 3.15 and cells transfected with pCMV6-FasLG, 4.12. The percentage 
of positive cells (the percentage of cells in the population with fluorescence levels 
above 10 AFU) was 5% for untransfected cells and 6% for pCMV6-FasLG 
transfected cells. This suggests that there is no, or little, detectable CD95L-Myc-
DDK on the surface of the transfected HEK293T cells. There is a slight shift in 
median fluorescence in CD95L-Myc-DDK-expressing cells which might suggest 
a few molecules of CD95L-Myc-DDK on the cell surface or could potentially be 
an artefact as a result of the transfection procedure. To test this, mock-
transfected cells should be used as a further negative control. This result could 
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be due to the concentration of antibody used being sub-optimal however, the 
concentration used was as per manufacturers recommendations (≤ 1 µg per 106 
cells in 100 µl volume). 
 
 
 
Figure 4.5. Histogram displays little or no plasma membrane expression of CD95L-Myc-
DDK in HEK293T cells, detected using NOK-1 mAb.   
HEK293T cells were seeded on 6-well plates and transfected with a vector (pCMV6-FasLG) 
coding for CD95L-Myc-DDK, green fluorescence protein (GFP) or left untransfected. Cells were 
harvested 48h post-transfection and pCMV6-FasLG transfected cells incubated with mouse, anti-
human CD95L, NOK-1 clone (BioLegend) and secondary antibody, donkey, anti-mouse IgG-FITC 
(Santa Cruz Biotechnology). Untransfected cells were also incubated with the same antibodies, 
as a negative control. 10,000 cells of normal size and granularity were gated to eliminate cell 
debris and focus on healthy cells. Results from representative experiments were overlain on the 
histogram, displaying distribution of fluorescence (arbitrary fluorescence units; AFU) against 
number of cells (counts) for all conditions. GFP expressing cells (green) were gated (black bar) 
showing a 70% transfection efficiency. Percentage of positive cells and median fluorescence for 
entire cell populations; untransfected cells (red) 5% and 3.15 AFU, for pCMV6-FasLG transfected 
cells (blue) 6% and 4.12 AFU and GFP expressing cells (green) 99.4 AFU.  
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4.2.4. Cellular localisation of recombinant CD95L-Myc-DDK 
transiently expressed in HEK293T cells  
Confocal microscopy was used to further investigate the expression and sub-
cellular localisation of CD95L-Myc-DDK, HEK293T cells were seeded onto glass 
coverslips and transfected with pCMV6-FasLG (section 2.6.1, 2.6.2 & 2.10).  
 
Figure 4.6. No CD95L-Myc-DDK is detected in HEK293T cells using NOK-1.  
(A) Untransfected HEK293T cells or HEK293T cells transfected with pCMV6-FasLG (B and C) 
were fixed using 3.7% (w/v) paraformaldehyde (PFA). Cells were left non-permeabilised (B) or 
permeabilised with 0.1% (v/v) Triton X-100 (A and C). In order to detect CD95L-Myc-DDK by 
immunofluorescence, mouse, anti-human CD95L NOK-1 clone (BioLegend) and goat, anti-mouse 
Alexa Fluor® 488 (Invitrogen) was used. Cell nuclei were stained with DAPI (4’,6-diamidino-2-
phenylindole; Invitrogen). Scale bars, 20µm. Images representative of the whole population are 
shown in each case. There is no positive staining in (A), (B) and (C).   
 
159 
 
 
Figure 4.7. CD95L-Myc-DDK is detected in HEK293T cells using G247-4.  
(A) Untransfected HEK293T cells or HEK293T cells transiently expressing CD95L-Myc-DDK (B 
and C) were fixed using 3.7% (w/v) paraformaldehyde (PFA). Cells were left non-permeabilised 
(B) or permeabilised with 0.1% (v/v) Triton X-100 (A and C). CD95L-Myc-DDK was detected by 
immunofluorescence using mouse, anti-human CD95L G247-4 clone (BD Pharmingen) and goat, 
anti-mouse Alexa Fluor® 488 (Invitrogen). Cell nuclei were stained with DAPI (4’,6-diamidino-2-
phenylindole; Invitrogen). DAPI and G247-4 staining shown in greyscale, merged images in 
colour (DAPI; blue, G247-4; green). Scale bars, 20µm. Images representative of the whole 
population are shown in each case. (A) Untransfected cells have no positive staining, (B) 3% of 
cells have positive, plasma membrane (PM) staining and (C) 18% of permeabilised cells show 
positive staining.  
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Figure 4.8. CD95L-Myc-DDK is detected in HEK293T cells using anti-c-MYC.   
(A) Untransfected HEK293T cells or HEK293T cells transiently expressing CD95L-Myc-DDK (B 
and C) were fixed using 3.7% (w/v) paraformaldehyde (PFA). Cells were left non-permeabilised 
(B) or permeabilised with 0.1% (v/v) Triton X-100 (A and C). CD95L was detected by 
immunofluorescence using mouse, anti-c-MYC (Sigma) and goat, anti-mouse Alexa Fluor® 488 
(Invitrogen). Cell nuclei were stained with DAPI (4’,6-diamidino-2-phenylindole; Invitrogen). DAPI 
and c-MYC staining shown in greyscale, merged images in colour (DAPI; blue, c-MYC; green). 
Scale bars, 20µm. Images representative of the whole population are shown in each case. (A) 
Untransfected cells have no positive staining, (B) 2% of cells have positive, plasma membrane 
(PM) staining and (C) 15% of permeabilised cells show positive staining. 
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Forty-eight hours post transfection, cells were fixed and incubated with either 
mouse, anti-human CD95L, NOK-1 clone (BioLegend; Figure 4.6), mouse anti-c-
MYC (Sigma; Figure 4.8) or mouse, anti-human CD95L clone G247-4 (BD 
Pharmingen; Figure 4.7) primary antibodies and secondary antibody, goat, anti-
mouse Alexa Fluor® 488 (Invitrogen). Cell nuclei were stained with DAPI (4’,6-
diamidino-2-phenylindole; Invitrogen). Prior to staining, cells were either 
permeabilised (to also view possible intracellular protein) or left non-
permeabilised (to view PM expression). Untransfected cells were also 
permeabilised to expose all possible antigens and incubated with the antibodies, 
as a negative control. Immunofluorescence was studied using a confocal, laser 
scanning microscope. 
 
No fluorescence was detected in the untransfected cells showing that under the 
conditions used there was no non-specific binding of the primary or secondary 
antibodies (Figures 4.6A, 4.7A and 4.8A). This is also consistent with the 
conclusions from the Western analyses (section 4.2.1) that HEK293T cells do not 
express CD95L endogenously. No fluorescence was detected when the cells 
were incubated with the NOK-1 antibody (Figure 4.6). The epitope of the NOK-1 
antibody is on the ECD (Nisihara et al., 2001) as is the epitope of the G247-4 
antibody and the -myc tag is C-terminal, so a signal should be detect. This 
antibody is recommended for immunofluorescence and has previously been used 
to detect CD95L in melanoma cells (Andreola et al., 2002). The melanoma cells 
were fixed using 70% ethanol rather than PFA so perhaps the fixation method 
affects functionality of this antibody.  
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In contrast, cells transiently-transfected, permeabilised and stained using the 
G247-4 antibody (Figure 4.7C) and the anti-c-MYC antibody (Figure 4.8C), a 
distinct fluorescent signal was detected in the permeabilised samples (18% and 
15% of cells, respectively), demonstrating expression of CD95L-Myc-DDK. 
Fewer positive cells were detected in non-permeabilised cells (Figure 4.7B, 3% 
of cells and figure 4.8B, 2% of cells), suggesting that in only a small fraction of 
the transfected population CD95L-Myc-DDK is present on the PM. There is a 
noticeable reduction in the number of cells after transfection, compared to the 
untransfected sample. For example, there are 65% and 41% fewer cells in Figure 
4.7B & C respectively, and a 63% and 53% decrease in cell number in Figure 
4.8B & C respectively. The precise intracellular localisation of CD95L-Myc-DDK 
has not yet been determined but co-localisation with an organelle-specific 
antibody such as calnexin (an endoplasmic reticulum marker) or Golgi matrix 
protein (GM130; a Golgi marker), would help to identify the subcellular 
compartment of the protein.  
 
4.2.5. Use of inhibitors to improve plasma membrane 
expression of CD95L-Myc-DDK transiently expressed in 
HEK293T cells  
The levels of detection of intracellular (~20% of cells) and PM CD95L (~2%) are 
low, despite the transfection efficiency being around 70% (Figure 4.5). It is 
possible that CD95L is being cleaved from the PM, since it is known to be a 
substrate of MMP-7 and ADAM10. The effects of two inhibitors of these 
endopeptidases were tested to determine if PM expression of CD95L-Myc-DDK 
could be stabilised. GM1006 (Merck), a cell permeable, broad spectrum MMP 
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inhibitor (of MMP - 1, 2, 3, 7, 8, 9, 12, 14, 26) and GI254023X (Sigma-Aldrich), 
which is marketed as selective ADAM10 inhibitor, were tested for inhibition of the 
MMP-7 and ADAM10, respectively. HEK293T cells were seeded onto glass 
coverslips and transfected with pCMV6-FasLG (encoding human CD95L-Myc-
DDK)\; section 2.6.1, 2.6.2 & 2.10). Twenty-four hours after transfection, cells 
were incubated with 20µM GM1006 or 20µM GI254023X, or both inhibitors in 
combination, in FBS-free media. Forty-eight hours post transfection, cells were 
fixed and incubated with mouse, anti-human CD95L mAb G247-4 and secondary 
antibody, goat, anti-mouse Alexa Fluor® 488. Cell nuclei were stained with DAPI. 
Cells were non-permeabilised to view CD95L-Myc-DDK PM expression and 
immunofluorescence was studied using a confocal laser, scanning microscope. 
 
Transfected cells incubated with the ADAM10 inhibitor GI254023X were 10% 
positive for CD95L-Myc-DDK staining (Figure 4.9A) and 12% of cells were 
positive when incubated with GM1006 (Figure 4.9B). When both inhibitors were 
used in combination, 18% of cells expressed CD95L-Myc-DDK at the cell surface 
(Figure 4.9C). However, cells were observed to be less healthy, which may be an 
additive effect of using both inhibitors. The use of inhibitors seems to have 
increased the amount of CD95L-Myc-DDK present on the PM, when comparing 
this staining to cells transfected without inhibitors (Figure 4.7B, 3% of cells and 
figure 4.8B, 2% of cells). Despite the apparent effects however, the amount of 
positive staining of CD95L-Myc-DDK on the PM is still low, in comparison to the 
transfection efficiency.  
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Figure 4.9. PM expression of CD95L-Myc-DDK in HEK293T cells is improved with inhibitors 
of MMP-7 and/or ADAM10.  
HEK293T cells transiently expressing CD95L-Myc-DDK (A, B and C) which were incubated with 
inhibitors 24 hours before being fixed using 3.7% (w/v) paraformaldehyde (PFA). CD95L was 
detected by immunofluorescence using mouse, anti-human CD95L G247-4 clone (BD 
Pharmingen) and goat, anti-mouse Alexa Fluor® 488 (Invitrogen). Cell nuclei were stained with 
DAPI (4’,6-diamidino-2-phenylindole; Invitrogen). DAPI and G247-4 staining shown in greyscale, 
merged images in colour (DAPI; blue, G247-4; green) Scale bars, 20µm. Images representative 
of the whole population are shown in each case. (A) Cells incubated with 20µM GI254023X 
(Sigma-Aldrich) with 10% of cells with positive staining, (B) Cells incubated with 20µM GM1006 
(Merck) with 12% of cells with positive staining and (C) Cells incubated with 20µM of both 
inhibitors with 18% of cells with positive staining. 
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Flow cytometry was used to more accurately quantify the effect of the inhibitors 
and determine the amount of PM CD95L-Myc-DDK on a larger sample of cells. 
The epitope of the G274-4 antibody is located on the ECD of CD95L although the 
exact location is unknown (personal communication, BD Pharmingen), however, 
this antibody is not usually recommended for flow cytometry. Due to the success 
of this antibody in staining and Western blot however, its use was optimised for 
use in flow. Firstly, the antibody was titrated against untransfected HEKs 
(Appendix 1 - Supplementary Figure 1), as was the anti-c-MYC antibody (to 
validate the results since the -myc tag is C-terminal; Appendix 1 - Supplementary 
Figure 3) to ensure there was no non-specific binding of these antibodies. The 
secondary antibody was also bound alone to ensure no non-specific binding 
(Appendix 1 – Supplementary Figure 2). Secondly, transfected HEKs (expressing 
CD95L-Myc-DDK) were incubated with 20µM GM1006 and working 
concentrations of both antibodies titrated against the cells (Appendix 1 – 
Supplementary Figures 5 & 6). This demonstrated that both the G274-4 and anti-
Myc antibodies detect the same population of transfected cells, and an 
appropriate working concentration (1µg mAb per 106 cells) was selected for both.  
 
HEK293T cells were transfected with pCMV6-FasLG or with pCINeoCD36-12His 
(mock transfection) or a plasmid which expresses a green fluorescent protein 
(GFP; to measure transfection efficiency; section 2.6.1). Twenty-four hours after 
pCMV6-FasLG transfection, cells were incubated with 20µM GM1006, in FBS-
free media. A well of pCMV6-FasLG transfected cells were also left without any 
inhibitor to compare the effects on PM expression.  
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Figure 4.10. Histograms displaying plasma membrane expression of CD95L-Myc-DDK in 
HEK293T cells incubated with GM1006. 
HEK293T cells were seeded on 6-well plates and transfected with a vector (pCMV6-FasLG) 
coding for CD95L-Myc-DDK, CD36-12His (mock-transfected), green fluorescence protein (GFP) 
or left untransfected. CD95L-Myc-DDK expressing cells were incubated with 20µM GM1006 
(Merck) inhibitor in FBS free media, 24 hours before harvesting. Untransfected, mock-transfected 
(negative controls) and CD95L-Myc-DDK expressing cells were incubated with primary antibody 
mouse, anti-human CD95L G247-4 clone (BD Pharmingen) and goat, anti-mouse Alexa Fluor® 
488 (Invitrogen). 10,000 cells of normal size and granularity were gated to eliminate cell debris. 
Results from representative experiments were overlain on the histogram, displaying distribution 
of fluorescence (arbitrary fluorescence units; AFU) against number of cells (counts) for all 
conditions. Cells were gated (black bar) to give percentage of positive cells and median 
fluorescence for the entire population was also calculated. (A) Untransfected cells (red) were 
1.1% positive which had a median green fluorescence of 2.8 AFU, mock-transfected (purple) 
0.8% positive with 3.41 AFU and GFP expressing cells (green) were 64% positive with 42 AFU. 
(B) Untransfected cells (red) were 1.1% positive with 2.8 AFU, pCMV6-FasLG transfected cells 
(blue) 10% positive with 4.14 AFU and pCMV6-FasLG transfected cells with GM1006 (orange) 
12% positive with 3.9 AFU.    
 
 
The concentration of GM1006 had previously been titrated from 1 - 100 µM on 
transfected HEKs to ensure 20µM was the most appropriate concentration 
(Appendix 1 - Supplementary Figure 4). Forty-eight hours post transfection, cells 
were incubated with mouse, anti-human CD95L mAb G247-4 and Alexa Fluor® 
488 (section 2.9.3). Untransfected and mock transfected cells were also 
incubated with the antibodies, as negative controls. Analysis by flow cytometry 
detected fluorescence emitted by the secondary antibody or GFP. Patterns of 
fluorescence from representative experiments were overlain on histograms 
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(Figure 4.10). The percentage of positive cells and median fluorescence over the 
whole cell population for each condition, was analysed by ANOVA for 3 
independent, repeat experiments (section 2.15; Figure 4.11). 
 
In Figure 4.10A, cells were mock-transfected to ensure that the shift in median 
fluorescence (as first observed in Figure 4.5) for pCMV6-FasLG transfected cells 
was not an artefact. The negative control conditions shift from 2.8 AFU 
(untransfected) and 3.41 AFU (mock-transfected; Figure 4.10A) to 4.14 AFU 
(pCMV6-FasLG transfected) and 3.9 AFU (pCMV6-FasLG and GM1006; Figure 
4.10B). There is also a change in percentage of positive cells. The gate was 
positioned such that fewer than 2% of the cells were positive in the controls 
(Figure 4.10A). CD95L-Myc-DDK positivity was detected in 10% and 12% in the 
transfected cells and in transfected cells treated with GM1006, respectively 
(Figure 4.10B). These data suggest that the peak shift in CD95L-Myc-DDK 
expressing cells is not an artefact and there are a few molecules of CD95L-Myc-
DDK detectable on the cell surface (as was also seen using the NOK-1 antibody; 
Figure 4.5). Furthermore, GM1006 increased the percentage of positive cells 
suggesting that it prevented cleavage of CD95L-Myc-DDK from the PM. This 
population of cells is noticeable as a small shoulder around 20 – 50 AFU in 
CD95L-Myc-DDK expressing cells treated with GM1006 (Figure 4.10B; orange) 
and similar patterns were seen when the anti-C-MYC antibody was used in to 
detect CD95L-Myc-DDK in flow (Appendix 1 – Supplementary Figure 6).  
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Figure 4.11. Statistical analysis demonstrates little plasma membrane expression of 
CD95L-Myc-DDK in HEK293T cells incubated with GM1006. 
HEK293T cells were seeded on 6-well plates and transfected with a vector coding for CD95L-
Myc-DDK or left untransfected. CD95L-Myc-DDK expressing cells were incubated with 20µM 
GM1006 (Merck) inhibitor in FBS free media, 24 hours before harvesting. Protein was detected 
using primary antibody mouse, anti-human CD95L G247-4 clone (BD Pharmingen) and goat, anti-
mouse Alexa Fluor® 488 (Invitrogen). 10,000 cells of normal size and granularity were gated to 
eliminate cell debris. Mean and SEM values are from three independent, repeat experiments 
(n=3). Significance was calculated by one-way ANOVA; * P ≤ 0.05. (A) Mean percentage of 
positive cells (CD95L-Myc-DDK expressing) without and with inhibitor, in comparison to 
untransfected cells. CD95L-Myc-DDK cells alone and with GM1006 inhibitor had statistically 
significant staining in comparison to untransfected cells. (B) Median fluorescence of cells 
untransfected, expressing CD95L-Myc-DDK without and with GM1006. There was no statistical 
difference between conditions.  
 
 
 
 
The percentage of positive cells and median cell fluorescence over the whole cell 
population for untransfected cells, CD95L-Myc-DDK expressing cells and 
CD95L-Myc-DDK expressing cells incubated with GM1006 was analysed by 
ANOVA for 3 independent, repeat experiments (section 2.15; Figure 4.11).   
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The percentage of cells expressing CD95L-Myc-DDK averaged 11 +/- 2%, which 
increased to 13 +/- 2% when incubated with GM1006 (Figure 4.11A). Both values 
were statistically different (P ≤ 0.05) to untransfected cells (0.6 +/- 0.3%). Despite 
there being a trend towards increased PM staining when using the inhibitor, there 
was no statistical difference between CD95L-Myc-DDK cells with or without 
GM1006 (P > 0.05). Although there is a significant increase in percentage 
staining with transfected cells however, the increase is not enough to shift the 
median fluorescence of the entire cell population (Figure 4.11B). There is 
therefore no statistical difference between the conditions, regardless of CD95L 
expression (median fluorescence of the untransfected cells, 3.5 +/- 0.5 AFU; 
CD95L-Myc-DDK, 5 +/- 0.4 AFU; and CD95L-Myc-DDK treated with GM1006; 4 
+/- 0.7 AFU). In conclusion, these data fit with what was seen by flow cytometry 
using the NOK-1 antibody and the confocal staining data using anti-C-MYC and 
G247-4. There is very little detectable PM expression of CD95L-Myc-DDK, even 
with the use of inhibitors to prevent surface cleavage of the protein. This makes 
the use of transfected HEKs for further study of uptake of CD95R-Fc coated 
particles impractical since there is not a large enough population of CD95L 
positive cells and it is difficult to distinguish the increase in abundance of CD95L-
Myc-DDK at the PM over the non-expressing cells. However, the antibodies used 
to detect native CD95L, particularly G247-4, have been validated. The anti-C-
MYC, anti-FLAG and G247-4 antibodies gave comparable results when used in 
western. G247-4 can also be used for immunofluorescent staining and flow 
cytometry, as was validated by using the anti-C-MYC antibody, (which was tested 
in IF against a positive control, myc-tagged PGP, data not shown). The G247-4 
antibody could be further validated by testing it with a positive control; a cell line 
or tissue with endogenous CD95L expression.  
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4.2.6. Detecting message for CD95L in MDA-MB-231 cells by 
RT-qPCR  
The targeting effect of CD95R-Fc coated microparticles depends on CD95L being 
present and on the surface of MDA-MB-231 cells, allowing the CD95R to interact 
with CD95L specifically. Messenger RNA (mRNA) is required to produce protein, 
so to test for the presence of CD95L mRNA, real-time quantitative PCR (RT-
qPCR) was utilised. RNA was extracted from MDA-MB-231 cells, and from 
untransfected HEKs and transfected HEKs expressing CD95L-Myc-DDK as 
negative and positive controls, respectively (section 2.11.1 & 2.11.2). Copy DNA 
was synthesised and diluted to the same concentration (200ng/µl; section 
2.11.3). CD95L primers (forward and reverse; Sigma, table 2.4) and GAPDH 
primers (housekeeping gene control; EuroFins Genomics) were mixed with each 
cDNA sample and SYBR™ Green master mix (Thermo Scientific; section 2.11.4).  
Samples were amplified in triplicate for 40 cycles on a 7500 Real Time PCR 
system (Applied Biosystems) and Ct (cycle threshold) values were calculated 
using the 7500 software version 2.3 (Applied Biosystems). Amplification plots for 
CD95L expression and the house-keeping gene control (GAPDH) are shown 
(Figure 4.12). The Ct mean for CD95L-Myc-DDK expressing HEKs was 13.34 
demonstrating the abundant presence CD95L mRNA in the transfected cells 
(Figure 4.12A). This Ct mean was much higher from MDA-MB-231 cells (30.65) 
suggesting that CD95L mRNA was lower in the MDA-MB-231 cells than the 
untransfected HEK293T negative control (27.88).  
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Figure 4.12. RT-qPCR analysis demonstrates little CD95L mRNA in MDA-MB-231 cells. 
Representative amplification plots showing delta Rn (normalised reporter value; fluorescent 
signal) against cycle number for detection of CD95L in triplicate for (A) CD95L-Myc-DDK 
expressing HEK293T cells (positive control; green), Ct (threshold cycle) mean 13.34, 
untransfected HEK293T cells (negative control; blue) Ct mean 27.88 and MDA-MB-231 cells (red) 
Ct mean 30.65. (B) Detection of GAPDH mRNA in HEK293T cells expressing CD95L-Myc-DDK 
(green) Ct mean 18.84, untransfected HEK293T cells (blue) Ct mean 17.15 and MDA-MB-231 
cells (red) Ct mean 15.40. 
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The Ct mean for GAPDH (housekeeping gene control) was 18.84 for HEK293T 
cells expressing CD95L-Myc-DDK and 17.15 for untransfected HEK293Ts. For 
MDA-MB-231s, the Ct mean for GAPDH was 15.40. Therefore, there is very little 
CD95L mRNA present in MDA-MB-231 cells, in comparison to the house-keeping 
control (GAPDH).    
 
4.2.7. Endogenous expression of CD95L in MDA-MB-231 cells  
A gene’s mRNA level does not always predict its protein level. For example, the 
low amount of CD95L mRNA detected in MDA-MB-231 cells does not mean there 
is low amounts of protein. Therefore, it is important to also investigate protein 
expression levels. To detect any CD95L protein, MDA-MB-231 cells were 
harvested using versene to avoid cleavage of any plasma membrane CD95L 
(section 2.7.5). Cells were lysed and whole-cell extracts run on an 8% SDS-
polyacrylamide gel (section 2.7.8). The protein was transferred onto a PVDF 
membrane and probed using the G247-4 antibody for detection of CD95L (section 
2.7.11; Figure 4.13). The blot shows a faint signal at the correct molecular weight 
of 40kDa for monomeric CD95L, however, a strong signal can be seen at 120kDa. 
Potentially, this could be the membrane bound, trimeric form of CD95L, however 
this has only been observed previously in non-reducing conditions in HEp-2 cells 
(Meza-Lamas et al., 2006). Higher molecular weight species of protein were 
detected with CD95L-Myc-DDK expressing HEK293T cells, however the mobility 
corresponded to 80kDa (Figure 4.2B). A comparison is required to ensure these 
bands have different mobilities, by running the lysates of MDA-MB-231 cells with 
untransfected and transfected HEK293T cells on the same gel, and analysing 
protein expression by Western blot. Furthermore, siRNA knockdown of CD95L in 
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MDA-MB-231 cells can be used to test whether the 120kDa signal is a trimer of 
CD95L (Figure 4.14). 
 
 
 
Figure 4.13. Endogenous expression of CD95L in MDA-MB-231 cells.  
MDA-MB-231 cells (2 x 106) were lysed and 0.02% of the total volume was reduced, denatured 
and loaded onto an 8% SDS polyacrylamide gel and proteins separated by electrophoresis. The 
blot was prepared on a PVDF membrane and probed using mouse, anti-human CD95L G247-4 
clone (BD Pharmingen).  
 
 
4.2.8. siRNA knockdown of CD95L in MDA-MB-231 cells  
In Figure 4.13, Western blot analysis on MDA-MB-231 cell lysate shows a faint 
signal at the correct molecular weight of 40kDa for monomeric CD95L, however, 
a strong signal can be seen at 120 kDa. The antibody used, G247-4, has been 
validated on CD95L-Myc-DDK expressing HEK cells. The absence of an 
appropriate negative control for the expression of CD95L in MDA-MB-231 cells 
makes these data difficult to interpret. However, if the 40kDa species is 
monomeric CD95L and the apparent 120 kDa species a higher order multimer, it 
should be possible to knock down their expression using two CD95L siRNAs 
targeted to different locations in the open reading frame (ORF) (Figure 4.14).  
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Figure 4.14. siRNA knockdown of CD95L in MDA-MB-231 cells. 
MDA-MB-231 cells were seeded on 6-well plates and transfected using Oligofectamine 
(Invitrogen) with 20µM (A) CD95L/FasLG targeting siRNAs (si-CD95L 08 & si-CD95L 07; 
Dharmacon), a non-targeting siRNA (as a negative control; Dharmacon), a transfection agent only 
control (no siRNA) and (B) a siRNA against C2β (as a procedural control). 48 hours post 
transfection cells were harvested, lysed and equal amounts of lysate denatured, loaded onto an 
8% SDS polyacrylamide gel and proteins separated by electrophoresis. The blots were prepared 
on a PVDF membrane and probed using primary antibodies, mouse, anti-human CD95L G247-4 
clone (BD Pharmingen), anti-β-tubulin (Sigma) or mouse, anti-human PI3-Kinase C2β (BD 
Biosciences). There has been successful knockdown of C2β (B). 
 
 
Cells were seeded in a 6-well dish and 24 hours later, transfected using 
oligofectamine (Invitrogen) with siRNAs (table 2.6) against CD95L (si-CD95L 08 
and si-CD95L 07; Dharmacon), a non-targeting siRNA pool (as a negative 
control; Dharmacon), and a transfection agent only control (no siRNA; section 
2.12.1). Another siRNA against another known expressed protein, PI3-Kinase 
C2β, in MDA-MB-231 cells (si-C2β) was also used as a procedural control. Forty-
eight hours post transfection, cells were harvested, lysed and whole-cell extracts 
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run on a 10% gel. The protein was transferred onto a PVDF membrane and 
probed using mouse, anti-human CD95L mAb G247-4, anti-β-tubulin (Sigma), or 
mouse, anti-human PI3-Kinase C2β (BD Biosciences; Figure 4.14; section 
2.12.2). There was no change in the intensity of the bands at 120kDa with either 
of the CD95L siRNAs (si-CD95L 07 and 08) in comparison to the controls (Figure 
4.14A). However, C2β was successfully knocked down (Figure 4.14B) indicative 
of efficient siRNA transfection. These data do not support the hypothesis that the 
120kDa band corresponds to the trimeric, membrane bound form of CD95L and 
this signal could be due to non-specific binding of the primary antibody. Again, a 
faint band around 40kDa was observed. This may be indicative of a small amount 
of monomeric CD95L and a reduction may have occurred with knockdown using 
si-CD95L 08, however this could be an artefact due to bad transfer during 
Western blot analysis, so this result is inconclusive. The 40kDa band may also 
represent non-specific binding of the primary antibody or a degradation product 
of the 120kDa protein which is either much more abundant or has more avidity 
with the antibody, or another non-specific interaction.  
 
4.2.9. Investigating presence of CD95L in MDA-MB-231 cells 
using immunofluorescent staining  
siRNA knockdown results show that the 120kDa band detected when probing for 
CD95L is likely due to non-specific binding of the primary antibody. However, the 
result for the faint band at 40kDa, which may be indicative of a small amount of 
monomeric CD95L, is inconclusive. The expression of CD95L was investigated 
using immunofluorescent staining along with GM1006, to prevent any cleavage 
of CD95L from the PM (section 2.10). 
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Figure 4.15. No CD95L is detected in MDA-MB-231 cells using G247-4, with or without an 
MMP-7 inhibitor.  
MDA-MB-231 cells were seeded and incubated with GM1006 (C) 24 hours before being fixed 
using 3.7% (w/v) paraformaldehyde (PFA). Cells were left non-permeabilised (B and C) or 
permeabilised with 0.1% (v/v) Triton X-100 (A). The presence of CD95L was investigated by 
immunofluorescence using mouse, anti-human CD95L G247-4 clone (BD Pharmingen) and goat, 
anti-mouse Alexa Fluor® 488 (Invitrogen). Cell nuclei were stained with DAPI (4’,6-diamidino-2-
phenylindole; Invitrogen). Scale bars, 20µm. Images representative of the whole population are 
shown in each case. There is no positive staining in (A), (B) and (C). 
 
 
MDA-MB-231 cells were seeded onto glass coverslips. Twenty-four hours later, 
cells were incubated with 20µM GM1006 in FBS-free media. Forty-eight hours 
post transfection, cells were fixed and incubated with mouse, anti-human CD95L 
mAb G247-4 (Figure 4.15) and secondary antibody, goat, anti-mouse Alexa 
Fluor® 488. Cell nuclei were stained with DAPI. Prior to staining, cells were either 
permeabilised (to also view possible intracellular protein) or non-permeabilised 
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(to view PM expression). Immunofluorescence was studied using an epi-
fluorescent microscope (Leica). 
 
No fluorescence was detected when the cells were incubated with the G247-4 
antibody, either when the cells are permeabilised (Figure 4.15A) or non-
permeabilised, without GM1006 (Figure 4.15B) or with GM1006 (Figure 4.15C). 
This antibody has been validated in transfected HEK293T cells, and the GM1006 
inhibitor has been found to improve PM expression of CD95L-Myc-DDK. It is 
therefore likely that there is no detectable expression of CD95L in MDA-MB-231 
cells, especially on the plasma membrane, where its presence is required to 
demonstrate any interaction with CD95R-Fc on a coated microparticle.  
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4.3. Discussion 
CD95L has been previously described as critical for cancer survival (Hadji et al., 
2014) and its expression in tumour endothelial tissue provides a counterattack 
against the immune system (Motz et al., 2014). It would therefore be possible to 
exploit CD95L expression by cancer cells as a therapeutic target if it is present 
on the plasma membrane of cancer cells, providing a targeted delivery of 
chemotherapeutic agents to prevent the side-effects associated with many 
cancer treatments (Ateh et al., 2011). However, recent publications have 
suggested that there is little or no CD95L in most tumours or cancer cell lines 
(Motz et al., 2014, Glukhova et al., 2018). In this chapter, methods to detect 
surface expression of CD95L were optimised, using HEK293T cells, transiently 
transfected to express CD95L-Myc-DDK. The endogenous expression of CD95L 
in MDA-MB-231 cells was then investigated.  
 
The antibodies used in the past to detect CD95L have been critically analysed 
and many have been found to lack specificity (Sträter et al., 2001). It was 
therefore necessary to validate the antibody used here to detect CD95L (G247-
4). HEK293T cells were successfully transfected with pCMV6-FasLG, and the 
expression of recombinant CD95L-Myc-DDK was demonstrated via Western blot 
using not only G274-4, but anti-flag and anti-C-MYC antibodies, which detect the 
two, C-terminal tags linked to CD95L. The G247-4 antibody failed to detect 
endogenous CD95L expression in HEK293T cells providing potential negative 
and positive controls to investigate the CD95R/L targeting theory. Higher 
molecular weight species detectable by G247-4 and anti-FLAG antibodies were 
also observed by Western blot of the transfected HEK293T cells. These were 
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resolved almost completely (even with heavily overloaded samples), to the 
monomeric form following reduction by the addition of a high volume of 2-
mercaptoethanol. The reduction of these higher molecular weight species 
suggests the presence of the disulphide bond found in CD95L (Figure 4.1); also 
shown in the crystal structure of CD95L ECD (Liu et al., 2014) (Figure 1.2). It is 
likely that CD95L-Myc-DDK has been trafficked through an appropriate oxidative 
environment, such as through the endoplasmic reticulum, to allow the disulphide 
bridge to form. It is also possible however, that a non-physiological bond has 
formed between proteins after cell lysis or during denaturation since without 
prevention, these processes can lead to the creation of new disulphide bonds 
with other thiols to yield non-physiological complexes (Poole, 2015). This can be 
prevented or blocked, with the addition of a thiol-alkylating agent in the lysis buffer 
for example, which covalently bonds to the thiol group of cysteine residues to 
prevent the formation of any disulphide bonds, within or between proteins (Poole, 
2015). 
 
CD95L has 3 N-linked glycosylation sites in the ECD (Voss et al., 2008). 
Deglycosylation experiments showed that the monomeric form of CD95L-Myc-
DDK is equally sensitive to PNGase-F and Endo-H, suggesting that these are 
high mannose glycans and the protein may be localised to the endoplasmic 
reticulum. Deglycosylation experiments on the higher molecular weight species 
of CD95L-Myc-DDK demonstrated differential sensitivity of these species to 
PNGase-F and Endo-H with Endo-H unable to fully degylcosylate the higher 
molecular weight species. This suggests that some of the glycans have been 
matured, which occurs in the Golgi apparatus. Immunocytochemistry 
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experiments using anti-CD95L and anti-C-MYC showed that there is a small 
amount of detectable CD95L-Myc-DDK at the PM, however a much stronger 
signal for CD95L was detected inside the cell following permeabilisation. CD95L 
can be shed from the PM to form soluble CD95L (sCD95L) by ADAM10 and 
MMP7. It therefore seemed possible that some of the matured CD95L-Myc-DDK 
has reached the PM, but little is detected using IF staining because it has been 
shed by these proteases. The proteases may be produced (ADAM10; (Lammich 
et al., 2010)) or secreted (MMP-7; (Liu and Wu, 2006)) by the HEK293T cells 
themselves or could already be present in the cell media from additives, such as 
Fetal bovine serum (FBS) for example (Hu and Beeton, 2010). The use of 
inhibitors improved PM retention of CD95L, however, not significantly enough to 
enable these cells to be used in uptake experiments (i.e. it would have been 
difficult to separate the CD95L-Myc-DDK expressing cells from the background 
by flow cytometry in order to test whether they were more proficient at CD95R-
Fc-coated MP uptake). 
 
Despite the sensitivity of monomeric form and higher molecular weight species 
of CD95L-Myc-DDK to deglycosidases, it is unknown whether all available sites 
for glycosylation on the recombinant CD95L have glycans attached. Mutation of 
the putative N-linked glycosylation sites correlates with reduced CD95L 
expression in COS-1 cell transfectants (detected using the mAb G247-4)  
(Orlinick et al., 1997) and glycosylation has been found to reduce CD95L 
aggregation, as has been shown by the mutagenesis of CD95L glycosylation 
sites with resulting aggregates eluted by size exclusion chromatography (Liu et 
al., 2014). If not glycosylated properly, the expressed protein in the HEK293T 
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cells may not traffic to the plasma membrane efficiently, which could help explain 
the lack of cell surface expression. Despite this, previous studies have 
demonstrated successful CD95L expression in HEK293T cells via Western blot 
and IF, using an anti-CD95L antibody, Fc2 (which was created with its epitope 
mapped in this study) (Lettau et al., 2014) and via Western blot of FLAG-tagged 
CD95L, detected using an anti-FLAG antibody (Schneider et al., 1997). One 
study has detected CD95L (using the anti-CD95L mAb NOK-1) on the cell surface 
of HEK293T cells using flow cytometry after a 24 hour incubation with 
G1254023X, the ADAM10 inhibitor used here (Kirkin et al., 2007). One 
observation of the data here was that the number of cells decreased when 
transfected with pCMV6-FasLG, which is most noticeable in the IF staining 
images. Normally, the level of CD95L expression in proliferating cells is low, since 
enhanced surface expression can lead to apoptosis of surrounding, CD95R-
bearing cells (Glukhova et al., 2018) and most cells, including HEK293Ts as 
shown by flow cytometry, express CD95R (Larregina et al., 1998). Furthermore, 
along with siRNAs designed against CD95L being toxic to cancer cells (discussed 
further in section 4.3.1), the CD95L mRNA itself has also been reported to induce 
cell death in HeyA8 (ovarian cancer) cells, with enforced expression (Putzbach 
et al., 2017). Although this data has yet to be published and explained in full (as 
has been referred to in their paper; (Putzbach et al., 2017)) it suggests that it is 
possible that the overexpression of CD95L-Myc-DDK and so, presence of the 
CD95L mRNA, may be inducing cell death in HEK293T cells. To test this potential 
effect, it may be possible to prevent full length CD95L protein from being 
produced by the CD95L mRNA, by introducing a premature stop codon after the 
start codon in the pCMV6-FasLG vector. If this construct produces mRNA with 
no detectable CD95L protein, it’s effect on cell death and growth can be 
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determined in HEK293T cells, in comparison to transfection with unmodified 
pCMV6-FasLG.  
  
Following validation of the anti-CD95L antibody, G247-4, in pCMV6-FasLG 
transfected HEK293T cells, CD95L expression in MDA-MB-231 cells was 
investigated. Firstly, very little mRNA was detected in the cells using RT-qPCR, 
in comparison to the housekeeping gene control. An abundance of CD95L was 
detected in transfected HEK293T cells however, demonstrating that the primers 
and experimental procedure was effective. Since a gene’s mRNA level does not 
always predict its protein level, MDA-MB-231 cells were then lysed and CD95L 
expression investigated using Western blot. A strong signal was seen at 120kDa 
under reducing conditions. A protein species migrating with a similar apparent 
molecular weight, has been detected previously when investigating CD95L 
expression in human laryngeal carcinoma (HEp-2) cells, which they were able to 
fully reduce to the monomeric form (Meza-Lamas et al., 2006). Here, the protein 
has been analysed under strong, reducing conditions (8% (v/v) 2-
mercaptoethanol), yet very little protein was detected corresponding to the 
40kDa, monomeric form of CD95L. Furthermore, Meza-Lamas et al., only 
reported Western blot data and did not provide any further evidence to 
demonstrate the presence of homotrimeric CD95L, rather than a hetero-
oligomeric form or CD95L aggregate, for example, by running the protein on a 
native gel, analytical centrifugation or mass spectrometry. When CD95L was 
knocked down by two separate siRNAs in the MDA-MB-231 cells, there was no 
detectable change in the abundance of the protein migrating at 120kDa, 
suggesting that it may not be CD95L. The effect of siRNA knockdown on the 
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40kDa protein however, which is barely detectable via Western blot, was 
inconclusive. Finally, the presence of CD95L was explored using IF, alongside 
GM1006, an MMP-7 inhibitor which was shown to improve detectable levels of 
CD95L-Myc-DDK at the PM of HEK293T cells. No intracellular or PM CD95L was 
detected, with or without GM1006. In conclusion, there is little or no evidence to 
suggest that CD95L protein is expressed by the MDA-MB-231s.     
 
Previous papers which have stated presence of CD95L in breast cancer cell lines 
include IF detection using a CD95L antibody (polyclonal rabbit anti-human 
CD95L, Santa Cruz Biotechnology) which has now been discontinued (Müschen 
et al., 2000). Evidence for CD95L expression in MDA-MB-231 cells specifically 
include the use of an ELISA kit which has also been discontinued (Hsu et al., 
2006) and detection via Western blot where the authors have not stated the 
antibody used (Kunigal et al., 2008). Therefore, there is a lack of clear evidence 
in the literature regarding CD95L expression in this cell line also. In 2013, Malleter 
et al., reported triggering of prometastatic signalling following CD95L cell surface 
cleavage in triple-negative breast cancer (TNBC) (Malleter et al., 2013). The 
study used an ELISA kit (Diaclone; antibody not specified) to detect serum CD95L 
in TNBC patients and found CD95L levels to be significantly higher in relapsed 
patients, which therefore correlated with a higher rate of metastasis (Malleter et 
al., 2013). More recent research (Motz et al., 2014) however, found CD95L to be 
expressed in endothelial cells of blood vessels surrounding tumour masses 
(using a validated anti-CD95L antibody), rather than the tumour cells themselves. 
Therefore, it cannot be assumed that the source of the soluble CD95L found in 
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the blood serum of some cancer patients comes from their tumour cells 
specifically.  
 
If CD95L is not expressed by MDA-MB-231 cells, then it is likely that the 
enhanced uptake seen with CD95R-Fc coated MPs is not due to a CD95R/L 
interaction, but perhaps something else. If cells do not require CD95L for MP 
uptake, the technology lacks the targeted delivery which is hypothesised to 
reduce side effects of chemotherapy. This also raises questions about whether 
this is a cancer cell specific effect, which will be explored further in the next 
chapter. Uptake of CD95R-Fc modified particles in neuronal, medulloblastoma, 
breast and ovarian cancer cell lines was reported in 2011 (Ateh et al., 2011) with 
IF staining provided to demonstrate CD95L expression by these cell lines. 
However, the anti-CD95L antibody used for IF was not stated nor validated. 
Incubating Daoy medulloblastoma cells with CD95R-Fc before the addition of 
particles did prevent the enhanced uptake of coated particles (Ateh et al., 2011) 
but this could also occur if CD95R-Fc is binding to another target protein on the 
cell surface. There is prior evidence that brain cancer cells express CD95L (using 
the antibody G247-4), but these data were derived from tumour samples and may 
have been influenced by the tumour microenvironment including by endothelial 
cells of the tumour vasculature (Kleber et al., 2008). IGROV1 cells have been 
found to preferentially internalise CD95R-Fc modified MPs and in a orthotopic 
ovarian cancer xenograft model, created using IGROV1 cells, CD95R-Fc 
modification improved efficacy of paclitaxel-loaded MPs to reduce tumour 
bioluminescence (Ateh et al., 2011). However, there is evidence that ovarian 
cancer cells lack plasma membrane expression of CD95L (Abrahams et al., 
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2003). Furthermore, the IGROV1 cell line has been found (by genotyping the cell 
line) to be hypermutated in comparison to ovarian tumours, and evidence 
suggests the cell line did not originate from a high-grade serous ovarian 
carcinoma (HGSOC) but from a different ovarian cancer subtype (endometrioid 
or clear cell carcinoma) (Domcke et al., 2013). There are examples of failed 
clinical trials conducted in HGSOC patients after preclinical studies in cell lines of 
endometrioid origin, among them IGROV1 (Coward et al., 2011) so these uptake 
experiments should be repeated using a more relevant cell line or model, to 
validate the effects seen with CD95R-modifed MPs.  
 
4.3.1. Limitations and possible future directions 
It is possible that incorrect glycosylation could affect trafficking of the expressed 
CD95L-Myc-DDK in HEK293T cells, explaining the abundance of intracellular 
CD95L, but lack of plasma membrane expression. Experiments here have 
indicated a level of glycosylation, yet do not indicate whether all available sites 
for glycosylation on the expressed CD95L have glycans attached. Mass 
spectrometry could be utilised to do so. Additionally, co-localisation of 
intracellular CD95L with an organelle-specific antibody such as calnexin (an 
endoplasmic reticulum marker), Golgi matrix protein (GM130; a Golgi marker) or 
Lamp-1/2 (lysosomal membrane markers) would identify the subcellular 
compartment of the protein. Co-staining PM CD95L with a marker of lipid rafts 
(such as caveolin-1; (Glukhova et al., 2018)) might also provide additional 
information to indicate whether there is CD95L translocation to lipid rafts in the 
cell membrane, as has been reported previously. However, if glycosylation and 
protein trafficking is not the issue regarding cell surface expression, it could be 
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that HEK293T cells expressing CD95L are inducing apoptosis in the surrounding 
cells. To overcome this, it may be possible to engineer cell lines with tetracycline-
inducible CD95L expression, that are dominant negative in FADD/MORT1, to 
prevent cell death via CD95R signalling (Glukhova et al., 2018). This would 
prevent cell death becoming an issue while overexpressing CD95L. However, if 
the presence of CD95L mRNA itself is toxic to cells, as was suggested by 
Putzbach et al. recently (Putzbach et al., 2017), there may not be a way to prevent 
cell death during CD95L expression. However, the full details supporting this 
theory have yet to be described.    
 
The siRNA experiment carried out on the MDA-MB-231 cells used two sequences 
from Dharmacon, targeting the CD95L ORF (table 2.6). The same two sequences 
were used to demonstrate the DISE effect of CD95L siRNAs in HeyA8 (ovarian 
cancer) cells (Putzbach et al., 2017). Previously, two lentiviral vectors targeting 
CD95L mRNA in MDA-MB-231 cells were tested and growth reduction and cell 
death was observed (supplementary information; (Hadji et al., 2014)). The siRNA 
experiment carried out here was performed before this evidence was published 
in 2017. Although no noticeable change in cell viability was specifically noted, it 
would be interesting to monitor this, for example, using propidium iodide to 
evaluate cell viability and cell cycle analysis in flow cytometry after CD95L siRNA 
knockdown. Furthermore, the use of a positive control, such as transfected 
HEK293Ts for CD95L knockdown, or a tissue or cell line that endogenously 
expresses CD95L (T-Cells, such as Jurkat cells) for RT-qPCR, would strengthen 
the conclusions of these experiments. The RT-qPCR experiment only provided 
CT mean data. This should be accompanied by   an agarose gel with the RT-
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qPCR products, displaying the presence or absence of CD95L cDNA, at the 
correct size, following the reaction. However, 3 different lines of evidence have 
been used to demonstrate that there are no detectable levels of CD95L in MDA-
MB-231 cells (Western blot, siRNA knockdown and RT-qPCR), as well as 
negative IF experiments with and without CD95L-sheddase inhibitors.   
 
There is evidence in a few tumour types that CD95L expression is induced by the 
tumour microenvironment, for example, SMA-560 (murine glioma) cells do not 
express CD95L on the cell surface but expression can be induced (as detected 
via Western blot using the antibody G247-4) by intracranial implantation 
suggesting a cross talk between host factions and the tumour cells (Kleber et al., 
2008). Similarly, CD95L expression found in tumour endothelial tissue is 
upregulated when exposed to common metastatic tumour markers such as 
VEGF-A and PGE2 (Motz et al., 2014). Therefore, the expression of CD95L in 
MDA-MB-231 cells could be investigated when used as a cancer orthotopic 
xenograft, in order to replicate more closely a breast tumour. Data inconsistency 
is a common issue however, and poor reproducibility between in vitro and in vivo 
models may be a complication here. Further evidence is required for CD95L 
expression in breast cancers, for example, IHC staining of patient tumours.  
 
The observation of DISE in cancer cells by si/shRNAs designed against CD95L 
is now being explored as a potential therapy. The siRNAs have been coupled to 
templated lipoprotein nanoparticles (TLP) and found to induce cell death in 
ovarian cancer (HeyA8) cells and reduce tumour growth in vivo (HeyA8 cells 
injected into immunodeficient (NSG) mice) (Murmann et al., 2017). Since DISE 
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preferentially kills transformed cells and cancer stem cells (Putzbach et al., 2017), 
this could be a novel form of targeted treatment against cancer. Cells must also 
express scavenger receptor SR-B1, since uptake of TLPs has been found to 
depend on the presence of this receptor, which has been shown in human 
prostate cancer, breast cancer, and renal cell carcinoma among others 
(McMahon et al., 2016). 
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4.4. Summary 
HEK293T cells were used to overexpress CD95L-Myc-DDK, in order to validate 
an anti-CD95L antibody. Plasma membrane expression of the protein was 
improved by using inhibitors of CD95L-sheddases. However, the level of cell 
surface expression was deemed too low to test uptake of CD95R-Fc coated MPs 
in the presence and absence of CD95L, which would have been useful to validate 
whether the target protein (CD95L) is necessary for uptake of CD95R-coated 
MPs. The reasons for low PM expression are unclear. 
 
The expression of CD95L was investigated in MDA-MB-231 cells to examine the 
proposed targeting mechanism of CD95R-Fc coated MPs. It was concluded that 
there are very low or undetectable levels of the CD95L protein in MDA-MB-231s 
as shown by Western blot and validated using immunofluorescent staining. This 
is in agreement with recent literature stating that there is little or no CD95L in 
most tumours or cancer cell lines (Motz et al., 2014, Glukhova et al., 2018) and 
expression of CD95L, if it does indeed occur in tumours, may be reliant on factors 
in the tumour microenvironment (Motz et al., 2014, Kleber et al., 2008). Despite 
MDA-MB-231 cells lacking CD95L protein at the plasma membrane, they very 
efficiently take up CD95R-coated MPs. The reasons for this enhanced uptake are 
explored in Chapter 5.  
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5. Investigating the mechanism of CD95R-Fc 
coated microparticle internalisation  
5.1. Introduction 
Nanomedicine has the potential to improve the efficacy of cancer treatments. By 
combining nanotechnology and medicine, this field of research has enabled the 
development of small particle, therapeutic carriers such as microparticles (MPs) 
(Wang et al., 2012). MPs can be made from biodegradable polymers such as 
poly(lactic-co-glycolic acid) (PLGA) and loaded with chemotherapeutic agents. 
Upon internalisation, PLGA MPs degrade into lactic and glycolic acid and release 
their cytotoxic payload to kill the cancer cell. Functionalising the surface of 
particles can improve uptake levels into cells or target them to particular cells of 
interest, for example, by coating or opsonising with tumour-targeting proteins. 
 
Micron-sized delivery systems have proved to be a good approach for drug 
delivery, allowing a high drug loading capacity, the use of poorly soluble 
therapeutics, improved bioavailability and sustained and controlled drug release 
within the target cell (Patiño et al., 2015, Kohane, 2007, Wang et al., 2012). In 
order to achieve high prognostic and treatment efficacy, the successful entry of 
MPs into cells plays a vital role (Zhao and Stenzel, 2018). Therefore, an 
understanding of MP interaction with the cell membrane during endocytosis is 
crucial in developing an efficient and “personalised” nanomedicine with minimal 
toxicity (Zhao and Stenzel, 2018). 
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The previous chapters have described the enhanced uptake of 0.5µm, CD95R-
Fc coated, polystyrene MPs into triple negative breast cancer, MDA-MB-231, 
cells. The original hypothesis of a targeted interaction between CD95R-Fc on the 
particle and CD95L expressed by the cells has been disproved. Here, the 
mechanisms of uptake are investigated, and the possibility of any targeting 
discussed.   
 
5.1.1. Uptake pathways into cells   
There are two major pathways present in mammalian cells which allow the uptake 
of cargo; phagocytosis and pinocytosis. Phagocytosis is a process most 
associated with cells of the innate immune system such as macrophages, 
neutrophils and dendritic cells (Botelho and Grinstein, 2011), but is also present 
in other cells (see section 5.1.3 below). This is a receptor-mediated engulfment 
of large (≥0.5µm) particles, such as cellular debris and pathogens, into plasma-
membrane derived vacuoles called phagosomes (Botelho and Grinstein, 2011).  
 
Pinocytosis consists of uptake mechanisms that are present in all cells and can 
be categorised as dynamin-dependent (such as clathrin, caveolae and RhoA-
mediated endocytosis) or dynamin-independent (such as macropinocytosis) 
(Mayor et al., 2014). Dynamin, the founding member of a family of dynamin-like 
proteins (DLPs) is a GTPase implicated in membrane remodelling (Ferguson and 
De Camilli, 2012). Dynamin-independent pinocytosis mechanisms and 
phagocytosis however, are dependent on large-scale actin-mediated reshaping 
of the plasma membrane  (Mayor and Pagano, 2007).  These large-scale 
pathways may share some of the same molecular machinery as the dynamin-
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dependent processes, especially those utilizing actin machinery in membrane 
remodelling (Mayor et al., 2014). Uptake pathways have also been defined 
depending on the size of the particles they can internalise; large micrometre-scale 
pathways include macropinocytosis (0.2 to 10µm) and phagocytosis, with 
pinocytic pathways restricted to those that internalise smaller particles (<200nm) 
(Mayor et al., 2014).  
 
5.1.2. Mechanisms of phagocytosis 
Macrophages actively probe their microenvironment for particulate targets by 
extending highly dynamic membrane extensions (Botelho and Grinstein, 2011). 
RAC GTPases and CDC42 are required for maintaining the dynamic actin 
cytoskeleton for the formation of membrane protrusions (Botelho and Grinstein, 
2011). Phagocytosis is induced by the interaction between ligands on the particle 
surface and receptors on the phagocytic membrane. For example, particles 
opsonised (coated) by immunoglobulins are ingested via an interaction with their 
specific Fc receptors. These are a well-known group of phagocytic receptors, 
which bind the Fc portion on antibodies. Other receptors include scavenger 
receptors, complement receptors and integrin receptors (see table 5.1).  
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Receptor Ligands 
FC Receptors:  
  FcγRI (CD64)  IgG-, CRP-, SAP-opsonized particles 
  FcγRII* (CD32) IgG-, CRP-, SAP-opsonized particles 
  FcγRIII (CD16) IgG-, CRP-, SAP-opsonized particles 
  FcεRI IgE-opsonized particles 
  FcεRII (CD23) IgE-opsonized particles 
  FcαRI (CD89) IgA-opsonized particles 
Complement Receptors:  
  CR1 (CD35) MBL-, C1q-, C4b-, C3b-opsonized particles 
  CR3 (αMβ2, CD11b/CD18, Mac1) iC3b-opsonized particle 
  CR4 (αXβ2, CD11c/CD18, gp150/95) iC3b-opsonized particles 
Various integrins:  
  α5β1 (CD49e/CD29) Fibronectin/Vitronectin-opsonized particles 
  α4β1 (CD49d/CD29)  
  αvβ3 (CD51/CD61)  
Scavenger receptors:  
  SRA Bacteria, LPS, Lipoteichoic Acid 
  MARCO Bacteria 
  Mannose receptor (CD206) Mannan 
  Dectin-1 β1,3-glucan 
  CD14 LPS, peptidoglycan, 
  C1qR(P) C1q, MBL, SPA 
  
Table 5.1. Receptors expressed by phagocytes and their binding ligands, adapted from 
Underhill and Ozinsky, 2002.  
*In humans, FcγRIIA is an activating phagocytic receptor, and FcγRIIB is an inhibitory receptor. 
Mice express only FcγRIIB. CRP, C-reactive protein; SAP, Serum amyloid P. 
 
 
 
 
 
194 
 
The receptor/ligand interaction triggers intracellular signalling pathways which 
result in efficient particle internalisation. Members of the Rho family of GTPases, 
Rac1 and CDC42, and Wiskott-Aldrich syndrome protein (WASP) family act as 
molecular scaffolds and mediate the polymerisation and assembly of actin at the 
base of the phagosome to form a phagocytic cup. Additionally, 
phosphatidylinositol-4,5-biphosphate (PIP2) is believed to play a major role in 
cytoskeletal modification, by driving actin polymerisation (Botelho and Grinstein, 
2011). This results in the circumferential projection of the cytoplasmic membrane 
as pseudopodia, which fuse around the particle to form a phagosome (Kumar 
and Clark, 2005). Phagocytosis is completed when pseudopods reach the apex 
of the particle and contract, via myosin X and perhaps myosin II, to sever the 
newly formed vacuole from the surface membrane (Botelho and Grinstein, 2011).  
 
5.1.3. Non-professional phagocytes 
Phagocytosis is well known and studied within “professional” phagocytes of the 
immune system. However, other cell types can also exhibit phagocytotic activity 
or “non-professional” phagocytosis. Examples of this have been found in a range 
of different cell types. MDA-MB-231 cells have been shown to locally degrade 
and phagocytose the extracellular matrix. Activation of alpha 3 beta 1 integrin 
was found to be necessary for initiating this phagocytosis (Coopman et al., 1996) 
(table 5.1). Airway epithelial cells can engulf neighbouring cells that undergo 
apoptosis after encountering environmental allergens; deletion of Rac1 in these 
cells resulted in defective engulfment (Juncadella et al., 2013).  
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In embryo development, apoptosis is a key tool to sculpt body shape. Apoptosed 
cells are not only phagocytosed and cleared by macrophages, but also by 
mesenchymal cells (albeit with less efficiency) as has been shown in a 
'macrophage-less' mouse embryo (Wood et al., 2000). Similarly, neural 
progenitor cells have been shown to elicit a phagocytic role during neurogenesis. 
This was found to be modulated by intracellular engulfment protein ELMO1, 
which promotes Rac activation downstream of phagocytic receptors (Lu et al., 
2011). Disruption of ELMO1 in vivo (Elmo1-null mice) or pharmacologically in 
wild-type mice, led to reduced phagocytosis, the accumulation of apoptotic nuclei 
and impaired neurogenesis (Lu et al., 2011).  
 
Following an injury, the clearance of apoptotic and necrotic cells is necessary for 
tissue repair.  Kidney injury molecule–1 (KIM-1) is an immunoglobulin 
superfamily cell-surface protein highly upregulated on the surface of injured 
kidney epithelial cells, which transforms epithelial cells into semi-professional 
phagocytes (Ichimura et al., 2008). KIM-1 was able to specifically recognize 
apoptotic cell surface-specific epitopes phosphatidylserine, and oxidized 
lipoproteins, leading to the phagocytosis of apoptotic bodies after injury in rat 
kidney tubules in vivo (Ichimura et al., 2008). Furthermore, KIM-1 was directly 
responsible for phagocytosis in cultured primary rat tubule epithelial cells, porcine 
and canine epithelial cell lines (Ichimura et al., 2008). 
 
Interestingly, macrophages can communicate with non-professional phagocytes 
(such as epithelial cells) and influence their phagocytic activity. Through the 
release of soluble growth factors and microvesicles, macrophages can alter the 
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type of particles engulfed by non-professional phagocytes and influence their 
inflammatory response (Han et al., 2016). For example, macrophages release 
insulin like growth factor 1 (IGF-1) during phagocytosis of apoptotic cells or in 
response to inflammation. The binding of IGF-1 to its receptor on the surface of 
LR73 fibroblasts and BEAS-2B (human lung epithelial) cells, non-professional 
phagocytes, redirected their phagocytosis such that the uptake of larger apoptotic 
cells was reduced, whereas the engulfment of liposomes was increased  (Han et 
al., 2016). 
 
5.1.4. Mechanisms of pinocytosis  
Macropinocytosis can internalise large particles (perhaps even up to 10µm) and 
extracellular fluid through cell surface membrane protrusions, often called ruffles, 
that curve into cup-like structures to from vesicles, via actin polymerisation 
(Swanson, 2008). These vesicles, called macropinosomes, often form 
spontaneously or 'non-selectively', however there is some evidence of formation 
in response to activation of cell-surface receptors. For example, coating 
extracellular vesicles (EVs; 30 – 200nm) in an octaarginine peptide (an arginine-
rich cell-penetrating peptide) initiates macropinocytosis in CHO-K1 (Chinese 
hamster ovary) cells by inducing proteoglycan clustering, resulting in uptake of 
EVs (Nakase et al., 2017). Common signalling mechanisms organise the 
construction of the cup-shaved invaginations of the plasma membrane, actin-
filament assembly, disassembly and contractions including guanosine 
triphosphates (GTPases) of the Ras superfamily and membrane phospholipids 
(Swanson, 2008). Macropinocytosis has been found to be an important pathway 
of protein acquisition in cancer cells, particularly those with activated Ras, such 
as pancreatic and colon cancer (Redelman-Sidi et al., 2018). Ras activation (by 
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growth factor stimulation or oncogenic mutation) leads to increased membrane 
ruffling and so macropinocytosis via activation of Rac1 and CDC42 (Recouvreux 
and Commisso, 2017). This in turn, stimulates p21-activated kinase 1 (Pak 1), 
which has been shown to co-localise with macropinosomes in 3T3 fibroblasts, to 
induce actin polymerisation (Dharmawardhane et al., 1997). 
 
Clathrin/receptor-mediated endocytosis generates small vesicles (60 – 120nm) 
to transport cargo molecules from the plasma membrane to the cytoplasm. 
Specific ligands are required to activate receptors in order for endocytosis to 
occur, so the pinocytosis in this case is not spontaneous. The iron chelation 
protein, transferrin, is a good marker for clathrin-mediated uptake, because once 
it has bound iron, it gains affinity for the transferrin receptor on the plasma 
membrane and is internalised (Vercauteren et al., 2010). After initiation, 
endocytic coat proteins including clathrin are recruited from the cytosol to cluster 
on the inner leaflet of the plasma membrane (Kaksonen and Roux, 2018). 
Clathrin forms a lattice-like coat around the nascent vesicle, 
promoting membrane bending, which transforms the flat plasma membrane into 
a ‘clathrin-coated pit’ (Kaksonen and Roux, 2018). In addition to clathrin, the coat 
is composed of many other proteins, including clathrin-adaptor proteins, such as 
the heterotetrameric adaptor protein AP2 complex, and scaffold proteins 
(Kaksonen and Roux, 2018). After the coat has assembled, a network of actin 
filaments polymerizes at the endocytic site, forming the actin module (Kaksonen 
and Roux, 2018), that enables the movement of the vesicle away from the plasma 
membrane i.e. via myosin motor proteins (Sun et al., 2006). The constriction and 
scission of the invagination neck is mediated by BAR domain (Bin, amphiphysin 
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and Rvs) proteins which interact with dynamin to mediate scission (Kaksonen 
and Roux, 2018). 
 
In comparison, caveolar endocytosis is a process which mediates uptake of 
smaller, 50 – 60nm, vesicles via bulb-shaped plasma membrane invaginations 
called caveolae. Caveolae are enriched in cholesterol and sphingolipids, and 
their formation is driven by integral membrane proteins called caveolins and coat 
proteins called cavins (Mayor and Pagano, 2007). Similar to clathrin endocytosis, 
constriction and scission of caveolae from the plasma membrane is mediated by 
BAR domain proteins and dynamin. The actin-binding protein Filamin A  plays a 
crucial role in trafficking of caveolae linked to actin (Muriel et al., 2011). 
Interestingly, caveolae can flatten in response to membrane stretch and this 
mechanosensitive response is thought to prevent membrane rupture, as well as 
activating protective downstream signalling responses (Parton and Del Pozo, 
2013). Often this pathway is utilised by pathogens to enter cells, such as the 
SV40 virus and cholera toxin subunit B, a protein complex secreted by the 
bacterium Vibrio Cholerae; the latter is often used as a marker for caveolar 
endocytosis (Vercauteren et al., 2010).  
 
Additional endocytic pathways that do not use clathrin, cavin or any other 
characterised coat proteins, have begun to be recognised. Some of these 
pathways are constitutive, whereas others are triggered by specific signals and 
are also exploited by pathogens (Mayor et al., 2014). RhoA-dependent, IL-2 
receptor endocytosis is a well-characterised example of a non-clathrin, non-
caveolin route (Gesbert et al., 2004). Electron-microscopy studies confirm that 
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IL-2 receptors are concentrated on the plasma membrane and then internalised 
via small invaginations (Mayor et al., 2014). Both the specific concentration of the 
receptors and uniform size (50 –100nm) of the endocytic vesicle indicate the 
presence of an, as yet, unidentified protein coat that may aid in the recruitment 
of these proteins to the site of endocytosis and form the endocytic pit (Mayor et 
al., 2014). Flotillin-dependent endocytosis has also been characterised as a 
dynamin-, caveolin- and clathrin- independent process. Internal and immuno-
electron microscopy has shown flotillin-1-containing regions of the plasma 
membrane budding into COS-7 (green monkey kidney) cells (Glebov et al., 2006). 
Cargo including fluid phase and a glycosyl-phosphatidylinositol (GPI)-anchored 
protein, CD59, are also endocytosed via this pathway in HeLa cells (Glebov et 
al., 2006). 
 
5.1.5. Elucidating the mechanisms of cellular uptake 
 Endocytic inhibitors are commonly used to assess how particles are being 
internalised into cells since they are simple, reliable and affordable tools, 
however, the specificity of these inhibitors and possible side effects are frequently 
overlooked and need to be considered (Zhao and Stenzel, 2018).  
 
In this chapter, a series of inhibitors have been introduced to block different 
endocytosis pathways. Cytochalasin D is an inhibitor of F-actin polymerisation 
commonly used to block macropinocytosis and phagocytosis (Thompson et al., 
2012), since these uptake pathways are dependent on large-scale actin-
mediated reshaping of the plasma membrane (Mayor and Pagano, 2007). 
Amiloride also inhibits macropinocytosis. Amiloride is used clinically to treat high 
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blood pressure or oedema due to heart failure (Baer et al., 1967) because it  
inhibits Na+/H+ exchange. This generates a submembranous acidic 
microenvironment that prevents the activation of GTPases that promote actin 
remodelling, and so macropinosome formation is also inhibited (Koivusalo et al., 
2010).  
 
Two commonly used inhibitors of clathrin-mediated endocytosis are 
chlorpromazine and dynasore. Chlorpromazine, a cationic, amphiphilic drug, 
prevents assembly of clathrin-coated pits at the cell membrane by translocating 
clathrin and AP2 from the cell surface to intracellular endosomes (Zhao and 
Stenzel, 2018). However, there is evidence that chlorpromazine may interfere 
with other forms of uptake, such as has been shown in four different cell lines, 
resulting in an increase of lactosylceramide (LacCer) uptake; a glycosphingolipid 
that partitions to lipid rafts, which is a marker of caveolae-mediated endocytosis 
(Vercauteren et al., 2010). Dynasore inhibits the GTPase activity of dynamin in 
the formation of clathrin-coated vesicles, preventing scission and membrane 
fission of vesicles (Macia et al., 2006) however it can also affect the involvement 
of dynamin in caveolae formation.   
 
Caveolae and lipid raft internalisations are known to be inhibited by the polyene 
antibiotics, nystatin and filipin (Ivanov, 2008). These are a class of antibiotics 
produced by Streptomyces that are toxic to fungi but not bacteria, which work via 
depletion of the cholesterol from the cell membrane by forming inclusion 
complexes with cholesterol (Kuhn et al., 2014). As a result, at high 
concentrations, these antibiotics can induce a profound distortion of the structure 
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and function of cholesterol-rich membrane domains resulting in cell toxicity 
(Milhaud, 1992). Fortunately, these effects can be minimised by lowering the drug 
concentration (Ivanov, 2008).  
 
Other inhibitors used here are mannan, which binds to the mannose-receptor, a 
competitive inhibitor which prevents mannose-receptor initiated internalisation 
(like phagocytosis, see table 5.1) (Cui et al., 2003). Mannan has been shown to 
block receptor-mediated, but not fluid-phase uptake of horseradish peroxidase 
(Lang and De Chastellier, 1985) and inhibit phagocytosis of zymosan by mouse 
peritoneal macrophages (Sung et al., 1983). Nocodazole is also used, which is a 
microtubule-disrupting agent that has been shown to affect MP internalisation 
and localisation of latex beads in B16 (melanoma) cells (Rejman et al., 2004). 
The effect of Nocodazole is non-specific however and could potentially affect 
many other cellular processes. 
 
Since the use of pharmacological inhibitors can have nonspecific effects on a cell 
(Ivanov, 2008) complementary techniques can be used to study uptake 
mechanisms, such as microscopy. Novak et al. used scanning ion conductance 
microscopy to allow high-speed topographical and fluorescence imaging of the 
interactions between red-fluorescent 200nm polystyrene particles and human 
lung cells (Novak et al., 2014). By transfecting the cells with actin-binding, green-
fluorescence protein (GFP) or clathrin-enhanced GFP, they were able to follow 
the 3D dynamics of topographic features of the membrane with 2D dynamics of 
the GFP labelled proteins, and the red fluorescent particles (Novak et al., 2014). 
Interestingly, they found that an initial interaction occurred between clathrin-
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coated pits and the particles, however, the particle was ultimately engulfed by a 
large membrane protrusion following disappearance of the GFP clathrin (Novak 
et al., 2014). The appearance of a large membrane protrusion suggests a 
macropinocytotic or phagocytotic route of uptake. This highlights a more complex 
relationship between uptake pathways and cell sensing of external particles and 
provides more detail regarding an internalisation mechanism than 2D imaging or 
inhibitor use alone. 
 
5.1.6. Factors affecting microparticle internalisation 
Uptake of microparticles or nanoparticles (NPs) is cell-type dependent, for 
example, HeLa cells internalise lipid NPs (~60nm) via macropinocytosis while 
NIH 3T3 fibroblasts take them up in clathrin-mediated endocytosis (Gilleron et al., 
2013). Uptake is known to be affected by the characteristics including size, 
shape, surface charge and material composition (Wang et al., 2012, Sun et al., 
2014, Zhao and Stenzel, 2018).  
 
Particle size can affect uptake efficiency, kinetics, internalisation mechanism and 
subcellular distribution  (Shang et al., 2014).  Different sized particles are 
preferentially internalised by certain cell types. For example, small diameter MPs 
(0.1 μm) are taken up more efficiently than larger MPs (1 and 10 μm) in Caco-2 
cells (Desai et al., 1997). This is likely due to an internalisation pathway 
preference in this cell type for one of the several pinocytic pathways that 
internalise particles <200nm. Höekstra et al. used a range of fluorescent latex 
beads of different sizes (50 – 1000nm) to investigate the effect of NP size on 
entry in B16 (murine melanoma) cells. Internalisation of particles <200nm 
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involved clathrin-coated pits, however as particle size increased, internalisation 
became caveolae-mediated; this was the predominant route of uptake for 500nm 
particles (Rejman et al., 2004).  This is a surprising result since the size of a single 
flask-shape caveolae is too small for accommodating particles as large as 
500nm. It was speculated that electrostatic interactions may localise the particles 
to caveolin-coated domains of the cell membrane but the recruitment of an 
internalisation machinery would be needed to accommodate particles that extend 
beyond the actual size of a caveolae domain (Rejman et al., 2004). 
 
In addition to size, particle surface charge can be a major factor affecting cellular 
and tumour uptake (Wang et al., 2012). In the case of nanoparticles, positively-
charged NPs are rapidly taken up by tumour cells but can lead to significant 
immune reactions (Wang et al., 2012, Gratton et al., 2008). Thus, neutral and 
negatively charged particles are preferable for clinical applications (Gratton et al., 
2008). A similar trend has been found with microparticle uptake into SK-BR-3 
(human breast cancer) cells. IgG functionalised, 3µm, polystyrene microparticles 
were coated with positively charged polyethyleneimine (PEI) of two different 
molecular weights, 25 and 750kDa (Patiño et al., 2015). Non-coated particles 
were negatively charged, and PEI coated particles were positively charged; the 
most positively charged particles were those with a 750 kDa PEI coating. This 
difference in charge affected uptake into SK-BR-3 cells in comparison to normal 
breast epithelial cell line MCF-10A, with the cancer cells preferentially 
internalising the more positively charged particles and the epithelial cells 
preferentially internalising the negatively-charged, non-coated particle. The 
mechanisms of uptake in each different cell line were investigated and the cancer 
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cells internalised all particles, regardless of charge, via macropinocytosis (as 
inhibited by Cytochalasin D). MCF-10A cells however showed different 
mechanisms of internalisation, depending on the microparticle type (Patiño et al., 
2015). Non-coated particle uptake was inhibited by both cytochalasin D and 
dynasore, suggesting they are internalised by macropinocytosis and a form of 
dynamin-dependent endocytosis. In contrast, the uptake of PEI-25K and PEI-
750K coated MPs was not affected by either inhibitor, suggesting an alternative 
mechanism of uptake (Patiño et al., 2015). Therefore, coating particles can affect 
surface charge, which may be internalised via different uptake pathways in 
different types of cell.   
 
The MPs used thus far in the current study are polystyrene and 0.5µm in size. 
The use of polystyrene particles is convenient as they are uniform in size and not 
broken down within the cell, allowing uptake to be easily quantified. The target 
MDA-MB-231 cells also showed a preference for the 0.5µm particles; CD95R-Fc 
coated, 0.5µm particles were preferentially internalised compared to CD95R-Fc 
coated, 1µm particles (70% compared to 40% uptake, respectively) (Ateh et al., 
2011). Whilst there has been a wide range of particle-cell interaction studies 
conducted with nanoparticles (Sun et al., 2014, Shang et al., 2014, Treuel et al., 
2013, Zhao and Stenzel, 2018), less is known about the interaction of larger 
micrometre-sized particles with cells. In this chapter I aim to investigate the 
mechanisms of uptake of CD95R-Fc coated MPs in MDA-MB-231 cells. Since 
there is no CD95L protein expressed on the plasma membrane, I test whether 
enhanced uptake is a cancer-cell specific effect by testing uptake in primary cells. 
Confocal imaging is used to confirm that the particles are internalised and 
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visualise the internalisation process, and coated MPs are characterised using 
dynamic light scattering (DLS). Finally, inhibitors of key internalisation pathways 
are used to explore the mechanisms of cellular uptake. 
 
5.1.7. Aims of Chapter 5  
• Investigate CD95R-Fc coated MP uptake in a non-cancerous cell line, 
primary dermal fibroblasts 
• Use confocal imaging to complement flow data, ensure MPs are 
internalised and live-cell imaging to visualise internalisation dynamics 
• Characterise differentially coated MPs using DLS 
• Use inhibitors to elucidate the key mechanisms involved in CD95R-Fc 
coated MP uptake  
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5.2. Results 
5.2.1. Investigating uptake of CD95R-Fc modified MPs in 
primary dermal fibroblasts 
In the previous chapter, it was concluded that there is no CD95L expression on 
the plasma membrane of MDA-MB-231 cells, suggesting that uptake does not 
occur via a CD95R-Fc/CD95L interaction. In order to see whether the enhanced 
uptake of CD95R-Fc coated particles is a cancer-cell specific effect, uptake was 
tested in primary dermal fibroblasts, sourced from facial skin. Dermal fibroblasts 
are an essential component of skin, producing and organising the extracellular 
matrix of the dermis and communicating with each other and other cell types, 
playing a crucial role in regulating skin physiology (Sorrell and Caplan, 2004).  
Primary cells were used to avoid any bias due to selection for growth in tissue 
culture which might alter the uptake properties of cancer or immortalised cell 
lines. MDA-MB-231 cells and primary dermal fibroblasts (passage number 15) 
were seeded to the same density and incubated with CD95R-Fc coated particles 
for 24 hours (section 2.9.1). Non-bound particles were washed off before analysis 
using flow cytometry. Control cells were also incubated with no particles (PBS 
only, negative control), non-coated particles, particles coated with human IgG Fc 
fragment (Abcam; to control for the Fc portion of CD95R-Fc) and particles coated 
with an excess of BSA. The population of cells was analysed by flow cytometry, 
gating on cells with normal size but including a large range of granularity because 
polystyrene particle uptake makes the cells appear more granular. Fluorescence 
emitted by the fluorescein label of the MP was detected in the FL-1 channel.  
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Figure 5.1. CD95R-Fc improves uptake of microparticles in primary dermal fibroblasts, as 
well as MDA-MB-231 cells. 
Cells were incubated with fluorescent, 0.5µm MPs for 24 hrs and analysed by flow cytometry. 
Cells were gated to eliminate cell debris and 10,000 gated cells were analysed. Mean and SEM 
values are from three independent, repeat experiments (n=3). Significance was calculated by 
one-way ANOVA; **** P ≤ 0.0001 and ** P ≤ 0.01. (A) Mean percentage uptake by MDA-MB-231 
cells incubated with no particles (negative control), non-coated particles, BSA-coated, Fc-coated 
and in-house-purified CD95R-Fc coated particles. In-house-purified CD95R-Fc coated MP uptake 
was statistically different to non-coated MPs, BSA and Fc coated MPs. (B) Mean percentage 
uptake of the same particles by primary dermal fibroblasts. In-house-purified CD95R-Fc coated 
MP uptake was statistically different to non-coated MPs, BSA and Fc coated MPs. (C) Means of 
the median fluorescence of cells (a measure of the number of particles internalised per cell over 
three independent experiments), incubated with in-house CD95R-Fc coated particles. There was 
no statistical difference between the two cell lines (P > 0.05; Mann-Whitney U test). (D) Fractions 
of cell lysate from transfected HEK293T cells (positive control, CD95L+; 0.0002% of total volume), 
primary dermal fibroblasts (4% of total volume) and MDA-MB-231 cells (negative control; 4% of 
total volume), were loaded onto an SDS polyacrylamide gel and the proteins separated by 
electrophoresis. The blot was prepared on PVDF membrane and probed for CD95L.  
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Efficiency of MP uptake was determined by measuring the percentage of the 
gated cells with a fluorescence level above the autofluorescence of cells in the 
absence of particles. The percentage uptake for each condition in MDA-MB-231 
cells and the primary fibroblasts was analysed by ANOVA for 3 independent 
repeat experiments (section 2.15; Figure 5.1A & B respectively). 
 
The percentage uptake of MPs in primary dermal fibroblasts coated with in-house 
CD95R-Fc was 53 +/- 1% (Figure 5.1B) and was found to be statistically different 
(P ≤ 0.0001) to the mean uptake of 9 +/- 2% for non-coated particles, 9 +/- 2% 
for BSA coated particles, and 10 +/- 3% for Fc coated particles. The percentage 
uptake of MPs opsonised with BSA or Fc protein was not statistically different to 
each other (P > 0.05), and neither of these proteins improved particle uptake (in 
comparison to non-coated particles). MP uptake by fibroblasts was the same as 
in MDA-MB-231 cells (and consistent with that previously observed in Chapter 
3). Uptake for in-house CD95R-Fc coated particles was 46 +/- 11% and was 
found to be statistically different (P ≤ 0.01) to the mean uptake of 6 +/- 1% for 
non-coated particles, 6 +/- 1% for BSA coated particles, and 6 +/- 1% for Fc 
coated particles. The median fluorescence of cells with particles, coated with in-
house CD95R-Fc, from 3 independent, repeat experiments was analysed to 
explore any differences in the number of particles internalised per cell, for each 
cell line (Figure 5.1C). The mean of these median fluorescence levels over three 
independent experiments for MDA-MB-231 cells was 94 +/- 22 AFU and for the 
fibroblasts it was 74 +/- 23 AFU. There was no statistical significance between 
the two cell lines (P > 0.05). Therefore, primary fibroblasts and MDA-MB-231 cells 
have a similar number of particles internalised per cell.  
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To assess expression of CD95L, cells were lysed and whole-cell extracts run on 
a 10% polyacrylamide gel (section 2.7.5, 2.7.7 & 2.7.8). HEK293T cells 
transfected with pCMV6-FasLG (coding for Myc-DDK-tagged Human CD95L; 
OriGene) was loaded as a positive control for CD95L (0.0002% of total lysate, 
from a 500µl stock created from a confluent well of a six well dish, see section 
2.7.6). Maximal loading volumes of lysate from primary dermal fibroblasts and 
MDA-MB-231 cells (negative control; both 4% of total lysate volume, as before) 
were loaded in order to detect even minimal amounts of CD95L. The protein was 
transferred onto a PVDF membrane and probed using mouse anti-human 
CD95L, clone G247-4 (BD Pharmingen; Figure 5.1D; section 2.7.11), which was 
validated in Chapter 4. For the positive control, a strong signal at the correct 
molecular weight of 40kDa for monomeric CD95L. A strong signal was also 
observed in the fibroblasts at around 120 kDa and 170kDa, which is also seen in 
the MDA-MB-231 cells that was previously determined to have no CD95L in the 
plasma membrane (see Chapter 4) suggesting non-specific binding of the 
antibody. There is further background binding of the antibody for both fibroblasts 
and MDA-MB-231 cells, which is likely due to over-loading of the gel, however 
neither cell shows any CD95L at the expected molecular weight for the monomer, 
40kDa.  
 
In summary, CD95R-Fc coating enhances the uptake of MPs in primary dermal 
fibroblasts, a non-cancerous cell line, suggesting that the uptake pathway is not 
a cancer-cell specific. Furthermore, the lack of CD95L expression in primary 
dermal fibroblasts suggests that uptake does not result from a CD95R/CD95L 
interaction, as with MDA-MB-231 cells.  
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5.2.2. Confocal imaging to determine microparticle 
internalisation  
As discussed in Chapter 3, steps are taken in the uptake procedure to ensure 
that non-internalised particles are washed from cells before flow cytometry. This 
includes repeatedly washing adhered cells with PBS and tapping the sides of the 
plate to dislodge any unbound particles, before cells are trypsinised and collected 
for flow analysis. The FACScan detects the level of fluorescence emitted by a 
microparticle, however cannot discriminate between surface bound and 
internalised particles. Since no evidence for CD95R interaction with CD95L was 
found to be required for microparticle uptake, and because CD95R-Fc also 
enhanced uptake in a non-cancerous cell line, it was important to ensure that the 
particles were internalised and not simply stuck to the cell surface. To test this, 
MDA-MB-231 cells were seeded onto a 6-well dish and incubated with CD95R-
Fc coated particles for 24 hours (section 2.13.1). Cells were also incubated with 
no particles (PBS only), non-coated particles, particles coated with human IgG – 
Fc fragment and particles coated with BSA. The cells were washed with PBS to 
removed unbound particles and two hours prior to imaging, the live, adhered cells 
were stained with Hoechst (Thermo Scientific), a cell-permanent nuclear 
counterstain that emits blue fluorescence when bound to double-stranded, 
(ds)DNA, washed again with PBS, and then incubated with CellMask™ deep red 
plasma membrane stain (Thermo Scientific) for 20 minutes, before imaging on 
the IN Cell Analyser 6000 (GE Healthcare). The plasma membrane of each cell 
was imaged using the confocal aperture and a 3D, Z-stack of 6 x 1.7µm slices 
(excluding the top of the cell) was taken in order to capture all particles within the 
cell. The Z-stack was then collapsed into 2D allowing all particles to be seen. 
Representative images are shown of cells with no particles, non-coated particles 
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and in-house CD95R-Fc coated particles (Figure 5.2A, B & C respectively). 'FITC’ 
shows the fluorescence of green particles only and ‘Merge’ overlays fluorescence 
from the nucleus, cell membrane and particles. To see each fluorescent channel 
separately, go to Appendix 2 – Supplementary Figure 8.  
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Figure 5.2. CD95R-Fc coated particles are internalised by MDA-MB-231 cells, and not 
bound to the plasma membrane.  
MDA-MB-231 cells were incubated with no particles (PBS; negative control) (A) non-coated 
particles (B) or in-house CD95R-Fc coated particles (C) for 24 hours. Cells were then washed to 
remove non-internalised particles. Live, adhered cells were then stained for imaging. Cell nuclei 
were stained with Hoechst (blue) and cellular membranes with CellMask™ (red). Particles are 
fluorescent green and detected in the FITC channel and ‘Merge’ overlays fluorescence from the 
nucleus, cell membrane and particles. White arrows show a particle which has not been 
internalised by a cell or washed away. Scale bars, 20µm. Images representative of the whole 
population are shown in each case (see section 2.13.1).  
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The live cell staining shows that the particles are internalised. For non-coated 
particles, the field of view shows two cells that have each internalised one 
particle, and one further particle can be seen which has not been internalised or 
washed away using PBS (white arrow). Few particles were found adhered to the 
dish in this manner, suggesting that the washing procedure was effective. For 
CD95R-Fc coated particles, more cells have internalised particles, and there are 
more particles per cell (two cells with 3 or more particles, one cell with 2 particles 
and two cells with one particle).    
 
Image quantitation and processing was performed using the Developer software 
version 1.9.1 (GE Healthcare) as described in section 2.13.1. Briefly, the software 
identifies the nucleus and the cell membrane based on size and fluorescence 
(blue pixels for the nucleus and red for the membranes). The two are linked 
together to determine the number of cells per well. The particles are also 
identified using similar parameters, and the number of cells with particles 
determined by linking particles (or foci) to the nucleus and membrane of a cell. 
Furthermore, each particle is counted separately, allowing the analyses to 
calculate the number of particles internalised by each distinct cell. Further 
stringencies were introduced to ensure only internalised particles were counted 
including that a particle should be 100% surrounded by the cell membrane; even 
if one pixel of a particle is not, the particle is not counted. The outer edge of the 
membrane was excluded during processing, so particles close to outside of the 
cell were also excluded from the count.  
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Figure 5.3. Confocal imaging demonstrates enhanced CD95R-Fc coated MP uptake in 
MDA-MB-231 cells, with more cells internalising a higher number of particles. 
Cells were incubated with green-fluorescent, 0.5µm MPs for 24 hrs. Live, adhered cells were then 
stained for imaging on an IN Cell Analyser 6000 (GE Healthcare). Cell nuclei were stained with 
Hoechst (blue) and plasma membranes with CellMask™ (red). Mean and SEM values are from 
three independent, repeat experiments (n=3). (A) Mean percentage uptake of MDA-MB-231 cells 
incubated with no particles (negative control), non-coated particles, particles coated with BSA, 
particles coated with Fc and particles coated with in-house-purified CD95R-Fc. Uptake of particles 
coated with in-house-purified CD95R-Fc was statistically different to uptake of non-coated MPs, 
BSA- and Fc- coated MPs. Significance was calculated by one-way ANOVA; **** P ≤ 0.0001. (B) 
The number of particles internalised by each cell (1, 2 or ≥3), expressed as a percentage of total 
cell number, was compared for non-coated particles (blue) and in-house CD95R-Fc coated 
particles (red). Significance was calculated by Welch’s t test and the difference between 
conditions for each particle number was found to be statistically significant; 1 particle *** (P ≤ 
0.001), 2 particles ** (P ≤ 0.01) and ≥3 particles * (P ≤ 0.05).  
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The uptake experiment was repeated independently 3 times, images quantified, 
and percentage uptake statistically compared by ANOVA (section 2.15; Figure 
5.3A).  
 
The percentage uptake of MPs coated with in-house CD95R-Fc was 62 +/- 6% 
(Figure 5.3A) and was found to be statistically different (P ≤ 0.0001) to the mean 
uptake of 7 +/- 3% for non-coated particles, 10 +/- 4% for BSA coated particles, 
and 9 +/- 5% for Fc coated particles. The percentage uptake of MPs opsonised 
with BSA or Fc protein was not statistically different to each other (P > 0.05), and 
neither of these proteins was statistically different in comparison to non-coated 
particles. Uptake of MPs by cells incubated with non-coated particles was not 
statistically different (P > 0.05) to the level of cellular fluorescence recorded in the 
absence of particles. This data complements the results obtained by flow 
cytometry (Figure 5.1A) even when far fewer cells are being analysed (150 – 200 
cells per condition here compared to 10,000 cells for flow analysis). It is therefore 
very likely that the particles are internalised by the cells, rather than simply 
peripherally attached to the cell surface. Furthermore, with a CD95R-Fc coating, 
significantly more cells internalise particles, and significantly more particles are 
internalised per cell (Figure 5.3B). For cells with one particle per cell, the mean 
population uptake was 5 +/- 1% for non-coated particles, compared to 22 +/- 1% 
for CD95R-Fc coated particles (P ≤ 0.001), for two particles per cell, the 
respective values were 1 +/- 1% compared to 15 +/- 1% (P ≤ 0.01), and for three 
or more particles per cell the respective values were 0.4 +/- 0.4% compared to 
17 +/- 3% (P ≤ 0.05). This confirms the data obtained by flow cytometry, which 
showed that the median green fluorescence of cells that had taken up particles 
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was higher when the particle was coated with CD95R-Fc, in comparison to all 
other conditions (Chapter 3), indicative of a higher number of particles 
internalised by each cell. See Appendix 2 – Supplementary Figure 9 for a more 
detailed breakdown of particle number, for each MP coating condition. 
 
5.2.3. Time-lapse imaging of particle internalisation 
The use and staining of adherent, live cells worked very well, opening the 
possibility of using the IN Cell 6000 for time-lapse imaging (section 2.13.2). This 
includes taking a series of images of the same cells in a time dependent manner, 
which may provide insights into the mechanisms of uptake. MDA-MB-231 cells 
were therefore seeded and stained with Hoechst. After two hours, the cells were 
washed with PBS to remove any excess stain. Cells were then incubated with 
CellMask™ deep red plasma membrane stain for 20 minutes, washed again and 
media added along with the CD95R-Fc coated MPs, for 30 minutes before 
imaging. The plate was sealed with a membrane and supplied with 5% CO2 and 
kept at 37°C whilst the cells were imaged on the IN Cell Analyser 6000 detecting 
Hoechst, CellMask™ and green fluorescence emitted by the MPs. Nine fields of 
view were imaged, every 15 minutes for 5 hours.  
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Figure 5.4. Live-cell, confocal imaging demonstrates a single microparticle interacting with 
a membrane protrusion.  
MDA-MB-231 cells were incubated with in-house CD95R-Fc coated particles for 30 minutes and 
imaged every 15 minutes for 5 hours (300 minutes in total). Cell nuclei were stained with Hoechst 
(blue) and plasma membranes with CellMask™ (red). Particles are fluorescent green and 
detected in the FITC channel. (A) - (D) show a cell in 15-minute time frames, starting at 240 
minutes. White arrows show a membrane protrusion stained with Cell Mask, which forms at 255 
minutes, and which may be interacting with the green MP (Merge) potentially prior to 
internalisation. Scale bars, 20µm.  
 
 
Frames are shown from 240 - 285 minutes (Figure 5.4.). From 255 - 285 minutes 
(and at 300 minutes, frame not shown) a single particle was seen interacting with 
a membrane protrusion (white arrow, Figure 5.4B - D). Imaging was completed 
before the particle was internalised. Potentially, this indicates an interaction 
between the coated MP and the plasma membrane of the MDA-MB-231, which 
might be important to initiate internalisation. The involvement of a membrane 
protrusion in 200nm particle uptake has been shown in lung cells using 
topographical imaging and GFP labelled actin (Novak et al., 2014) and may 
indicate a macropino- or phagocytotic mechanism of internalisation.  
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5.2.4. Characterisation of microparticles using dynamic light 
scattering (DLS) 
Previous studies have shown that coating polystyrene microparticles in different 
chemicals can impart a distinct surface charge or zeta (ζ)-potential and this has 
been suggested to influence uptake. For example, coating polystyrene particles 
in polyethyleneimine (PEI) imparts a positive surface charge on the otherwise 
negatively-charged, non-coated particles. By using two different PEI polymers of 
25 and 750kDa, particles can be made less or more positive, respectively (Patiño 
et al., 2015). The surface charge affected the internalisation of particles 
differentially in cancerous and non-cancerous epithelial cells, with cancer cells 
internalising more particles with increasing positive surface charge. The non-
cancerous epithelial cells however, internalised more negatively-charged, non-
coated particles. 
 
To investigate the surface charge of the polystyrene particles used and whether 
it changes with the different coats, dynamic light scattering (DLS) was measured 
in a Zetasizer Nano ZS (Malvern; section 2.14). DLS is a non-invasive technique 
for measuring the size and size distribution (polydispersity index, PDI) of 
molecules and particles typically in the submicron range. Typical applications of 
DLS are the characterization of particles, emulsions and molecules, which have 
been dispersed or dissolved in a liquid (Ganguly, 2018). The Brownian motion of 
the particles or molecules in suspension causes laser light to be scattered at 
different intensities. Analysis of these intensity fluctuations is a measure of the 
velocity of the Brownian motion and hence the particle size using the Stokes-
Einstein relationship (see section 2.14, equation 2.2). The Zetasizer can also 
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measure the zeta potential of particles; the electrostatic potential at the electrical 
double layer surrounding a particle in solution (Clogston and Patri, 2011). A 
charge is applied across the solution, leading to electrophoresis of the particles. 
The velocity with which particles move is dependent on factors such as dielectric 
constant and viscosity of the medium, and the zeta potential. The Zetasizer 
measures electrophoresis using the Doppler effect, in which a laser beam is 
passed through a sample undergoing electrophoresis to measure the scattered 
light from the moving particles. 
 
Particles were coated by passive adsorption (section 2.8). Briefly, proteins were 
incubated with particles at a ratio of 0.5µg protein:1µg MP (except BSA, where 
an excess of protein is used) in PBS, for 90 minutes at 37°C, with mixing every 
20 minutes. Adsorption occurs based on hydrophobic attractions between the 
hydrophobic portions of the adsorbed protein and the polymeric surface of the 
microspheres (Bangs, 2008a). Samples were then diluted to 1ml and triplicate 
size measurements were recorded; the z-average diameter (d.nm); PDI (a 
measure of the breadth of the size distribution within a sample); and surface 
charge (ζ-potential) measurements (section 2.14). These measurements were 
recorded for each of the non-coated, BSA coated, Fc-coated and CD95R-Fc 
coated (with and without BSA) samples. The mean size and zeta potential for 
each coating condition was analysed by ANOVA for 3 independent repeat 
experiments (section 2.15; Figure 5.5A & B respectively). 
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Figure 5.5. Characterisation of Microparticles with and without protein coats.  
Microparticles (MPs) were diluted to 1ml in PBS and triplicate readings for each condition taken 
using a Zetasizer Nano ZS (Malvern). Significance was calculated by one-way ANOVA; **** P ≤ 
0.0001, *** P ≤ 0.001 and * P ≤ 0.5. (A) Mean z-average Diameter (particle diameter; nanometres 
(nm)) for each condition; Non-coated (mean polydispersity index (PDI) value: 0.321 ± 0.053), BSA 
coated (PDI: 0.468 ± 0.044), Fc coated (PDI: 0.300 ± 0.035), CD95R-Fc coated (PDI: 0.294 ± 
0.059) and CD95R-Fc + BSA coated (PDI: 0.488 ± 0.074). The size of particles coated in BSA 
and CD95R-Fc + BSA was statistically different to non-coated MPs. (B) Mean ζ-potential 
(millivolts; mV) measurement of each condition; Non-coated, BSA coated, Fc coated, CD95R-Fc 
coated and CD95R-Fc + BSA coated MPs. The ζ-potential of particles coated in BSA, CD95R-Fc 
and CD95R-Fc + BSA was significantly different to non-coated MPs. There was no statistical 
significance between the ζ-potentials of non-coated and Fc coated MPs (P > 0.05). 
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The mean particle diameter of non-coated particles is 909 +/- 41nm, larger than 
the expected mean diameter of 530nm, which may be due to the presence of 
aggregates. The fluorescent MPs which have been coated and characterised 
here, and previously used for uptake, are commercially available and purchased 
at a specific size range. The quality control data states the mean diameter of this 
batch is 0.53µm (530nm). However, the particles can aggregate in solution 
depending on several factors including temperature, particle size or concentration 
(Bangs, 1999). Coating in BSA gave a mean particle size that is expected, 520 
+/- 42nm, which is statistically different (P ≤ 0.0001) to the mean size of non-
coated particles. This could be because BSA blocks the exposed hydrophobic 
surfaces of the MPs, reducing nonspecific binding and self-aggregation (Bangs, 
2008a). This effect is seen to a lesser extent when particles are coated in CD95R-
Fc with additional BSA (which was initially included as a cryoprotectant; see 
Chapter 3), with a mean particle diameter of 719 +/- 33nm which is also 
statistically different (* P ≤ 0.5) to the size of non-coated particles. This suggests 
a further advantage to adding BSA to the in-house expressed CD95R-Fc used 
for coating. There was no statistical difference in particle diameter (P > 0.05), in 
comparison to non-coated particles, when using Fc (767 +/- 27nm) or CD95R-Fc 
(857 +/- 51nm) to coat particles. There was no statistically significant difference 
between the PDI values for each condition, which range from 0.3 – 0.5, 
suggesting that the particles in all samples are polydisperse. 
 
BSA coating decreased the surface charge of particles to the greatest extent, with 
a mean zeta potential of -12.7 +/- 0.2 mV, which is statistically significant (P ≤ 
0.0001) in comparison to non-coated particles (-9.9 +/- 0.4 mV). However, since 
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neither the non-coated particles nor BSA-coated particles are readily internalised 
by MDA-MB-231 cells, this imparted negative charge doesn’t affect uptake, but it 
does show that the surface charge on the particle can be changed (albeit subtly) 
by protein absorption. Coating particles in CD95R-Fc with additional BSA slightly 
increases the surface charge, -8.5 +/- 0.1 mV, which is also statistically different 
(* P ≤ 0.5) to non-coated particles. CD95R-Fc coating reduces the negative 
surface charge of particles to the greatest extent, with a zeta potential of -7.8 +/- 
0.5 mV which is also statistically different (*** P ≤ 0.001) to non-coated particles. 
However, there is no statistical difference (P > 0.05) between the surface charge 
of Fc coated particles (-8.9 +/- 0.3 mV) and non-coated particles, or Fc coated 
particles and CD95R-Fc coated particles (with or without BSA). Fc coated 
particles are internalised to a similar extent to non-coated particles, however, 
there is a large difference in the percentage uptake of Fc coated particles 
compared to CD95R-Fc coated particles (with or without BSA).  
 
In conclusion, these small changes in surface charge don’t consistently reflect 
the differences observed in uptake. The size and zeta potential difference of the 
BSA coated particles suggests that the absorption technique results in 
modification of the particle surface. When particles are coated with CD95R-Fc 
with BSA, this BSA-effect is not apparent or perhaps is prevented by the CD95R-
Fc. This suggests both that the CD95R-Fc functionalises the particle surface and 
has a higher avidity for the particles than the BSA, since there is 50x more BSA 
in the coating mix than CD95R-Fc.  
 
223 
 
5.2.5. Chemical inhibition of CD95R-Fc coated microparticle 
internalisation 
Previous studies have suggested that breast cancer cells internalise 3µm, 
polystyrene particles via macropinocytosis, regardless of particle surface charge  
(Patiño et al., 2015). This conclusion was based on almost complete inhibition of 
particle internalisation by 20µM cytochalasin D. The uptake of 200nm polystyrene 
particles into human lung cells has been suggested to involve actin-supported 
membrane protrusions, as imaged using fast ion conductance microscopy 
(Novak et al., 2014) which could be a form of macropinocytosis or phagocytosis. 
I therefore applied a range of known endocytosis inhibitors to investigate the role 
of different endocytic pathways in the uptake of CD95R-Fc coated MPs. 
 
MDA-MB-231 cells were pre-treated with inhibitors for 1 hour prior to incubation 
with CD95R-Fc coated MPs (section 2.5.3 & 2.9.2). Two inhibitors of each 
pathway were used; cytochalasin D and amiloride to inhibit macropinocytosis, 
chlorpromazine and dynasore to inhibit clathrin-dependent endocytosis and 
nystatin and filipin to inhibit caveolin-dependent endocytosis. Mannan was used 
to inhibit mannose-receptor mediated endocytosis. Nocodazole, was also tested 
to investigate the involvement of microtubules in uptake. Non-treated cells were 
incubated with non-coated particles (negative control) and CD95R-Fc coated 
particles (positive control). After 12 hours, unbound particles were washed off 
before analysis using flow cytometry. Efficiency of MP uptake was determined by 
measuring the percentage of the gated cells with a fluorescence level above the 
autofluorescence of cells in the absence of particles. The percentage uptake over 
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the gated population for each condition was analysed using a paired t test for 3 
independent repeat experiments (section 2.15; Figure 5.6A).  
 
Only amiloride, which prevents the activation of macropinocytosis (Dangoria et 
al., 1996), caused a statistically significant reduction in uptake of particles (43 +/- 
5%; P ≤ 0.05), compared to CD95R-Fc coated MP uptake in non-treated cells (61 
+/- 7%; Figure 5.6A). There was a statistical difference between non-coated 
particle uptake (17 +/- 3%) and CD95R-Fc coated particle uptake (61 +/- 7%; P 
≤ 0.01) in non-treated cells. There was also a statistical difference between non-
coated particle uptake and all inhibitor conditions; P ≤ 0.05 for filipin; P ≤ 0.01 for 
amiloride, cytochalasin D, dynasore, nystatin and nocodazole; P ≤ 0.001 for 
chlorpromazine and mannose. There was a trend toward reduced percentage 
uptake (45 +/- 5%) when cells were incubated with cytochalasin D, an inhibitor of 
actin polymerisation (Thompson et al., 2012) which is also required for 
macropinocytosis. There was also a consistent trend toward increased uptake 
when cells were treated with Chlorpromazine (117 +/- 12 %) an inhibitor of 
clathrin-dependant endocytosis. Further experimental repeats may determine 
whether these trends are significant or not.  
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Figure 5.6. Effects of endocytic pathway inhibitors on CD95R-Fc coated microparticle 
uptake in MDA-MB-231 cells.  
Cells were pre-treated for 1 hour with the indicated inhibitor prior to the addition of CD95R-Fc 
coated MPs. Non-treated cells were incubated with non-coated particles (blue, negative control) 
and CD95R-Fc coated particles (red, positive control). After 12 hours, cells were washed and 
analysed by flow cytometry. Cells were gated to eliminate cell debris and 10,000 gated cells were 
analysed. Mean and SEM values are from three independent, repeat experiments (n=3). 
Significance was tested using a paired t test; ** P ≤ 0.01, * P ≤ 0.5. (A) Percentage uptake of 
CD95R-Fc coated MPs in MDA-MB-231 cells with different inhibitors. Treatment of cells with 
amiloride statistically reduced uptake of CD95R-Fc coated MPs, compared to non-treated cells. 
Non-coated particle uptake in non-treated cells was statistically different to CD95R-Fc uptake in 
non-treated cells. Non-coated particle uptake in non-treated cells was also statistically different to 
all inhibitor treatments, (not shown on graph; P ≤ 0.05 for filipin; P ≤ 0.01 for amiloride, 
cytochalasin D, dynasore, nystatin and nocodazole; P ≤ 0.001 for chlorpromazine and mannose) 
(B) Mean median fluorescence (AFU) of cells with particles (a measure of the number of particles 
internalised per cell over three independent experiments) treated with different inhibitors. 
Treatment with amiloride statistically reduced median fluorescence of cells compared to non-
treated cells incubated with CD95R-Fc coated MPs.    
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These trends can also be seen when comparing the median fluorescence of cells 
with particles (Figure 5.6B). There was a statistically significant, lower median 
fluorescence (and so fewer particles per cell) when cells were treated with 
amiloride (74 +/- 12 AFU) compared to non-treated cells incubated with CD95R-
Fc coated particles (115 +/- 14 AFU; P ≤ 0.01). There was a trend toward lower 
median fluorescence with cytochalasin D (85 +/- 7 AFU) and with chlorpromazine, 
there is an increase in median fluorescence (137 +/- 25 AFU) indicating that cells 
internalised more particles. This trend is not as pronounced with Dynasore (114 
+/- 8 AFU). Further experimental repeats could determine whether these trends 
are significant or not. 
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5.3. Discussion 
CD95R-Fc enhances the uptake of MPs into MDA-MB-231 cancer cells, however 
the mechanisms involved in targeting and uptake were not known. Since the use 
of micro- and nanosystems for drug delivery has shown a strong potential for 
biomedical applications, a deeper understanding of their interaction with cells is 
needed for more efficient design of drug delivery systems (Patiño et al., 2015). In 
this chapter, the mechanisms of uptake of CD95R-Fc coated particles were 
investigated using confocal microscopy, live-cell imaging, endocytic inhibitors 
and DLS characterisation of coated MPs.  
 
It was hypothesised that enhanced uptake of CD95R-Fc coated particles was due 
to an interaction of this protein with its natural ligand, CD95L, which had been 
reported to be expressed on the surface of cancer cells and so should be present 
on MDA-MB-231 cells. In Chapter 4, this hypothesis was tested and rejected 
because no evidence for plasma membrane, CD95L expression in this cell line 
was found (or by cancerous cells in general). Nevertheless, coating in CD95R-Fc 
stimulated high level uptake of the particles in MDA-MB-231 cells. In order to test 
whether the enhanced uptake is a cancer-cell specific effect, CD95R-Fc coated 
MP uptake was measured in primary dermal fibroblasts sourced from facial skin. 
Primary cells were used to avoid any bias due to selection for growth in tissue 
culture which might alter the uptake properties of cancer or immortalised cell 
lines. A statistically significant improvement in uptake (53 +/- 1%) of CD95R-Fc 
coated MPs was recorded in comparison to several control particle preparations, 
which is similar to the levels observed in MDA-MB-231 cells. The controls 
included Fc coated and BSA coated particles, which did not improve uptake to 
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the extent of CD95R-Fc coated particles, showing that the CD95R ECD is 
responsible for the enhanced uptake. There was no statistical difference in the 
median fluorescence of cells with particles, between the two cell lines, suggesting 
that they have internalised a similar number of particles per cell. These data 
suggest that the CD95R-Fc enhanced uptake effect is not specific to cancer cells. 
However, as described in the introduction, some cells exhibit the phagocytic 
activity similar to immune cells, classed as “non-professional” phagocytes. 
Indeed, a mechanism has been described where phagocytes can alter and 
dampen the phagocytic activity of neighbouring cells via IGF-1, including LR73 
cells, which are a type of Chinese hamster ovary fibroblast cells (Han et al., 
2016). These fibroblasts have a phagocytic activity and are classed as “non-
professional” phagocytes, with the potential to clear apoptotic cells and particles 
(Gregory and Pound, 2010). Similarly, human dermal fibroblasts have the ability 
to phagocytose the apoptotic bodies of neutrophils which are recognised by the 
fibroblast via the vitronectin receptor and a mannose/fucose-specific lectin (Hall 
et al., 1994). Fibroblasts in the wound sites of rats have also been found to 
internalise non-coated, IgG coated and collagen coated fluorescent beads (1µm) 
(Arlein et al., 1998). Therefore, it is perhaps not particularly surprising that the 
primary dermal fibroblasts used here have internalised MPs.  
 
The expression of CD95L was investigated via Western blot, however, none was 
detected in the fibroblasts. Even though CD95L doesn’t seem to play a role in 
uptake in primary dermal fibroblasts or the MDA-MB-231 cells, the uptake 
mechanisms active in these two cell lines are not necessarily identical. 
Internalisation pathways are often cell-type specific. For example, in breast 
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cancer cells, non-coated, negatively charged particles appear to be internalised 
via macropinocytosis but in breast epithelial cells, they are internalised via two 
pathways; macropinocytosis and a dynamin-dependent endocytosis method 
(clathrin or caveolae-mediated endocytosis) (Patiño et al., 2015). The uptake 
pathway in primary dermal fibroblasts would need to be determined and 
compared to MDA-MB-231 cells; potentially the two cell lines share a common 
receptor, which is recognising the CD95R coat or the particle itself to trigger 
uptake, but this would need to be investigated. In terms of clinical application, a 
CD95R-Fc coated MP for cancer drug-delivery, given intravenously, risks 
inducing side-effects if non-cancerous cells are able to internalise the MPs as 
demonstrated here.  
 
When working with MPs it is important to distinguish between MPs that have been 
completely internalised by cells from those that are simply membrane-attached, 
since they are utilised for intracellular drug delivery. Several methods have been 
developed to address this. For example, when using polystyrene particles that 
are surface-labelled with fluorescent antibodies (such as Alexa488-IgG), the 
fluorescence can be quenched using trypan blue. Since trypan blue is not capable 
of penetrating live cells, the quenching effect only occurs in the extracellular 
space, so the fluorescence of MPs bound to the membrane can be quenched, 
whereas internalised MPs, separated from the quencher, fluoresce intracellularly 
(Patiño et al., 2015). An added benefit of using trypan blue is that it can also 
determine cell viability since it can only enter cells with damaged plasma 
membranes (Patiño et al., 2015). However, the polystyrene particles used here 
are internally labelled with dragon green fluorescence using dye 
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diffusion/entrapment. This involves the swelling of polymeric microspheres in an 
organic solvent or dye solution where the water-insoluble dye diffuses into the 
polymer matrix and is entrapped when the solvent is removed from the 
microspheres (Bangs, 2013). This means that fluorescence cannot be quenched 
using a substance like trypan blue because the dye is inaccessible to the 
quencher.  
 
The FACscan used for flow cytometry cannot discriminate between surface 
bound and internalised particles. Some forms of flow cytometry can do this, such 
as an ImageStream (Merck) which can provide low to medium resolution images 
of every cell analysed, allowing the user to assess whether a particle is 
membrane bound or internalised, although the analysis remains subjective and 
the resolution is limiting. For analysis of live cells, the approach adopted here, 
making use of an IN Cell 6000 provides an excellent compromise. Confocal 
imaging of adhered cells at medium to high resolution can be automated and 
quantified to provide high throughput analyses. Such an approach proved useful 
to demonstrate the effectiveness of the washing procedures used to remove non-
internalised particles from cells. With analysis stringencies in place to ensure non-
bound particles were not counted, CD95R-Fc coated MP uptake was found to be 
statistically different with more cells internalising particles, and more particles per 
cell than the control conditions. This technique allowed discrete numbers of 
particles internalised by cells to be seen and complements the uptake and 
median fluorescence data obtained by flow, even when far fewer cells were 
analysed (150 – 200 cells per condition here compared to 10,000 cells for flow 
analysis). There is however, a margin of error when using confocal imaging to 
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take optical slices throughout a cell, since the slice (the Z-intensity profile) is not 
sharp but has a Gaussian profile and is shaped like a bell. The practical thickness 
of each slice may therefore deviate from theoretical estimation. The exact Z-
intensity profile, or optical slice thickness, can vary with objective (numerical 
aperture; NA), size of confocal aperture and wavelength of light. The confocal 
slices for the experiment here were taken at 40x, NA=0.6 at 1 AU (airy unit), 
meaning that the theoretical 1.7µm slices may include light over a 5µm slice. 
Confocal settings can be optimised by using an objective with a higher numerical 
aperture, improving the resolution, however the amount of time required to image 
each cell in focus would increase, which may be impractical. Another way to 
optimise confocal settings is via sample preparation, for example, by seeding the 
MDA-MB-231 cells onto thin, glass bottomed wells, ensuring the entirety of the 
cells are included in the confocal slice. The plate curvature of typical 6-well plate 
(as was used) means part of the sample may not be included or imaged since 
confocality does not solve the issue of light scattering caused by plate bottom 
curvature, it only removes out of focus light. To help counteract this, multiple 3D 
Z-images were flattened into one, 2D image, hoping to get all cells in focus.  
 
Protein-coated particles were characterised using dynamic light scattering (DLS). 
Even though the particles used are purchased at a discrete size (quality control 
suggests 0.53µm diameter), the presence of aggregates in solution distorts the 
particle size reading obtained for most samples, and likely explains the larger 
values obtained than 530nm. Aggregation was reduced by coating particles in 
BSA, which is recommended technique to reduce nonspecific binding and self-
aggregation since BSA blocks the exposed hydrophobic surfaces of the MPs 
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(Bangs, 2008a). Other methods to reduce particle aggregation include sonication, 
(particularly by using a bath sonicator with samples in a glass vial), vortexing and 
pipetting which provide shear forces to break up particle masses (Bangs, 1999). 
These techniques however are not recommended after passively absorbing a 
ligand to the surface of non-functionalised MPs, since the shear forces involved 
can dislodge protein adsorbed to the particle surface (Bangs, 1999). Despite this, 
they may be useful prior to coating. Having a monodisperse population will mean 
more free, single particles are available for cells to internalise, as large 
aggregates are not as readily taken up by cells.  
 
A combination of electrophoresis and DLS was also utilised to measure the 
surface charge of non-coated versus protein-coated particles, since this is a 
factor that can affect particle uptake. Previous studies have suggested that 
tumour and cancer cells preferentially internalise positively-charged 
nanoparticles and 3µm polystyrene particles (section 5.1.6.) (Patiño et al., 2015, 
Wang et al., 2012, Gratton et al., 2008). The size and zeta potential difference of 
the BSA coated particles suggests that the absorption technique results in 
modification of the particle surface. When particles are coated with CD95R-Fc 
with BSA, this BSA-effect is not apparent or perhaps is prevented by the CD95R-
Fc. This suggests both that the CD95R-Fc functionalises the particle surface and 
has a higher avidity for the particles than the BSA. However, the difference in 
charge caused by coating in different proteins did not correlate well with the 
differences in uptake seen, for example, there was no statistical difference in 
surface charge of Fc-coated MPs and CD95R-Fc coated MPs (with or without 
BSA), yet there was a pronounced and statistically significant difference between 
233 
 
these conditions when uptake was tested. It is therefore unlikely that a difference 
in surface charge explains the differences in uptake. Although subtle differences 
in surface charge were seen here, particles with a zeta potential between -10 and 
+10mV are considered approximately neutral, while particles with zeta potentials 
of greater than +30mV or less than -30mV are considered strongly cationic and 
strongly anionic, respectively (Clogston and Patri, 2011). All particles, coated or 
non-coated, had a zeta-potential that would be considered close to neutral, 
(perhaps excluding BSA coated MPs which are slightly anionic with a surface 
charge of -12.7 +/- 0.2mV). In vivo, the BSA coated particles would be considered 
advantageous, because negatively-charged particle therapies have been shown 
to be less likely to induce an immune reaction. This may be explained by the 
display of negatively charged sialic acids by macrophages, that readily interact 
with cationic substances (Chellat et al., 2005). Uptake by macrophages can then 
lead to the release of inflammatory cytokines, as shown by Lucarelli et al., who 
exposed human macrophages to non-toxic concentrations of different 
nanoparticles that triggered distinct inflammatory responses (Lucarelli et al., 
2004). Silicon dioxide (SiO2) nanoparticles, for example, induced the production 
of inflammatory cytokines interleukin 1 beta (IL-1β) and tumour necrosis factor 
alpha (TNF-α) (Lucarelli et al., 2004).  
 
Preliminary investigations of the uptake mechanism of CD95R-Fc coated MPs 
was also investigated, using a panel of commonly used inhibitors. Two inhibitors 
for each pathway were used to maximise confidence in the conclusion. Since 
endocytic inhibitors can induce cellular side-effects and are prone to act non-
specificity, use of two inhibitors helps to ensure that any observed effect 
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genuinely impacts a particular uptake pathway since inhibitors of the same 
pathway tend to work via different mechanisms and on different targets. A 
statistically significant reduction in uptake and number of particles per cell was 
discovered with amiloride treatment. Amiloride inhibits macropinocytosis by 
affecting Na+/H+ exchange, which has been linked to macropinosome formation. 
By inhibiting this exchange, Amiloride acidifies the submembranous pH of a cell 
and so, prevents the activation of GTPases (Rac1 and CDC42) that promote actin 
remodelling, since they have been found to be extremely sensitive to these pH 
changes (Koivusalo et al., 2010). Selective inhibitors of the Na+/H+ exchange 
(such as amiloride) may have the fewest side effects and may be considered as 
a first choice for the pharmacological probing of macropinocytosis (Ivanov, 2008). 
However, possible endocytosis-unrelated effects on ion transport and the 
cytoskeleton may still be an issue, affecting the viability of tested cells. A similar 
reduction in cellular uptake and median fluorescence was seen when cells were 
treated with cytochalasin D, however this did not reach statistical significance. 
Cytochalasin D blocks actin polymerisation by occupying the faster-growing 
“barbed” end of actin filaments (Ivanov, 2008). It was predominantly used here 
as an inhibitor of macropinocytosis, but it can affect the formation of large F-actin-
coated vesicles (phagosomes and macropinosomes) associated with both 
phagocytosis and macropinocytosis. It is possible that MDA-MB-231 cells may 
possess a “non-professional” phagocytic activity to internalise the MPs since they 
have been shown to locally degrade and phagocytose the extracellular matrix 
(Coopman et al., 1996). However, the actin cytoskeleton is involved in 
endocytosis for nearly all internalisation pathways, such as the formation of the 
actin module, which enables movement of vesicles away from the plasma 
membrane irrespective of vesicle-coat protein. As a result, cytochalasin D might 
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be considered as a global and nonselective inhibitor of all internalisation 
pathways, rather than a specific blocker of macropino- and phagocytosis (Ivanov, 
2008). Despite this, particle size also has a large part to play in the pathways of 
cellular uptake. Since phagocytosis (≥0.5µm) and macropinocytosis (0.2 to 
10µm) are capable of internalising micrometre-scale particles, it is logical to 
assume that one or both of these pathways are in effect to internalise the 0.5µm, 
CD95R-Fc coated MPs. Additionally, none of the inhibitors of small-scale 
endocytosis mechanisms (which usually internalise particles <200nm), had any 
noticeable reduction on particle uptake. More investigation is required to 
determine whether uptake is due to macropinocytosis, phagocytosis (alone or 
combined), or whether the CD95R-Fc protein coat has any targeting or activating 
effect on uptake (see section 5.3.1.).  
 
Interestingly, chlorpromazine seemed to have a positive effect on particle uptake 
and number of particles internalised (as reproducible trends which did not reach 
statistical significance) by the MDA-MB-231 cells. Potentially, this could be an off-
target effect since chlorpromazine is an amphipathic molecule, which can 
incorporate into the lipid bilayers and can increase lipid fluidity within the plasma 
membrane (Ogiso et al., 1981). Such gross changes of the membrane are likely 
to have knock-on effects on the endocytic pathways. However, there is also some 
prior evidence suggesting that inhibition of clathrin-coated uptake upregulates 
other pathways. When chlorpromazine was used on ARPE-19 (human retinal 
epithelial), HuH-7 (human liver), Vero (monkey kidney epithelial) and COS-7 
(monkey kidney fibroblast) cells, it enhanced uptake of lactosylceramide 
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(LacCer); a glycosphingolipid that resides preferably in lipid rafts, which is a 
marker of caveolae-mediated endocytosis (Vercauteren et al., 2010).  
 
In contrast, a study by Novak et al. found a potential link between clathrin-
dependent uptake and uptake via membrane protrusions (potentially indicating 
macropino- or phagocytosis). They used scanning ion conductance microscopy 
to allow high-speed topographical and fluorescence imaging of the interactions 
between 200nm polystyrene particles and human lung cells (Novak et al., 2014). 
A particle was imaged being engulfed by a large membrane protrusion, but prior 
to this, there was an initial interaction between fluorescently-tagged clathrin pits 
and the particle. It was hypothesised that the disproportion in diameters of the 
pits (~100nm) to the particles led to failure in uptake and may reflect a form a 
‘cell-sensing’, allowing the cell to test whether or not a particle is the correct size 
for a particular internalisation pathway. Perhaps, removing a cells’ ability to 
internalise via clathrin-mediated endocytosis and this cell-sensing procedure, 
speeds up or leads to a reliance on actin-only forms of uptake and the increase 
in MP uptake seen with chlorpromazine. Time-lapse, live-cell imagining 
demonstrated an interaction between a CD95R-Fc coated MP and a membrane 
protrusion from MDA-MB-231 cells. Further testing of uptake of CD95R-Fc coated 
MPs using a scanning ion conductance microscopy and fluorescently labelled 
clathrin and actin, might elucidate more detailed information regarding the 
mechanism of particle internalisation. 
 
237 
 
5.3.1. Limitations and possible future directions 
Although DLS measurements found that different protein coats affect particle size 
and surface charge, the experiments were undertaken in the coating buffer, PBS. 
After coating, the particles are added to cells which are growing in DMEM 
supplemented with 2% (reduced) FBS. Ideally, particle properties should be 
measured again, after suspension in this medium. Medium contains many 
different biomolecules, such as proteins, which can adsorb onto the particle 
surface to produce a protein corona (Shang et al., 2014). The reduced FBS 
component of the media (2% rather than a standard 10% FBS (v/v) component) 
was to reduce the amount of free protein that can interact with the particle and 
form a corona. The likely presence of a protein corona will change the properties 
of the particles, including important factors that affect uptake, such as surface 
charge and aggregation. Potentially, the initial protein coat could affect the 
characteristics of this protein corona, thus modulating particle/cell interactions. 
Furthermore, the CD95R-Fc used for coating could interact with proteases in the 
cell media and it is unknown whether it is cleaved or modified during particle 
incubation with the cells. This could be difficult to determine, however, the 
CD95R-Fc used for coating could be incubated in spent media (from the MDA-
MB-231 cells) for 24 hours, and its stability determined by Western blot.  
 
It is likely that the particles are being internalised via macropino- or phagocytosis 
because of their size. The results of the inhibitor experiments may also indicate 
this; however, some important factors were not tested in this experiment. This 
includes cell viability in response to the inhibitor concentrations used, which has 
been found to be cell type-dependent. For example, high chlorpromazine 
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concentrations (12µg/ml, ~38µM and above) have very little effect on ARPE-19 
and D407 (human retinal epithelial) cells but are toxic to COS-7 cells at 5µg/ml, 
16µM (Vercauteren et al., 2010). Chlorpromazine was used at 15µM for the 
experiments described here yet the effect of this concentration on MDA-MB-231 
cells is not known. Furthermore, the use of positive controls, to ensure that 
specific endocytic pathways had been inhibited, would have improved this 
experiment. Some markers of uptake pathways have already been described 
such as human transferrin, which is a good specific marker for clathrin-mediated 
uptake and LacCer or cholera toxin subunit B as a marker of caveolae-mediated 
endocytosis. DMSO only controls would also be useful, i.e. cells incubated with 
matching volumes of DMSO and then non-coated and CD95R-Fc coated 
particles, since many of the inhibitors were solubilised in DMSO and this can be 
toxic to cells. To elucidate the specific pathways further and complement the 
inhibitor experiment data (without the complications associated with using 
endocytic inhibitors) siRNA experiments could be utilised. This has been used to 
determine the uptake of folate-functionalised glycol chitosan nanogels (Pereira et 
al., 2015). Knockdown of specific proteins of each pathway, such as clathrin and 
caveolin, is possible. For macropinocytosis, Pereira et al., knocked down CDC42 
and p21-activated kinase (Pak-1), since it is associated with growth-factor-
induced macropinosomes and can be activated by CDC42 and Rac1; well-known 
GTPases involved in macropinocytosis (Pereira et al., 2015). 
 
Since MDA-MB-231 cells have been shown to elicit a “non-professional” 
phagocytic capability, it is possible that they internalise MPs this way. 
Phagocytosis is induced by interaction between ligands on the particle surface 
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and receptors on the phagocytic membrane. Therefore, knockdown of known 
scavenger, complement and integrin receptors (see table 5.1) that are present in 
MDA-MB-231 cells, would be a good strategy to determine whether the CD95R-
Fc protein coat or perhaps, the resulting protein corona, is initiating uptake. 
Previous reports of the phagocytic ability of MDA-MB-231 cells showed that it 
was dependent on alpha 3 beta 1 integrin (Coopman et al., 1996). Since CD95L 
is likely not involved in uptake, this would be crucial in determining whether there 
is any specific effect due to the CD95R coat, for preferential internalisation by 
MDA-MB-231 cells and primary dermal fibroblasts.  
 
Finally, along with the uptake mechanisms, it would be important to determine 
the intracellular fate of internalised particles. This could be determined by 
incubating the cells with an endosomal (such as EEA1) or lysosomal (LAMP-1) 
markers, and analysing uptake of CD95R-Fc MPs over time, using the IN Cell 
6000. Both end point and live-cell imaging could be utilised where possible. The 
3µm polystyrene particles internalised by SKBR-3 and MCF-10A were found to 
localise to lysosomes, regardless of coat or surface charge (Patiño et al., 2015).    
 
5.4. Summary 
CD95R-Fc coated MPs are more readily internalised by MDA-MB-231 cells but 
not via a CD95L interaction as was previously hypothesised. In Chapter 5, the 
mechanisms involved in particle uptake were investigated. Uptake was tested in 
non-cancerous cells and again, CD95R-Fc coated MPs were preferentially 
internalised. This effect therefore, is not specific to cancer cells. Confocal imaging 
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showed that the particles are fully internalised, and not simply bound to the cell 
surface. Particles were characterised by dynamic light scattering (DLS) which 
suggested that the protein absorption technique results in modification of the 
particle surface, which is most noticeable when coating with BSA. Although 
coating in different proteins affects particle size and surface charge, the subtle 
differences measured suggest that it is unlikely that these are responsible for the 
enhanced uptake of CD95R-Fc coated MPs. Finally, common endocytic 
pathways were inhibited. There was a statistically significant reduction in uptake 
when treating cells with amiloride and a similar trend when treating with 
cytochalasin D, inhibitors of macropinocytosis, however no inhibitor fully blocked 
uptake. Due to particle size, MP uptake likely occurs via macropino- or 
phagocytosis. More investigation is required to determine which pathway is 
preferred in this cell type, and whether or not the CD95R is binding to a specific 
receptor or lipid on the cell surface to initiate the process.  
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6. General Discussion 
The aim of this study was to develop an expression and purification system for 
CD95R-Fc to allow the mechanisms of coated microparticle (MP) uptake in 
cancer cells to be investigated. In Chapter 3, a baculoviral system was optimised 
for expression of recombinant CD95R, fused to the Fc region of human IgG1, in 
Sf21 and Hi5 cells. The protein was purified by affinity chromatography with a 
potential yield of 1.2mg per 100ml culture and a purity of 90%. The purified 
CD95R-Fc was used to coat microparticles that were efficiently taken up by MDA-
MB-231 (triple negative breast cancer) cells, in comparison to non-coated 
particles. It had been suggested that this enhanced uptake was due to a 
CD95L/CD95R interaction. Stability of the in-house CD95R-Fc was tested, and 
long-term storage conditions were optimised. In Chapter 4, anti-CD95L 
antibodies (many of which have been critically appraised and found to lack 
specificity) were validated by overexpressing CD95L-Myc-DDK in HEK293T 
cells, with and without CD95L-sheddase inhibitors. The expression of supposed 
target ligand CD95L was then tested in MDA-MB-231 cells to examine the 
proposed targeting mechanism of CD95R-Fc coated MPs. It was concluded that 
there are undetectable levels of the CD95L protein in MDA-MB-231s, as shown 
by Western blot and immunocytochemistry. Despite MDA-MB-231 cells lacking 
CD95L protein at the plasma membrane, they very efficiently take up CD95R-
coated MPs. In Chapter 5, the reasons for this enhanced uptake were explored 
and mechanisms of particle uptake examined. Uptake was tested in a non-
cancerous cell line and CD95R-Fc enhanced uptake was also found in primary 
dermal fibroblasts and so the effect is not cancer-cell specific. Confocal imaging 
demonstrated that the particles are fully internalised, and not simply bound to the 
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cell surface. Particles were characterised by dynamic light scattering (DLS) and 
electrophoresis and notable differences in surface charge, due to coating in 
CD95R-Fc, were not apparent. Finally, common endocytic pathways were 
inhibited which suggested that MP uptake likely occurs via macropino- or 
phagocytosis and may involve membrane protrusions as seen via time-lapse 
microscopy.  
 
In the following sections, the findings of this study are discussed in relation to the 
data in the literature, and possible further work is considered that may lead to 
fuller understanding of whether this delivery system is plausible for use as a cargo 
delivery system.  
 
6.1. Targeted chemotherapeutics for triple negative breast 
cancer 
The main cell line used in this study was MDA-MB-231 cells, a triple negative 
breast cancer cell line. Triple negative breast cancers, which represent ~15 - 20% 
of breast carcinomas, lack the three main breast cancer biomarkers; oestrogen, 
progesterone or HER2 (human epidermal growth factor receptor 2) receptors 
(Denkert et al., 2017). Patients with triple negative breast cancer do not benefit 
from any endocrine or anti-HER2 therapy (such as Herceptin, a mAb), and 
chemotherapy is the only established therapeutic option (Denkert et al., 2017). 
Chemotherapies such as the taxane, paclitaxel, are associated with common off-
target toxicities including neutropenia, leukopenia, anaemia, neuropathy and 
fatigue (Wood et al., 1995) and tumours often develop resistance to such 
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cytotoxic compounds (Longley and Johnston, 2005). Furthermore, taxanes are 
poorly soluble in water and the agents in which they are solubilised in (such as 
cremophor) can lead to hypersensitivity reactions in patients (Wang et al., 2012). 
Therefore, there is a need for targeted treatments for triple negative breast 
tumours, which can deliver cytotoxic compounds directly to the cancerous cells 
to reduce systemic toxicity. Abraxane is one example of a solvent-free treatment 
for breast cancer, a 130 nm, albumin-bound particle form of paclitaxel (Miele et 
al., 2009). This treatment option utilises the natural uptake pathway of albumin, 
which binds to a cell surface, 60kDa glycoprotein (gp60) receptor called albondin. 
The gp60/ligand complex interacts with caveolin-1 to form vesicles which 
transcytose the albumin (and bound paclitaxel) into the cell cytoplasm (Miele et 
al., 2009). This results in a higher penetration of Abraxane into tumour cells with 
an increased anti-tumour activity, compared to an equal dose of standard 
paclitaxel (Miele et al., 2009). Despite the improved solubility, uptake and 
reduced toxicity seen with Abraxane, it doesn’t actively target cancer cells for 
treatment.  
 
A study in 2011 found a novel use for CD95R in targeted drug delivery; when 
used to coat microparticles, >0.5µm in diameter, they were preferentially 
internalised by neurons, medulloblastoma, breast and ovarian cancer cells in vitro 
(Ateh et al., 2011). When biodegradable MPs, made from PLGA and loaded with 
paclitaxel, were coated in CD95R-Fc, they were significantly more effective 
compared to conventional paclitaxel therapy (taxol) at the same dose in 
subcutaneous medulloblastoma and orthotopic ovarian cancer xenograft models  
(Ateh et al., 2011). This drug delivery system potentially represented a way to 
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improve function of cytotoxics in cancer by increasing drug targeting and efficacy 
whilst reducing toxicity, without the need for any toxic solvents. This study has 
provided some further evidence to support this previous data, showing that 
CD95R modifies the surface of particles and is responsible for the increase in 
uptake into MDA-MB-231 cells. However, the precise mechanisms behind this 
are still not known, although it has been shown not to involve CD95L. Initially, this 
improved uptake suggested a potential cancer targeting mechanism of drug 
delivery however, it was then seen in a non-cancerous cell line which alludes to 
potential off-target toxicities. This puts into question the conclusions of the 2011 
paper, and more study is required in cellular systems (see section 6.4) before 
further testing in in vitro models. Animal models are an important tool to test drug 
delivery systems on since they can more closely mimic the tumour 
microenvironment in a way that is not possible using 2D, cellular systems. 
Considerable efforts have been made to develop more clinically relevant models, 
for example, by use of orthotopic transplantation of tumour material in rodents 
(Bibby, 2004).  It has been shown that transplanting tumour material from a 
variety of tumour types into the appropriate anatomical site results in tumours that 
will metastasise in a similar manner and to similar locations as the same tumour 
type will in human cancer (Bibby, 2004). An animal model like this could prove 
more relevant than the orthotopic model used by Ateh et al. in 2011, since this 
was developed using IGROV1 cells rather than real tumour material.  
 
6.2. The use of micron-sized particles for drug delivery 
0.5µm MPs, coated in CD95R-Fc, were found to be internalised to a greater 
extent than 1µm, CD95R-Fc coated MPs in MDA-MB-231 cells (Ateh et al., 2011) 
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which is why 0.5µm particles were selected for the current study. There has been 
extensive study into nanoparticle systems for drug delivery since nanoparticles 
are easily internalised by cells (by either active or passive uptake) (Shang et al., 
2014). However, there are advantages of using a large or micron-sized particle 
for drug delivery, rather than nano-scale methods, including providing a greater 
volume for drug loading. For example, the volume of 1µm diameter particles is 
125-fold greater than their 200nm counterparts, enabling more drug molecules to 
be packaged and potentially allowing more to be delivered directly to the 
cytoplasm of cancer cells (Ateh et al., 2011). Particle size however can also affect 
drug loading efficiency and drug release profiles. A very large particle, for 
example, 20µm compared to 1µm, may have a lower drug loading efficiency. 
Dawes et al., found this when comparing drug loading and release profiles of 
differently sized PLGA particles. The drug loading efficiency was tested by 
dissolving particles in acetonitrile and measuring encapsulated drug release by 
High Performance Liquid Chromatography (HPLC); for 1µm particles, the 
efficiency was 11% compared to 1% for 20µm particles (Dawes et al., 2009). 
Additionally, over a 550 hour release period, where particles were placed in PBS 
at 37°C with drug release measured again by HPLC, the larger particles were 
found to release 90% of encapsulated drug in a linear fashion, whereas the 1µm 
particles released only 30%; 20% within the first 25 hours (Dawes et al., 2009). 
This demonstrates a biphasic, ‘burst effect’ release profile, where an initial bolus 
of drug is released before the release rate reaches a stable profile (Huang and 
Brazel, 2001). Both of these effects can be attributed to the higher surface area 
per unit volume of the 1µm particles. During formulation, the level of polymer-
water interface is increased in the smaller particle allowing more drug to be 
encapsulated by the emerging polymer spheres (Dawes et al., 2009). Similarly, 
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during drug release, the rate of inclusion of water into the polymer increases, 
permitting faster diffusion of the loaded drug (Dawes et al., 2009). In addition to 
particle size, the type of PLGA used to create particles can affect how 
encapsulated drug is released. The hydrophilicity of PLGA (as defined by the 
lactide:glycolide ratio) and the polymer molecular weight are the key factors 
influencing drug release. The rate of degradation is inversely proportional to the 
proportion of lactide monomer in the polymer strands (Anderson and Shive, 2012) 
and the rate of diffusion of drugs through the polymer matrix is inversely 
proportional to the molecular weight of the PLGA polymer (Dawes et al., 2009). 
These examples describe the advantages of using PLGA microparticles for drug 
delivery, since their size and polymer characteristics allow tuneable drug loading 
and release profiles. Furthermore, micron-based systems can be loaded with 
more drug and provide a sustained release for longer periods of time than 
nanoparticle drug delivery methods. Microscale spheres have been typically used 
in applications where the drugs can be delivered to a particular site without 
diffusing away; the most effective size range for this has been quoted as 10 – 
200µm (Dawes et al., 2009). Particles smaller than 10µm can be phagocytosed 
by immune cells. The downsides of this not only include potential side-effects (as 
is discussed in section 6.4) but the immune cells will transport the particles away 
from their intended site of action. Using microspheres larger than 200µm can 
disrupt the tissue structure of the implantation site, leading to an increased 
immune response and unnecessary inflammation (Dawes et al., 2009). 
Additionally, due to the increased radius and decreased surface area, the rate of 
water permeation into these particles would reduce significantly, reducing the 
maximum possible rate of drug release (Dawes et al., 2009). 
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6.3. Potential advantages of using microparticles in a clinical 
setting 
In a clinical setting, micron-sized PLGA particle therapies may reduce a patients’ 
visits to hospital to receive treatment. A standard chemotherapy regime for triple-
negative breast cancer is FEC-T (Fluorouracil, Epirubicin, Cyclophosphamide 
and doceTaxel) in which there are 3 or 4 cycles of FEC and then 3 or 4 cycles of 
T, each cycle lasting for 21 days (Roché et al., 2006). This means that a patient 
may visit a hospital 6 - 8 times, potentially more if there are bad reactions and 
side-effects to the chemotherapy. Dutta et al., tested the release period of 
differently sized PLGA particles, loaded with BSA (Dutta et al., 2016). Lyophilised 
particles were resuspended in PBS and incubated at 37°C under constant 
agitation. At specified time points, the particle suspensions were centrifuged, and 
supernatants removed and replaced with fresh PBS. The release media samples 
(supernatants) were quantified for protein content using a BCA assay and for 
particles with an average diameter of 541nm, the total release period was 72 days 
(Dutta et al., 2016). In relation to the FEC-T regime, a microparticle-based 
treatment may have the potential to reduce hospital visits by a patient, to 2 – 3 
visits for example, which is more convenient for a patient and could reduce the 
burden on hospital resources. With successful targeting, a MP treatment could 
also reduce the adverse side-effects to improve a patient’s quality of life 
throughout their treatment.     
 
6.4. Lack of active targeting by CD95R-Fc coated MPs 
The potential of CD95R-Fc coated MPs for use as a delivery system for 
chemotherapeutic treatments relies on the successful targeting of these MPs 
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directly to the cancer cells. In the paper by Ateh et al, when discussing the 
success of the CD95R-Fc MP treatment in an orthotopic ovarian cancer xenograft 
model, it is stated that any immune cell involvement as a side-effect of this 
treatment (uptake by peritoneal macrophages or NK cells for example), would 
need to be determined further (Ateh et al., 2011). Not only do immune cells have 
a natural phagocytotic activity for particles (≥0.5 µm), but it was thought that off-
target effects may also be induced by the CD95R-Fc on the particle binding to 
CD95L or an Fc receptor endogenously expressed on the surface of immune cell. 
The targeting mechanism of the CD95R-Fc drug delivery system was 
investigated in the current study for targeting potential to MDA-MB-231 cells, and 
despite increased uptake of CD95R-Fc modified MPs, there was no convincing 
evidence to suggest this cell line expresses CD95L. Furthermore, the enhanced 
uptake of CD95R-Fc coated MPs was found in a non-cancerous cell line; primary 
dermal fibroblasts. Primary cells were used to avoid any bias due to selection for 
growth in tissue culture which might alter the uptake properties of cancer or 
immortalised cell lines. The potential for CD95R-Fc to interact with another 
protein to initiate uptake is discussed below in ‘future work’ (see section 6.8), but 
it seems likely that this system lacks a sufficient targeting mechanism. This could 
present problems if a future treatment was administered systemically, as 
chemotherapeutics often are. It means that potential off-target effects could 
include not only MP uptake by innate immune phagocytes, but any cells that have 
phagocytic activity; non-professional phagocytes (such as fibroblasts). Uptake of 
MPs by non-cancerous cells means that patients could still suffer the side effects 
associated with standard chemotherapeutics.  
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6.5. Passive targeting of cancer nanomedicines  
Not all nano/microparticle therapies rely on active targeting, such as 
functionalising the particle surface with a natural ligand or biological marker 
(Kohane, 2007). Passive targeting involves using a specific physiological 
parameter to act as a filter. In the case of cancer, many nanoparticle therapies 
rely on the EPR (enhanced permeability and retention) effect, whereby molecules 
of a certain size range tend to accumulate in tumour tissues more than healthy 
tissues. This is due to the blood vessels in the tumour system having leaky walls 
and generally the lymphatic system in a tumour is absent or dysfunctional, 
therefore insufficient drainage leads to particle accumulation within the tumour 
tissue (Sun et al., 2014). The effect results from dysregulated tumour 
angiogenesis, whereby the rapid growth of blood vessels surrounding the tumour 
leads to the reduced density of endothelial cells and thus loss of tight junctions 
and formation of large gaps between the cells (Sun et al., 2014). Furthermore, 
the underlying basement membrane of the blood vessels is mostly abnormal or 
missing (Baban and Seymour, 1998). The openings in the tumour vasculature 
are typically in the size range of 100 – 800nm, and vary depending on the tumour 
type (Sun et al., 2014). When liposomes of different mean sizes were tested, the 
cut off size for extravasation into tumours was approximately 400nm, whereas 
particles with diameters smaller than 200nm were found to work most effectively 
(Yuan et al., 1995). This is because particles larger than 200nm were cleared 
from the blood stream more rapidly by the spleen, as it contains a tight reticular 
mesh which preferentially clears particles of ≥200nm (Sun et al., 2014). 
Experiments have shown for example, that 50% of polystyrene nanoparticles with 
a diameter of 250nm and coated in poloxamine 908 (a hydrophobic, block co-
polymer) accumulate in the spleen within 24 hours of injection because of this 
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physical filtration effect (Moghimi et al., 1993). Taken together, this evidence 
suggests that CD95R-Fc modified, 0.5µm MPs may not be suitable for passive 
targeting, since they could be too large to extravasate into tumours, and their size 
means they would likely be cleared systemically by the spleen.    
 
6.6. Intratumoral injection  
A potential way to counteract the lack of active targeting would be to inject 
CD95R-Fc coated MPs directly into the target tumour. In the peritoneal ovarian 
cancer xenograft model, where CD95R-Fc modified PLGA particles were more 
effective than free paclitaxel at the same dose, the particles were injected directly 
into the peritoneum of the mice (Ateh et al., 2011). Potentially this effect may be 
partially due to the microparticles staying where they have been placed; they are 
retained within the tumour environment allowing local release of the cytotoxic. 
The difference between micro- and nanoparticles has been described in the 
abdominal cavity (Kohane, 2007). PLGA microparticles, 5, 25, 60 and 250µm in 
diameter, injected into the peritoneum of mice, remained there for at least two 
weeks, whereas an equal mass of nanoparticles (265nm) of the same material 
showed almost complete clearance in the same time frame (Kohane et al., 2006). 
The nanoparticles were sequestered in the spleen and liver, with ‘foamy’ 
macrophages noted, likely due to the accumulation of a large amount of polymeric 
material (Kohane et al., 2006). This could also apply to the tumour 
microenvironment since microparticles injected directly into a tumour may be 
more likely to be retained with their larger size preventing redistribution. This 
approach has been utilised recently, using microparticles within an injectable 
hydrogel, to treat TNBC (Davoodi et al., 2017). Core-shell microparticles (ranging 
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from 12 – 18µm), encapsulating cisplatin and paclitaxel, were embedded into an 
injectable hydrogel (Davoodi et al., 2017). The use of the hydrogel serves many 
advantages such as providing a diffusion barrier to prevent premature release of 
the loaded drugs, preventing surgical site infection due to its inherent antibacterial 
properties, but most importantly, it retains the particles in the tumour resected 
cavity during the injection, following debulking (tumour removal) surgery (Davoodi 
et al., 2017) thus ensuring a localised delivery of the loaded drugs. The 
performance of the microparticle/hydrogel carrier was tested using three-
dimensional, MDA-MB-231 spheroids. These in vitro tumour models are thought 
to more accurately recapitulate human solid tumour architecture and biology 
(Sant and Johnston, 2017). The microparticle/hydrogel carrier was found to 
provide a superior efficacy and reduction on spheroid growth compared to free-
drug treatment (Davoodi et al., 2017). This demonstrates the use of 
microparticles in injectables, which do not rely on systemic delivery. Perhaps 
there is a use for CD95R-Fc in these sorts of treatments since coating particles 
could target them for cellular uptake, ensuring better intracellular drug delivery 
within the localised environment.  
 
6.7. CD95R-Fc microparticles for transfection 
Despite the implications discussed, a CD95R-Fc coated MP system could be 
useful as a method of transfection, since these particles have been shown here 
to be efficiently taken up by different cell types. PLGA microparticles can be 
loaded with many different types of cargo, not just toxic chemotherapeutics. For 
example, siRNAs, miRNAs or peptides. The system described here may provide 
useful for delivering such agents successfully into cells, without the toxicity and 
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cell death that standard transfection reagents can induce. An example of this has 
been shown by Haggag et al., who have used pegylated PLGA nanoparticles to 
deliver anti-Ran-GTPase peptides to MDA-MB-231 cells. Ran is a small RAS-
related GTPase which is highly expressed in aggressive breast carcinoma, and 
these peptides were predicted to prevent Ran hydrolysis and activation by 
blocking activity of RCC1, which catalyses the exchange of GDP for GTP on the 
nucleotide binding pocket of Ran (Haggag et al., 2017). Although these peptides 
have suggested anti-Ran activity in silico, peptide activity was limited in vitro due 
to poor delivery and reduced bioavailability. Delivery of these peptides, enclosed 
in pegylated PLGA nanoparticles however (with a mean diameter of 182 – 
227nm), led to 56.8 +/- 12.7% uptake by MDA-MB-231 cells and caused greater 
cell cycle arrest after 24 hours, compared to cells incubated with free peptide only 
(38% compared to 0.1% respectively) (Haggag et al., 2017). Western blot 
analysis confirmed the mechanism was via inhibition of Ran-GTP formation, 
which is essential for tumorigenesis and metastasis (Haggag et al., 2017). 
 
6.8. Perspectives for Future Work  
It has been demonstrated here that uptake of MPs into MDA-MB-231 cells does 
not occur via cell surface expression of CD95L. However, it would be important 
to test cell lines which have previously shown enhanced uptake of CD95R-Fc 
coated MPs, to further validate this finding. In the paper by Ateh et al., enhanced 
uptake was shown in human Daoy (medulloblastoma), human IGROV1 (ovarian 
cancer) and primary DRG sensory neurons (Ateh et al., 2011). An antibody for 
detecting CD95L has been validated here for use in Western blot, 
immunohistochemistry and flow cytometry, which could allow this to be done. 
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Additionally, the use of a positive control, such as Jurkat cells which 
endogenously express CD95L, would be a useful tool for comparison.  
 
Finally, a global siRNA screen would be useful using the CD95R-Fc coated MP 
system in MDA-MB-231 cells to identify how the CD95R coat drives uptake into 
cells. Systematically knocking down genes in the human genome provides a 
powerful way to investigate the mechanism MP uptake and to identify any genes 
which aid or hinder uptake. Furthermore, it may identify any potential surface 
scavenger, complement or integrin receptors (see table 5.1) that may play a part 
in initialising uptake of these particles into cells. This is a key piece of information 
to discover and would allow this system to be tailored for uses outside of 
delivering chemotherapeutics. 
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Appendices 
Appendix 1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
255 
 
 
Supplementary Figure 1. Histogram displaying G247-4 antibody titration against 
untransfected HEK cells.  
HEK293T cells were seeded on 6-well plates and left untransfected. Cells were harvested 48h 
later and 1 x 106 cells were incubated with different concentrations (0.1 – 1 µg) of primary 
antibody, mouse, anti-human CD95L G247-4 clone (BD Pharmingen), and goat, anti-mouse 
Alexa Fluor® 488 (Invitrogen). 10,000 cells of normal size and granularity were gated to eliminate 
cell debris. Results from representative experiments were overlain on the histogram, displaying 
distribution of fluorescence (arbitrary fluorescence units; AFU) against number of cells (counts) 
for all conditions. Cells were gated (black bar) to give percentage of positive cells and median 
fluorescence for the entire population was also calculated. Results for cells only (red) was 0.04% 
and 2.22 AFU, for 0.1 µg (blue) 1.6% and 2.25 AFU, 0.25 µg (green) 0.6% and 2.01 AFU, 0.5 µg 
(orange) 1.6% and 2.19 AFU and 1 µg (turquoise) 1.2% and 2.16 AFU. This demonstrates no 
non-specific binding of the primary antibody.  
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Supplementary Figure 2. Histogram displaying secondary antibody only control.  
HEK293T cells were seeded on 6-well plates and left untransfected. Cells were harvested 48h 
later and 1 x 106 cells were incubated with goat, anti-mouse Alexa Fluor® 488 (Invitrogen). 10,000 
cells of normal size and granularity were gated to eliminate cell debris. Results from 
representative experiments were overlain on the histogram, displaying distribution of fluorescence 
(arbitrary fluorescence units; AFU) against number of cells (counts) for all conditions. Cells were 
gated (black bar) to give percentage of positive cells and median fluorescence for the entire 
population was also calculated. Results for cells only (red) was 0.04% and 2.22 AFU, for 
secondary only (blue) 0.5% and 2.12 AFU. This demonstrates no non-specific binding of the 
secondary antibody.  
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Supplementary Figure 3. Histogram displaying anti-c-MYC antibody titration against 
untransfected HEK cells.  
HEK293T cells were seeded on 6-well plates and left untransfected. Cells were harvested 48h 
later and 1 x 106 cells were incubated with different concentrations (0.1 – 2 µg) of primary antibody 
mouse, anti-c-MYC (Sigma) and goat, anti-mouse Alexa Fluor® 488 (Invitrogen). 10,000 cells of 
normal size and granularity were gated to eliminate cell debris. Results from representative 
experiments were overlain on the histogram, displaying distribution of fluorescence (arbitrary 
fluorescence units; AFU) against number of cells (counts) for all conditions. Cells were gated 
(black bar) to give percentage of positive cells and median fluorescence for the entire population 
was also calculated. Results for cells only (red) was 0.04% and 2.22 AFU, for 0.1 µg (blue) 1% 
and 2.33 AFU, 0.25 µg (green) 1.3% and 2.35 AFU, 0.5 µg (orange) 1.3% and 2.39 AFU, 1 µg 
(turquoise) 1.7% and 2.47 AFU, 1.5 µg (pink) 1.3% and 2.49 AFU and 2 µg (brown) 1.1% and 
2.59 AFU. This demonstrates no non-specific binding of the primary antibody.  
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Supplementary Figure 4. Histogram displaying GM1006 inhibitor titration against CD95L-
Myc-DDK expressing HEK cells.  
HEK293T cells were seeded on 6-well plates, transfected with a vector coding for CD95L-Myc-
DDK and incubated with different concentrations (0 µM – 100 µM) of GM1006 (Merck) inhibitor in 
FBS free media, 24 hours before harvesting. 1 x 106 cells were incubated with primary antibody 
mouse, anti-human CD95L G247-4 clone (BD Pharmingen) and goat, anti-mouse Alexa Fluor® 
488 (Invitrogen). 10,000 cells of normal size and granularity were gated to eliminate cell debris. 
Results from representative experiments were overlain on the histogram, displaying distribution 
of fluorescence (arbitrary fluorescence units; AFU) against number of cells (counts) for all 
conditions. Cells were gated (black bar) to give percentage of positive cells and median 
fluorescence for the entire population was also calculated. Results for cells only (green) was 0.1% 
and 2.49 AFU, for 0 µM (red) 7% and 3.55 AFU, 1 µM (orange) 10% and 3.49 AFU, 2.5 µM 
(turquoise) 9% and 3.44 AFU, 5 µM (pink) 9% and 3.36 AFU, 15 µM (brown) 9% and 3.75 AFU, 
20 µM (blue) 8% and 3.15 AFU, 40 µM (mauve) 7% and 3.57 AFU and 100 µM (dark blue) 5% 
and 3.13 AFU. 20 µM of GM1006 was selected, as recommended and used previously. GFP 
expressing cells were 60% positive (transfection efficiency; not shown).  
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Supplementary Figure 5. Histogram displaying G247-4 antibody titration against CD95L-
Myc-DDK expressing HEK cells, incubated with GM1006.  
HEK293T cells were seeded on 6-well plates, transfected with a vector coding for CD95L-Myc-
DDK and incubated with 20 µM GM1006 (Merck) inhibitor in FBS free media, 24 hours before 
harvesting. 1 x 106 cells were incubated with different concentrations (0.1 – 1 µg) of primary 
antibody, mouse, anti-human CD95L G247-4 clone (BD Pharmingen) and goat, anti-mouse Alexa 
Fluor® 488 (Invitrogen). 10,000 cells of normal size and granularity were gated to eliminate cell 
debris. Results from representative experiments were overlain on the histogram, displaying 
distribution of fluorescence (arbitrary fluorescence units; AFU) against number of cells (counts) 
for all conditions. Cells were gated (black bar) to give percentage of positive cells and median 
fluorescence for the entire population was also calculated. Results for cells only (red) was 0.1% 
and 3.22 AFU, for 0.1 µg (blue) 7% and 3.21 AFU, 0.25 µg (green) 5% and 3.14 AFU, 0.5 µg 
(orange) 7% and 3.64 AFU and 1 µg (turquoise) 8% and 3.39 AFU. 1 µg G247-4 was selected for 
further experiments. Population of positive cells detected is the same as the anti c-MYC antibody 
(Supp. Figure 6). GFP expressing cells were 51% positive (transfection efficiency; data not 
shown) 
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Supplementary Figure 6. Histogram displaying anti-c-MYC antibody titration against 
CD95L-Myc-DDK expressing HEK cells, incubated with GM1006.  
HEK293T cells were seeded on 6-well plates, transfected with a vector coding for CD95L-Myc-
DDK and incubated with 20 µM GM1006 (Merck) inhibitor in FBS free media, 24 hours before 
harvesting. 1 x 106 cells were incubated with different concentrations (0.1 – 2 µg) of primary 
antibody mouse, anti-c-MYC (Sigma) and goat, anti-mouse Alexa Fluor® 488 (Invitrogen) and 
goat, anti-mouse Alexa Fluor® 488 (Invitrogen). 10,000 cells of normal size and granularity were 
gated to eliminate cell debris. Results from representative experiments were overlain on the 
histogram, displaying distribution of fluorescence (arbitrary fluorescence units; AFU) against 
number of cells (counts) for all conditions. Cells were gated (black bar) to give percentage of 
positive cells and median fluorescence for the entire population was also calculated. Results for 
cells only (red) was 0.1% and 3.22 AFU, for 0.1 µg (blue) 6% and 3.12 AFU, 0.25 µg (green) 6% 
and 3.46 AFU, 0.5 µg (orange) 7% and 3.34 AFU, 1 µg (turquoise) 9% and 3.74 AFU, 1.5 µg 
(pink) 11% and 3.74 AFU and 2 µg (brown) 11% and 3.76 AFU. 1 µg anti-C-MYC was selected 
for further experiments, since non-specific binding was occurring with high concentrations (data 
not shown). Population of positive cells detected is the same as the G247-4 antibody (Supp. 
Figure 5). GFP expressing cells were 51% positive (transfection efficiency; data not shown). 
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Supplementary Figure 7. Protein sequence of Human CD95L. 
In blue – CD95L cytoplasmic domain, residues 1 to 80, green – transmembrane domain, residues 
81 to 102 and red – extracellular domain, residues 103 to 281.  
  
CD95L Protein Sequence 
                      10         20         30         40         50 
MQQPFNYPYP QIYWVDSSAS SPWAPPGTVL PCPTSVPRRP GQRRPPPPPP  
                   60        70         80         90        100 
PPPLPPPPPP PPLPPLPLPP LKKRGNHSTG LCLLVMFFMV LVALVGLGLG  
                   110       120         130        140        150 
MFQLFHLQKE LAELRESTSQ MHTASSLEKQ IGHPSPPPEK KELRKVAHLT  
                  160        170        180        190        200 
GKSNSRSMPL EWEDTYGIVL LSGVKYKKGG LVINETGLYF VYSKVYFRGQ  
                210        220          230        240        250 
SCNNLPLSHK VYMRNSKYPQ DLVMMEGKMM SYCTTGQMWA RSSYLGAVFN  
                260  270   280       . 
LTSADHLYVN      VSELSLVNFE       ESQTFFGLYK L 
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Supplementary Figure 8. MDA-MB-231 cells internalise more CD95R-Fc coated particles.  
MDA-MB-231 cells were incubated with no particles (PBS; negative control) (A) non-coated 
particles (B) or in-house CD95R-Fc coated particles (C) for 24 hours. Cells were then washed to 
remove non-internalised particles. Live, adhered cells were then stained for imaging. Cell nuclei 
were stained with Hoechst (blue) and plasma membranes with CellMask™ (red). Particles are 
fluorescent green and detected in the FITC channel. Scale bars, 20µm. Images representative of 
the whole population are shown in each case.    
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Supplementary Figure 9. Confocal imaging demonstrates enhanced CD95R-Fc coated MP 
uptake in MDA-MB-231 cells, with more cells internalising a higher number of particles. 
Cells were incubated with fluorescent, 0.5µm MPs for 24 hrs. Live, adhered cells were then 
stained for imaging on an IN Cell Analyser 6000 (GE Healthcare). Cell nuclei were stained with 
Hoechst (blue) and plasma membranes with CellMask™ (red). Particles are fluorescent green 
and detected in the FITC channel. Mean and SEM values are from three independent, repeat 
experiments (n=3). The number of particles internalised by each cell (1, 2, 3, 4, 5, 6, 7, 8, 9, 10 
or ≥ 10), expressed as a percentage of total cell number, was compared for non-coated particles 
(blue), Fc coated particles (purple), BSA coated particles (green) and in-house CD95R-Fc coated 
particles (red). With a CD95R-Fc coating, cells internalise more particles, and more particles per 
cell across all particle numbers.  
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